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Abstract 
Epidermolysis bullosa (EB) is a clinically and genetically heterogeneous group of 
inherited blistering skin diseases that affect 500,000 individuals worldwide. The clinically 
more severe recessive dystrophic (RDEB) variant affects ~5% of EB individuals with a 
prevalence of 8 per one million of the population. RDEB is caused by loss-of-function 
mutations in the type VII collagen gene, COL7A1, which leads to reduced or absent type 
VII collagen (C7) and structurally defective anchoring fibrils at the dermo-epidermal 
junction (DEJ). From a clinical perspective, individuals with RDEB have fragile skin and 
are susceptible to blistering following minimal trauma, which leads to poor wound 
healing, scarring, contractures and oesophageal strictures. The major cause of mortality 
in RDEB is metastatic cutaneous squamous cell carcinoma (SCC). At present, care is 
mainly supportive and there are no effective treatments for this debilitating disease.  
The main therapeutic challenge, therefore has been to develop gene, protein, cell and drug 
therapies that are safe, effective and affordable. The basis of this thesis is to evaluate 
safety and efficacy of allogeneic cell-based therapies and attempt to elucidate their 
mechanism of action in wound healing in RDEB. 
To examine if allogeneic fibroblasts promote healing of chronic wounds in RDEB I 
intradermally injected allogeneic fibroblasts around the wound margins in an individual 
with RDEB. I demonstrated that these injections result in Heparin-Binding EGF-like 
Growth Factor encoding gene (HBEGF) and COL7A1 upregulation followed by C7 
production. These led to reduction in wound size by 30% at 8 months post injections. HB-
EGF, a member of the EGF family, has been implicated in RDEB-associated SCC. I also 
assessed whether another growth factor, EGF, which is commercially available for human 
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use and which is related to HB-EGF, could upregulate COL7A1 expression in RDEB 
epidermal cells. I demonstrated in vitro that 100ng/ml EGF at 90 minutes and 10ng/ml at 
15 minutes led to 3-fold and 5-fold COL7A1 upregulation in RDEB keratinocytes and 
fibroblasts respectively. HB-EGF also led to COL7A1 upregulation in RDB keratinocytes 
(6-fold) but to a lesser extent in RDEB fibroblasts (2-fold).  
To evaluate the effects of intradermally injected allogeneic fibroblasts in a larger number 
of RDEB individuals, I conducted a prospective, randomised, vehicle-controlled, phase 
II clinical trial. Twenty-six wounds in 11 adults with RDEB were injected. Fourteen 
wounds received fibroblasts and 12 were injected with vehicle only. I showed that 
allogeneic fibroblasts are safe and lead to a greater reduction in erosion area compared to 
vehicle within the first 28 days following treatment with a single set of injections to the 
wound margins, but not thereafter.  
Finally, I explored the safety and potential of intravenously administered allogeneic bone 
marrow-derived mesenchymal stromal cells (BM-MSCs) in children with RDEB in an 
open-label trial. I showed that the infusions were well-tolerated, with no serious adverse 
events. Although, there was no increase in C7 deposition, children and their parents 
reported improved wound healing, reduction in blister numbers and pruritus, increased 
skin resilience to trauma, and reduced pain during dressing changes. In addition, 
significant reduction in circulating inflammatory cytokines (IL-10, p<0.001; IFN-γ, 
p=0.04 and IL-17A, p=0.03) was observed. 
Taken together, these data reveal new insights into the mechanisms of action of allogeneic 
cell-based therapies in RDEB and provide evidence for their efficacy in wound healing 
and reducing morbidity in the context of clinical trials.  
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1                                                                                    INTRODUCTION                                                                       
1.1 The cutaneous dermo-epidermal junction 
 
The basement membrane zone (BMZ) of the skin consists of an extremely complex 
network of interconnecting proteins that has a typical morphological appearance at the 
ultrastructural level (Eady et al. 1994; McGrath et al. 1994a). It consists of at least 20 
distinct structural macromolecules that form a complex attachment zone at the dermal-
epidermal interface (Lai-Cheong et al. 2011) (Figure 1.1).  
 
Figure 1.1 The structure of the dermo-epidermal junction and the molecular basis of the major forms of 
EB. 
(a) Light microscopy image of the skin; the boxed area indicates the dermo-epidermal junction. (The section is stained 
with haematoxylin & eosin; scale bar = 50 μm); (b) Transmission electron microscopy image of the dermo-epidermal 
junction; hemidesmosome-anchoring fibril attachments are boxed (scale bar = 0.1 μm); (c) schematic representation of 
the protein organisation of dermo-epidermal attachment complexes; RDEB results from mutations in COL7A1 
encoding C7, the major component of anchoring fibrils. (IC = intracellular; PM = plasma membrane; LL = lamina 
lucida; LD = lamina densa; EC = extracellular). (Amended from Trends Mol Med. 2011 March; 17(3): 140–148). 
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On the epidermal side of the cutaneous BMZ, one can recognise the underlying BMZ 
components (Peltonen et al. 1989; Kurpakus et al. 1991; Sonnenberg et al. 1991). The 
hemidesmosomal proteins form a network that extends from the intercellular milieu of 
the basal keratinocytes to the extracellular space and physically secures the attachment of 
the epidermis to the underlying basement membrane. The core of the cutaneous BMZ 
consists of the basement membrane, which by transmission electron microscopy (TEM) 
can be divided into two distinct layers. The upper, electron lucent layer, is known as the 
lamina lucida and the lower portion, which is electron-dense, is known as the lamina 
densa. The lamina lucida is 20 to 40 nm thick and is traversed by anchoring filaments (5 
to 7 nm in diameter), rich in laminin-332 and laminin-311 which interact with the 
extracellular domain of α6β4 integrin subunits at the cell surface of keratinocytes to form 
an adhesion structure with the hemidesmosomes. Between the hemidesmosomes, 
anchoring filaments are less abundant. 
The lamina densa has a thickness which varies with age (30 to 60 nm) and is mainly 
composed of type IV collagen but contains also laminin-511 and laminin-322, nidogen, 
and heparan sulphate proteoglycans. It constitutes the intermediate anchorage zone for 
the anchoring filaments originating from the epidermis and the anchoring fibrils 
originating from the fibrillar zone of the dermis. The lamina densa is thicker in males 
compared to females, while the lamina lucida has a similar thickness in both sexes.  
The fibrillar zone includes the anchoring fibrils which are 20 to 60 nm thick, and which 
enlarge at their extremities and possess central cross-banding with an irregular 
periodicity, either dense and thick or clear and thin (Burgeson 1993). The anchoring 
fibrils are composed of C7. They make the link between the lamina densa and the 
anchoring plaques of the papillary dermis or, more commonly, form intermingled loops 
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which join two different areas of the lamina densa and thus provide a bridge that is 
transversed by dermal interstitial collagens (type I and III).  
 
1.2 Type VII collagen (C7) 
C7 is the major, if not exclusive, component of the anchoring fibrils (Sakai et al. 1986). 
C7 molecules consist of a central collagenous, triple-helical segment flanked by the non-
collagenous NC-1 and NC-2 domains. (Sakai et al. 1986). Cloning of the human C7 
collagen gene and the corresponding complementary DNA (cDNA) indicated that the 
initially synthesised C7 subunit polypeptide, the pro-α1(VII) chain is a complex modular 
protein consisting of a central 1530-amino acid triple-helical domain (Christiano et al. 
1994b; Christiano et al. 1994c). However, unlike interstitial collagens, the repeating Gly-
X-Y sequence of the triple-helix is interrupted by 19 insertions or deletions of amino 
acids. These interruptions provide flexibility to the rod-like collagen molecules and also 
provide sites susceptible to non-specific proteolytic cleavage of the primary sequence. 
Notably, in the middle of the triple-helical domain, there is a 39-amino acid non-
collagenous “hinge” region that is susceptible to proteolytic digestion with pepsin. The 
amino-terminal NC-1 domain of C7, approximately 145 kDa in size, consists of 
submodules with homology to known adhesive proteins, including segments with 
homology to cartilage matrix protein, nine consecutive fibronectin type III-like (FN-III) 
domains, a segment with homology to the A domain of von Willebrand factor, and a short 
cysteine and proline-rich region (Christiano et al. 1992). The carboxy-terminal non-
collagenous domain, NC-2 is approximately 30 kDa, and it contains a segment with 
homology to the Kunitz protease inhibitor molecule (Greenspan 1993; Christiano et al. 
1994b). In addition to playing a role in dystrophic epidermolysis bullosa (DEB), C7 has 
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been found to play a role in acquired blistering disorders, such as epidermolysis bullosa 
acquisita (Woodley et al. 2005; Chen et al. 2012; Vorobyev et al. 2015), bullous systemic 
lupus erythematosus (SLE) (Chan et al. 1999) and, more recently, inflammatory bowel 
disease (Chen et al. 2002b; Hundorfean et al. 2010). 
 
1.3 Inherited epidermolysis bullosa 
 
The term epidermolysis bullosa (EB) was first introduced in 1886 (Koebner 1886). Since 
the introduction of the term EB there have been decades of diagnostics and research in 
EB. The first half of the 20th century was significant for defining phenotypes followed by 
recognition of the three major subtypes (simplex, junctional and dystrophic) in the 1960s 
(Pearson 1962). TEM established distinct planes of cleavage for these categories of EB. 
In the 80s and 90s, the advent of monoclonal and polyclonal antibodies to components of 
the cutaneous BMZ led to rapid diagnosis using skin immunohistochemistry (Heagerty et 
al. 1986; Leigh et al. 1988; Schofield et al. 1990), and identification of putative candidate 
genes. Currently, there are four main categories of EB (those listed above, and Kindler 
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Table 1.1 Known genes implicated in EB. 
EBS, Epidermolysis bullosa simplex; JEB, Junctional epidermolysis bullosa; DEB, Dystrophic epidermolysis bullosa 
Level of skin 
cleavage 
Major EB type Targeted protein Mutated gene (s) 
Intraepidermal EBS 
Transglutaminase 5 TGM5 
Plakophilin 1 PKP1 
Desmoplakin DSP 
Plakoglobin JUP 
Keratin 5 KRT5 
Keratin 14 KRT14 










Collagen XVII COL17A1 
Integrin α6β4 ITGA6, ITGB4  
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Early observations on disease pathomechanisms were followed by identification of 
genetic mutations in candidate genes with diagnostic implications (Christiano et al. 1993; 
Hilal et al. 1993; Varki et al. 2006; Varki et al. 2007). Establishment of DNA-based 
prenatal testing revolutionised disease diagnostics and led to preimplantation genetic 
diagnosis as a further choice for couples at risk for recurrence of EB (McGrath et al. 1996; 
Fassihi et al. 2006). The early 21st century saw the development of preclinical model 
systems (Heinonen et al. 1999; Palazzi et al. 2000; Cao et al. 2001; Fritsch et al. 2008) 
and enabled early proof-of-principle clinical trials. Over the past 5 years, phase I/II 
clinical trials, which are discussed in Section 1.4, have introduced molecular therapies 
into the clinical setting. EB has served as a prototype of heritable skin diseases in which 
significant progress has been made over the past few decades from a condition defined 
purely by clinical description to an entity with profound understanding of the molecular 
defects at the genomic level.  
 
 
Inherited EB encompasses genetically transmitted diseases with the unifying 
characteristic feature being the presence of recurrent blistering and erosions, due to minor 
mechanical trauma, that affects certain epithelial-lined tissues and the skin.  
Calculating the incidence of EB can be difficult and data vary within different populations 
worldwide. In the United States the incidence of EB is estimated at approximately 20 per 
one million live births with a prevalence of 8 per 1 million of the population (Fine 2010). 
EB simplex represents 92% of the total of EB cases, dystrophic EB 5%, junctional EB 
1%, whereas the remaining 2% are still unclassified. Prevalence of Kindler syndrome is 
unknown, although more than 250 cases have been reported to date. These estimates are 
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very similar to the European and Japanese EB Registries (Inaba et al. 1989; Pavicic et al. 
1990; McKenna et al. 1992; Castiglia and Zambruno 2010; Duipmans and Jonkman 
2010). Of note, a greater prevalence of EBS has been reported in Scotland of at least one 
in 30,000 individuals (Horn et al. 1997). It is unclear whether this reflects possible greater 
accessibility of EBS patients for identification and recruitment in the Scottish Registry or 
the presence of some underlying genetic differences which might distinguish the Scottish 
EB population from those in other geographic regions. An important unifying finding 
among all populations is the lack of any EB predilection by gender or ethnicity (Fine and 
Mellerio 2009a; Fine and Mellerio 2009b). 
 
 
There have been several advances in the classification of EB since the early ultrastuctural 
plane of cleavage subtyping that began in 1962 (Pearson 1962). The first international 
consensus meeting on diagnosis and classification of EB was held in 1989 (Fine et al. 
1991). Early classifications were based on ultrastructural determination of the plane of 
cleavage, as well as immunohistochemical labelling for basement membrane proteins, 
and were further subclassified on the basis of genetic mode of transmission and clinical 
phenotype, resulting in 23 EB phenotypes. The second meeting, in 1999, took into 
account newly described clinical entities and the results of early mutational analyses (Fine 
et al. 2000). During the third meeting, Kindler syndrome was included as a fourth subtype 
within the EB groups (Fine et al. 2008). Of note, the proposed classification separated EB 
into four major types, depending on the level of blistering: EB simplex (blistering within 
the epidermis), junctional (cleavage within the lamina lucida), dystrophic (separation 
below the lamina densa) and Kindler syndrome (multiple and variable levels). Patients 
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were then further distinguished by minor and major subtypes; Notably, EB simplex was 
separated in two subgroups (basal and suprabasal). A new classification system (“onion 
skin approach”) was introduced in 2013, during the most recent international consensus 
meeting (Fine et al. 2014). The new system takes into account the investigative resources 
(or lack thereof) available to the clinician and the different “onion layers” can include the 
EB type, mode of inheritance, phenotype, immunofluorescence, antigen mapping 
findings, and mutation(s) present in each patient, and is the one used throughout this 
thesis. Nevertheless, EB is still separated into four major groups, based on the level within 
which blisters develop. The next level of subclassification takes into account the clinical 
phenotypic features present in a given patient, most notably the distribution (localised vs 
generalised), and severity of cutaneous and extracutaneous disease involvement. Each 
patient then can be further subclassified on the basis of the mode of transmission and, if 










P a g e  31 | 275 
 
Table 1.2 The 2014 proposed “onion skin” terminology–representative examples. 
DDEB, dominant dystrophic epidermolysis bullosa; EBS, epidermolysis bullosa simplex; JEB, junctional 
epidermolysis bullosa; RDEB, recessive dystrophic epidermolysis bullosa; MP, mottled pigmentation; BDN, bullous 
dermolysis of the newborn. 
 
2013 “onion skin” nomenclature (examples) 
EBS localised, normal keratin 5 and 14 staining, 
KRT5 or KRT14 mutation (specify type) 
EBS generalised severe, normal keratin 5 and 14 staining, 
KRT5 or KRT14 mutation (specify type) 
EBS generalised intermediate, normal keratin 5 and 14 staining, 
KRT5 or KRT14 mutation (specify type) 
EBS-MP, normal keratin 5 staining, 
KRT5 mutation (specify type) 
JEB generalised severe, laminin-332 absent, 
LAMA3, LAMB3, or LAMC2 mutations (specify type) 
JEB generalised intermediate, laminin-332 or collagen XVII reduced staining, 
LAMA3, LAMB3, LAMC2, or COL17A1 mutations (specify type) 
RDEB generalised severe, C7 absent, 
COL7A1 mutations (specify type) 
RDEB generalised intermediate, C7 reduced staining, 
COL7A1 mutations (specify type) 
RDEB-BDN, granular intraepidermal C7 staining, 
COL7A1 mutations (specify type) 
DDEB generalised, normal C7 staining, 
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DEB can be inherited in an autosomal dominant (DDEB) or recessive (RDEB) pattern. 
All forms of DEB are caused by mutations within COL7A1, which encodes for the major 
component of the anchoring fibrils, C7 (Sakai et al. 1986; Keene et al. 1987). As of 2011, 
a web-based DEB patient registry (http://www.deb-central.org) contains worldwide 
information on 1039 DEB patients and their 659 COL7A1 mutations (last accessed 17th 
March 2017) (van den Akker et al. 2011; Wertheim-Tysarowska et al. 2012). These 
include nonsense, missense, deletion, insertion, insertion-deletion, splice-site and 
regulatory mutations. Mutations occur throughout all 118 exons and flanking introns of 
COL7A1; most of which are family specific, with few recurrent or hotspot mutations. 




Phenotypes may show intra- and interfamilial variability with the same pathogenic variant 
(Murata et al. 2000; Nakamura et al. 2004). The dominant forms of DEB typically have 
a heterozygous glycine substitution (GS) affecting one allele and sited within the 
collagenous domain of C7, usually leading to a relatively mild phenotype (Varki et al. 
2007). In contrast, the recessive forms of DEB frequently result from premature 
termination codons (PTC), frameshift or splice site mutations on both alleles of COL7A1 
(Christiano et al. 1993; Hilal et al. 1993; Christiano et al. 1994a; Hovnanian et al. 1994). 
Patients with RDEB-SG show a clinically severe phenotype because of a complete 
absence of C7 and total loss of functional anchoring fibrils. Patients with less severe 
generalised RDEB show a milder clinical picture with various amounts of C7. 
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Intermediate RDEB is caused by a combination of PTC, missense and splice site 
mutations on both alleles of COL7A1. Some GS mutations can underlie both dominant 
and recessive forms of DEB (Almaani et al. 2009). In part, genotype-phenotype 
correlation depends on the nature of the substituted amino acid, the position of the GS in 
C7, as well as the biochemical changes to the collagen helix (Almaani et al. 2011). 
 
 
The clinical hallmarks of DEB are trauma-induced blisters and healing with scarring. The 
main clinical subtypes of DEB are dominant DEB and recessive DEB. There can be 
significant overlap in the clinical features between the subtypes. Patients with dominant 
DEB generally have milder clinical phenotypes, which range from mainly acral 
involvement to disseminated blistering and scarring. Severe mucosal involvement, 
however, is rare, and the teeth are usually normal. Blistering typically starts at birth or 
soon thereafter, but the disease activity may diminish with advancing age. There is a 
predilection for the extremities in severe cases, but mechanical stress can induce blisters 
anywhere on the body. Scars, milia, and dystrophy or loss of nails are common. 
Dystrophic nails, especially toenails, are often seen and may be the only manifestation of 
DDEB (Dharma et al. 2001; Sato-Matsumura et al. 2002; Tosti et al. 2003). A rare variant 
is EB pruriginosa which is characterised by intense pruritus and nodular prurigo-like 
lesions mainly localised to the extremities (McGrath et al. 1994b). Most cases of EB 
pruriginosa are autosomal dominant although some are autosomal recessive. DDEB has 
an excellent prognosis with normal life expectancy. Unusually, onset of the clinical 
manifestations of EB pruriginosa may be delayed with signs only starting in adult life. 
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Generalised severe RDEB, on the other hand, is characterised by extensive blisters 
resulting in scarring and contractures. Pseudosyndactyly resulting in mitten deformities 
of hands and feet start in childhood and is unique to RDEB. There is extensive mucosal 
involvement, particularly in the oral cavity, the oesophagus and the eyes. Feeding can be 
problematic due to poor dentition, microstomia, inability to move the tongue due to 
scarring and oesophageal strictures. Perianal involvement often leads to painful 
defaecation, which results in severe constipation. Further extracutaneous manifestations 
are discussed in Section 1.3.7. RDEB individuals have significant lifelong morbidity, 
with complications such as poor mobility, poor vision and dependence on others for their 
daily personal and skin care. The leading causes of death are sepsis, metastatic squamous 
cell carcinoma and renal failure.  
Intermediate RDEB, has similar clinical manifestations to RDEB-SG but the blistering is 
less severe and less extensive. Patients usually have a better prognosis, survive longer, 
but the risk of SCC remains elevated.  
 
 
RDEB is a multi-system, severely debilitating, disease that can have a variable clinical 
picture (Figure 1.2) that is mainly determined by the causative genetic mutations in 
COL7A1 and the amount of functional C7 protein each individual is able to make. 




Figure 1.2 Clinical appearance of an individual with severe generalised RDEB.  
There is extensive skin involvement with multiple non-healing erosions.  
 
1.3.7.1 Cutaneous involvement 
Patients with severe RDEB have extensive skin involvement. They have intact blisters 
and open wounds at various stages of healing. These wounds occur anywhere on the body 
but tend to be more pronounced on trauma-prone areas such as knees, feet, hands and 
elbows, and skin overlying bony prominences. Many wounds heal with scarring leading 
to contractures, most notably of the hands and feet. Scarring and contractures lead to loss 
of functional digits as these become encased in scar tissue – this is known as mitten 
deformity or pseudosyndactyly (McGrath et al. 1992a). Recurrent wound infections are 
also a common problem because of extensive areas of denuded skin and the accumulation 
of serum and moisture on the surface which enhances the growth of bacteria (Pillay 2008). 
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1.3.7.2 Gastrointestinal involvement  
Gastrointestinal complications frequently affect the mouth, where ankylostomia and 
microstomia – as a result of scarring and oral mucosa fragility, lead to poor oral hygiene 
with resultant loss of dentition. Loss of teeth makes mastication difficult and dentures are 
usually contraindicated because of the mucosal fragility (Serrano-Martinez et al. 2003). 
Malnutrition is therefore common and compounded by increased nutritional requirements 
due to the burden of multiple chronic wounds. Oesophageal erosions, web formation and 
strictures cause severe dysphagia which further exacerbates the malnutrition (Azizkhan 
et al. 2006). Gastric reflux is a common problem that also increases oesophageal damage 
and which requires management with proton-pump inhibitors (Freeman et al. 2008). 
Chronic constipation occurs as result of blistering of the anal margins causing pain on 
defaecation and recurrent wounds over that area. The gut can also show inflammatory 
changes leading to diarrhoea (Shah et al. 2007). 
 
1.3.7.3 Chronic anaemia 
Most individuals with severe generalised forms of RDEB have anaemia, although the 
precise aetiology of anaemia, which often has an iron-deficiency profile, is not entirely 
clear. It is postulated that the main cause is continuous blood loss from open wounds, 
gastrointestinal erosions, poor nutritional intake and anaemia of chronic disease (Mellerio 
et al. 2007). In some cases, the anaemia can be severe, with haemoglobin levels as low 
as 5-6 gm/dl, and often refractory to oral iron (Fridge and Vichinsky 1998). 
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1.3.7.4 Dilated cardiomyopathy 
Cardiomyopathy, which is frequently asymptomatic, is a not uncommon pathology in 
RDEB. The aetiology of this complication is not properly understood but possible causes 
could be deficiencies in carnitine and selenium, drug toxicity caused by amitriptyline, 
infection, chronic anaemia and iron overload (Lara-Corrales et al. 2010; Lara-Corrales 
and Pope 2010; Taibjee and Moss 2010). Dilated cardiomyopathy can be fatal in some 
cases and therefore patients require surveillance with echocardiography. 
 
1.3.7.5 Osteoporosis 
Almost all patients with severe RDEB suffer from osteoporosis from an early age, often 
accompanied by vitamin D deficiency. Bone loss occurs as a result of lack of weight-
bearing exercise, generalised inflammation, malnutrition and lack of adequate exposure 
to sunlight (Bruckner et al. 2011; Fu et al. 2011). Regular DEXA scans can be useful for 
detecting osteopaenia and osteoporosis. If present, calcium and vitamin D 
supplementation should be commenced, and the serum bone profile monitored (Martinez 
and Mellerio 2010). Long bone and vertebral fractures may also occur in patients with 
the severe forms of EB (Reyes et al. 2002; Cheung 2014). 
 
1.3.7.6 External eye disease 
The most common ocular finding in RDEB is corneal blister formation, manifesting as 
painful corneal erosions, followed by corneal scarring. Symblepharon formation has a 
higher incidence in RDEB compared to other subtypes of EB and approximately half of 
all people with RDEB have some degree of ectropion, although this tends to be less severe 
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than the ectropion complicating junctional EB (Fine et al. 2004). Sometimes, lacrimal 
duct obstruction is seen, especially in the inversa type of RDEB. The incidence of 
impaired vision is also increased in RDEB, attributed in some cases to severe corneal 
scarring (Smith et al. 2009). 
 
1.3.7.7 Genitourinary tract involvement 
Genitourinary tract involvement in EB is not uncommon and in some cases, it can result 
in end stage renal failure. Pathology may be broadly divided into problems resulting in 
obstruction or disease primarily affecting the renal parenchyma. Most genitourinary 
complications reported have involved junctional EB patients. Ulceration and scarring of 
the glans penis and labia may occur in the inverse form of dystrophic EB (Farhi et al. 
2004; Almaani and Mellerio 2010; Kajbafzadeh et al. 2010). Urethral meatus stenosis is 
the commonest genitourinary complication, occurring in 8% of RDEB patients (Rubin et 
al. 2007). Severe constipation in patients with RDEB may also result in urinary outflow 
obstruction with hydroureter and hydronephrosis (El Shafie et al. 1979; Price et al. 2001). 
The main causes of renal parenchymal disease are: post-infectious glomerulonephritis, 
mesangial IgA nephropathy and secondary renal amyloidosis (Almaani and Mellerio 
2010).  
 
1.3.7.8 Growth and pubertal delay 
Profound growth retardation occurs early in the course of severe RDEB and at least half 
of children show signs of malnutrition (Colomb et al. 2012). Two consequences of 
inadequate nutrition is pubertal delay and short stature. Females with severe forms of EB 
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and pubertal delay have been found to have hypogonadotrophic hypogonadism due to 
reduced serum luteinising hormone (LH) and follicle-stimulating hormone (FSH) (Pass 
et al. 2009; Martinez et al. 2010), although males with this complication may express low 
androgen levels. 
 
1.3.7.9 Pain and pruritus 
EB is a painful condition. The expanding and often tense bullae resulting in erosions and 
chronic wounds cause considerable pain and discomfort. Sources of long-term chronic 
pain include dental and periodontal disease, the formation of scar tissue and contractures 
causing immobility and pain on extension of the affected joints (Denyer 2012; 
Goldschneider et al. 2014). 
Pruritus is a common problem in people with EB (van Scheppingen et al. 2008). Pruritus 
correlates with EB severity and extent of skin damage, with severe RDEB individuals 
being more severely affected compared to EB simplex (Devries et al. 2004). The main 
reasons for itch in EB are still unclear but it is postulated that dry skin, increased heat and 
moisture from dressings contribute to the intensity of itch. On the other hand, pruritus can 
be caused by wound healing and inflammation leading to a vicious itch-scratch-blister 
cycle of skin damage and skin healing (Danial et al. 2015a). 
 
1.3.7.10 Squamous cell carcinoma (SCC) 
Malignancy, typically SCC, is the major cause of premature mortality in RDEB. SCC was 
first documented in association with EB in 1913 (Reed et al. 1974). SCCs often arise in 
areas of non-healing cutaneous wounds. Often, they occur at multiple sites 
simultaneously and can affect all skin types, in contrast to the non-EB population. The 
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sites of the SCCs are mainly in areas prone to maximal trauma and scarring. Clinically, 
early SCCs can be difficult to distinguish from reactive proliferation in the setting of 
chronic wound healing (Figure 1.3).  
 
Figure 1.3 Squamous cell carcinoma (SCC) on the scarred, mitten-like hand of a 30-year old individual 
with RDEB-SG. 
The dashed line represents clinically the SCC which was subsequently excised and histologically confirmed as a 
moderately differentiated SCC.  
 
Multiple biopsies may be needed to establish a diagnosis of SCC (Mellerio et al. 2016). 
Initial SCCs are often well-differentiated but there is clearly a widespread field effect 
associated with chronic inflammation in RDEB as multiple primary SCCs, separated by 
shorter time intervals, and with increasing loss of differentiation, occur. SCCs arising in 
RDEB are biologically aggressive with most people developing metastatic disease within 
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5 years after diagnosis of the initial SCC. The data from the USA National EB Registry 
(1986-2006) demonstrate that at least one SCC will arise in at least 80% and 90% of 
RDEB-SG patients by ages 45 and 55, respectively (Fine et al. 2009c). The mortality rate 
from SCC in this type of EB is 38.7% by age 35 years, 70% by 45 years and 78.7% by 55 
years. This is in contrast with an estimated lifetime risk of only 7%-11% within the white 
non-EB American population (Miller and Weinstock 1994). Furthermore, the overall 
mortality rate from SCC (0.26 per 100,000 per year) within the non-EB American 




The development of a severity score for EB is challenging because one needs to take into 
account the multiple systems involved and the different subtypes. Since the first scoring 
tools were developed (Tamai et al. 2003; Moss et al. 2009), there was criticism that it did 
not discriminate between activity and permanent damage and irreversible scarring. The 
Birmingham EB severity score (BEBSS) (Moss et al. 2009) takes into account eleven 
items, including area of damaged skin, involvement of nails, mouth, eyes, larynx and 
oesophagus, scarring of hands, skin cancer, chronic wounds, alopecia and nutritional 
compromise. The score is simple to define, easy to use and applicable to all types of EB. 
Its limitations are that only one item takes into account disease activity (c.f. the other 
components that reflect disease severity) and not all items are applicable to all types of 
EB; i.e pseudosyndactyly is only applicable in RDEB. Over the past few years with the 
development of clinical trials there has been intense discussion amongst EB experts about 
the development of other validated tools as quantitative ways of assessing therapy-
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associated changes in clinical status for all types of EB. Recently, two new scores have 
been introduced. The Epidermolysis Bullosa Disease Activity and Scarring Index 
(EBDASI) has the capacity to distinguish activity scores that are responsive to therapy 
separately from damage (Loh et al. 2014). However, it has not been tested in severe 
RDEB and takes longer to complete than the BEBSS. Another group attempted to develop 
an instrument that would serve as an outcome measure for clinical research studies 
(Schwieger-Briel et al. 2015). The iscorEB (Instrument for Scoring Clinical Outcome of 
Research for Epidermolysis Bullosa), in contrast to previous scoring models (Tamai et al. 
2003; Moss et al. 2009), includes not only the perceptions of disease severity of EB 
healthcare professionals, but also patient and parent perception of disease severity. 
Almost all EB types show some degree of oropharyngeal involvement and therefore the 
EB Oropharyngeal Severity (EBOS) score was developed specifically to measure 
oropharyngeal disease activity and structural damage (Fortuna et al. 2013a; Fortuna et al. 
2015b). In addition, EB-specific quality of life evaluation tools have also been developed 




1.3.9.1 Principles of wound care 
The presence of multiple wounds of varying duration and ability to heal makes 
management of DEB difficult and complex. The underlying principle of erosion 
management is to apply an atraumatic dressing to protect the wounds and facilitate 
healing as well as prevent pain and bleeding on removal (Caldwell-Brown 1992). Blisters 
occur following trauma and minimal friction. Blisters are not self-limiting and will extend 
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rapidly if left intact. Intact blisters should be lanced at their lowest point to facilitate 
drainage and limit tissue damage (Denyer 2010). 
Management of DEB must address skin colonisation and infection, offer protection from 
trauma, avoid contractures and reduce pruritus. Dressings are often extensive and large 
sizes must be sought in order to avoid blistering where two smaller dressings join. 
Exudate can be copious and needs careful containment to avoid maceration and leakage. 
Odour can be a feature and must be addressed to avoid embarrassment and social 




1.3.9.2 Pain management 
Pain is a feature of all types of EB. Pain management should be individual and person-
focused. The use of recognised age-appropriate pain score tools, if available, is 
recommended (Melzack 1987; McCormack et al. 1988). Best practice guidelines have 
been developed and published by the patient advocacy group, Dystrophic epidermolysis 
bullosa Research Association (DebRA) International, as part of a project to improve care 
of EB individuals (Goldschneider et al. 2014). Pain in DEB has several aspects and all of 
them should be addressed. It is divided into acute pain related to wounds, procedures 
(dressing changes, blister lancing and bathing) and chronic pain (wounds, abdominal 
pain, dental and constipation).  
Recommendations for wound pain include: treating infections, topical therapies for pain 
and systemic pharmacologic therapy for both acute and chronic forms of skin pain. For 
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localised wound pain, topical lidocaine jelly (2% concentration) has been used in some 
cases. In adults, topical opioids (morphine sulphate in hydrogel) with dressing changes 
can be used on individual wounds (Twillman et al. 1999; LeBon et al. 2009). Topical 
anaesthetics are routinely used in children prior intravenous access and skin biopsies.  
Systemic analgesics include use of paracetamol, non-steroidal anti-inflammatory drugs 
and opioids. Transmucosal analgesics (including intranasal fentanyl and transbuccal 
opioids) should be considered for short procedures such as dressing changes while 
midazolam should be considered for anxiety prior procedures. The IV form of ketamine 
given orally has been used with variable success for chronic pain (Blonk et al. 2010). 
Psychological therapies for pain management have been shown to modify pain intensity, 
reduce related distress, decrease pain-related functional disability, and improve pain 
coping (Goldschneider et al. 2014). Dressing changes and blister lancing can cause 
anxiety and pain. Analgesia should be given beforehand and tense blisters should be 
lanced. Leaving the wounds uncovered causes pain and therefore, new dressings should 
be ready. Distraction is helpful especially in children. Rectal analgesics are not 
recommended due to the fragility of the perianal skin. Table 1.3 summarises the pain 
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Table 1.3 Summary of pain management treatments. 
Topical treatments 
 Occlusive and non-adherent dressings 
 Adhesive removers 
 Topical lidocaine 
 Topical morphine 
 Lubrication and bath additives 
Systemic treatments 
 Paracetamol 




Non-traditional systemic treatments 




 Self hypnosis 
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1.3.9.3 Dental care 
The approach to dental care has dramatically changed over the last 30 years. It was 
initially considered extraction of all teeth to be the treatment of choice for patient with 
RDEB (Crawford et al. 1976). More recently, it was illustrated that it is possible to 
manage dental abnormalities more conservatively (Wright et al. 1993). Recently it has 
been demonstrated that caries can be prevented by regular dental follow-up, oral hygiene, 
professional cleaning and fluoride therapy (Fortuna et al. 2013b; Fortuna et al. 2015a). 
As part of a multidisciplinary approach, patients should be reviewed by a dentist 
regularly. Prevention of dental disease is the main aim. Tooth brushing, even for severe 
RDEB is possible and recommended. Toothbrushes with small heads, soft and short 
bristles are available. Daily exercises can also help to improve/maintain the mouth 
opening (Kramer et al. 2012). 
 
1.3.9.4 Management of pseudosyndactyly 
Neonates with RDEB-SG are frequently born with wounds extending over their limbs, 
hands and feet, caused by intrauterine movement and delivery trauma. In many cases 
careful dressing of these wounds, with attention paid to separating the digits, can prevent 
early fusion.  
Degloving injuries following trauma are not uncommon and these also require immediate 
action to separate the digits to prevent digital fusion (Figure 1.4).  
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 Figure 1.4 Degloving injury. 
 Severe ulceration of the hand with degloved fingers (courtesy of Dr Jemima Mellerio).  
 
Despite these measures, over time and following repeated trauma the web spaces are 
gradually lost and digital fusion and contractures will develop. Surgery is usually 
successful in releasing the contractures and separating the fingers, but this is complex and 
requires skin grafting, repeated general anaesthesia and compliance with postsurgical 
splinting (Terrill et al. 1992; Bernardis and Box 2010; Luria et al. 2014). In many patients, 
the process of fusion and contractures begins again within a short time. Some adult 
patients may decline hand surgery because of the need for repeat procedures, preferring 
instead to manage with hands that may in some cases exhibit complete ‘mitten deformity’ 
(Figure 1.5).  
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Figure 1.5 Different levels of pseudosyndactyly in DEB individuals. 
These photos show very mild level of pseudosyndactyly (top left), to mitten deformity of the hand in the bottom right 
corner in RDEB-SG. 
 
1.3.9.5 Management of pruritus  
Pruritus is one of the most challenging aspects of the management of DEB. Intense itch 
provokes scratching leading to further cutaneous damage.  
Almost healed wounds are particularly pruritic and scratching can lead to wound 
breakdown. Apart from skin breakdown, intense pruritus can be part of the pain spectrum 
and can lead to insomnia and depression (Danial et al. 2015a; Danial et al. 2015b). This 
is particularly marked in EB pruriginosa. If the skin is dry it tends to be itchier too. In 
DEB, one should aim for a balance between moisturising without making it prone to 
blistering. Menthol containing, oil-based products may be useful to relieve itch 
(www.debra-international.org for best practice guidelines).  
Non-pharmacological treatments include cognitive behavioural therapy, hypnosis and 
meditation (Chida et al. 2007). Habit reversal is a specific behavioural intervention where 
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specific behavioural techniques are developed as a competing response to the urge to itch 
and is frequently combined with cognitive behavioural therapy and relaxation (Azrin and 
Nunn 1973).  
 
1.4 Therapies for RDEB 
 
Given that keratinocytes and fibroblasts are responsible for the synthesis of all the key 
adhesive proteins within the BMZ, attempts at gene therapy for EB are likely to focus on 
genetic modification of these cells. There are two main strategies that are used for 
cutaneous gene delivery. In the first, in vivo strategy, the corrected gene is directly 
delivered into the skin by topical application or by intradermal injections, such as by using 
biolistic particle bombardment (“gene gun”) (Furth 1997; Woodley et al. 2004b). In the 
second, ex vivo strategy, genetically corrected autologous or allogeneic keratinocytes are 
cultured in vitro and grafted onto the patient (Featherstone and Uitto 2007). Most gene 
therapy efforts initially were being focused on ex vivo transfer of the wild-type COL7A1 
cDNA into affected keratinocytes or fibroblasts to correct the RDEB phenotype (Murauer 
et al. 2011).  
Integrating COL7A1 cDNA into human C7-null RDEB keratinocytes has been achieved 
with a variety of vectors (Chen et al. 2002a; Ortiz-Urda et al. 2002; Gache et al. 2004). 
Retroviral vectors are the most widely used vehicles in human gene trials (Khavari et al. 
2002; Gache et al. 2004). The use of these vectors, however, has been limited by the large 
size (9.2 kb) of the COL7A1 cDNA (Goto et al. 2006b). The application of large viral 
vectors to gene therapy also raises some safety concerns and plasmid-based approaches 
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offer poor efficiency for stable gene transfer. The development of lentiviral vectors holds 
promise for gene transfer in skin diseases as shown by the successful in vivo transduction 
of a C7 lentiviral vector containing full-length COL7A1 transgene into RDEB 
keratinocytes and fibroblasts in animal studies (Chen et al. 2002a; Ortiz-Urda et al. 2002; 
Baldeschi et al. 2003). Limitations of these therapies are a) the short-term correction of 
phenotype (Goto et al. 2006a), b) production of truncated C7 (if a modified mini-gene is 
used to reduce cDNA size) that may induce dominant-negative interference in DDEB 
(Chen et al. 2000), c) unstable accommodation of the large COL7A1 transgene in viral 
vectors, and d) ectopic expression of the recombinant C7 in all layers of the transgenic 
epidermis (Baldeschi et al. 2003; Gache et al. 2004). 
After transcription, most pre-RNAs are processed through splicing to become a mature 
RNA. There are two types of splicing: cis- and trans-splicing. Trans-splicing involves two 
pre-RNA molecules, whereas cis-splicing occurs within a single pre-mRNA. Trans-
splicing aims to reduce the size of the cDNA transcript by recombining an endogenous 
target pre-mRNA and an exogenously delivered RNA molecule called the pre-trans-
splicing molecule (PTM). A partial, wild-type coding sequence from the PTM is then 
inserted to replace disease-causing sequences in order to generate a new, reprogrammed 
wild-type mRNA to correct the disease phenotype (Wally et al. 2008). Although 
keratinocytes produce more C7 in vivo, gene-corrected RDEB fibroblasts have been 
shown to produce greater c7 at the mouse DEJ compared to gene-corrected RDEB 
keratinocytes and might have greater therapeutic potential (Ryynanen et al. 1992; Ortiz-
Urda et al. 2003; Goto et al. 2006a). 
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One further innovation is gene editing, a new means of silencing or repairing genes that 
has relevance to both RDEB and DDEB. This technology and its potential applications to 
COL7A1 and DEB are discussed in Section 6.4.3.1. 
1.4.1.1 Induced pluripotent stem cells (iPSCs) 
Induced pluripotent stem cells are reprogrammed from somatic cells and have the 
potential to differentiate into any cell type. The reprogramming process is initiated by the 
introduction of certain embryonic transcription factors (c-MYC, SOX2, OCT4 and KLF4). 
The development and use of iPSCs first emerged in 2006 with the pioneering and 
remarkable demonstration that somatic cells, such as skin fibroblasts (Yamanaka and 
Takahashi 2006), epidermal keratinocytes (Aasen et al. 2008), and hair follicle outer root 
sheath (Aasen and Izpisua Belmonte 2010) could be reprogrammed into pluripotent cells 
with many of the properties and characteristics of embryonic stem cells derived from the 
inner cell mass of an embryo. So far, murine studies have successfully generated iPSCs 
in culture from multipotent keratinocyte lineages capable of forming a fully developed 
epidermis (Bilousova et al. 2011). Subsequently, Itoh et al. reported successful generation 
of iPSCs from healthy human skin fibroblasts and individuals with RDEB (Itoh et al. 
2011). These two studies used application of specific proteins to allow differentiation of 
iPSCs into keratinocytes. A third study (Tolar et al. 2011c) took a different approach 
using direct injections and teratoma formation which allows spontaneous differentiation 
of iPSCs into an epidermis. Another group generated patient-derived COL7A1-corrected 
epithelial keratinocyte sheets for autologous grafting (Sebastiano et al. 2014). Revertant 
mosaicism (see Section 1.4.1.2) offers a unique opportunity for generation of iPSCs for 
patient-specific stem cell therapy, perhaps paving the way for personalised therapy in EB 
(Tolar et al. 2014; Umegaki-Arao et al. 2014). 
P a g e  52 | 275 
 
1.4.1.2 Revertant mosaicism and natural gene therapy phenomenon 
One striking observation in recent years has been that some patches of skin in patients 
with various inherited skin diseases can undergo spontaneous correction of the genetic 
defect underlying the skin pathology, a concept known as revertant mosaicism or “natural 
gene therapy”. This was first noticed in the late 1990s in a patient with non-Herlitz 
junctional EB (now classified as generalised intermediate junctional EB) due to 
autosomal recessive mutations in COL17A1, encoding type XVII collagen (Jonkman et 
al. 1997). Revertant mosaicism is a naturally occurring process characterised by 
spontaneous genetic repair that can lead to a partial or complete reversal of an affected to 
a wild-type phenotype. In addition to generalised intermediate junctional EB, other 
variants of EB, including EB simplex, RDEB and Kindler syndrome have all shown 
evidence of revertant mosaicism (Jonkman et al. 1997; Darling et al. 1999; Hirschhorn 
2003; Pasmooij et al. 2005; Almaani et al. 2010; Kiritsi et al. 2012; Lai-Cheong et al. 
2012). Likewise, skin diseases such as ichthyosis with confetti and dyskeratosis congenita 
(Choate et al. 2010; Jongmans et al. 2012; Choate et al. 2015), have also been shown to 
display this phenomenon. There is evidence that natural gene therapy may occur in all 
patients with generalised intermediate junctional EB (Pasmooij et al. 2012) and in an 
increasing number of individuals with dystrophic EB (Pasmooij et al. 2010; van den 
Akker et al. 2012; Kiritsi et al. 2014). The predominant mechanisms of gene correction 
include back mutation, gene conversion, intragenic recombination and second-site 
mutation (Jonkman et al. 1997; Jonkman and Pasmooij 2009). The genetic correction 
appears to be limited to keratinocytes rather than fibroblasts or other skin cell populations, 
perhaps reflecting higher proliferation rates in keratinocytes (Jonkman et al. 1997). The 
main clinical consequence of revertant mosaicism is the phenotypic improvement of 
disease, although the timing of the reversion may influence the extent of revert mosaicism 
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and the severity of the condition, i.e. early reversion during embryonic development is 
more likely to result in larger revertant patches.  
 
1.4.1.3 Revertant cell therapy for epidermolysis bullosa 
The opportunity to expand keratinocytes derived from a patch of revertant mosaicism 
creates a translational opportunity for revertant cell therapy that is personalised and 
patient-specific. The key advantage of this approach is that the cells are naturally 
corrected and therefore additional genetic manipulation should not be necessary. The first 
attempt at revertant cell therapy was reported in an individual with revertant mosaicism 
in junctional EB (Gostynski et al. 2009). Revertant keratinocytes from this patient were 
isolated, expanded into epidermal sheets and grafted onto a de-epidermised area of mutant 
skin. In culture, ~30% of keratinocytes displayed reversion but, for reasons unknown, 
fewer than 3% of the corrected cells persisted in the graft and thus clinically, the graft 
remained fragile and skin integrity did not improve. Nevertheless, punch grafting 
techniques have been used to successfully implant reverted skin into unreverted sites 
(Gostynski et al. 2014). 
  
 
The main determinant of the blistering phenotype in DEB is the absence or reduced 
expression of C7. Therefore, therapeutic approaches for direct administration of 
recombinant human C7 at the DEJ are also of interest. Studies of Col7a1 null mice that 
were treated with intradermal injections of recombinant human C7 successfully 
incorporated into the DEJ and improved the phenotype for up to 2 months (Woodley et 
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al. 2004a; Remington et al. 2009). This also translated to increased survival rate for DEB 
mice. Topical application of human recombinant C7 (rC7) accelerated wound healing 
(Wang et al. 2013) in mice and intravenously administered rC7 homed to engrafted 
RDEB mouse skin and restored C7, anchoring fibrils, and epidermal–dermal adherence 
(Hovnanian 2013; Woodley et al. 2013). Intravenous administration of rC7 in a 
spontaneous animal model of inbred Golden Retriever dogs with mild RDEB revealed no 
side effects and led to reduced wound erythema and blistering (Palazzi et al. 2000). 
However, the mechanisms of this process remain to be elucidated as well as the necessary 
amount of rC7 that is needed for the best and safest result, taking into account the potential 
for development of antibodies to C7 (Woodley et al. 2014). 
 
1.4.2.1 HMGB-1  
The high mobility group (HMG) proteins were discovered and isolated 40 years ago from 
calf thymus (Goodwin et al. 1973). They comprise three families: HMG-A, HMG-N and 
HMG box (HMGB) proteins. The HMGB family consists of the HMGB-1, HMGB-2, 
HMGB-3 and HMGB-4 members. HMGB-1-3 contain two DNA-binding domains 
(HMG boxes A and B). HMGB-1, also known as amphoterin, is most abundantly 
expressed and plays a key role in nuclear homeostasis, inflammatory response, tissue 
repair (Wang et al. 1999) and cancer (Sims et al. 2010; Tang et al. 2010; Andersson and 
Tracey 2011). It is primarily a DNA-binding nuclear protein, which is released actively 
during inflammatory responses and tissue repair as well as passively during cell death 
(Scaffidi et al. 2002; Bianchi 2004). Although predominantly located in the nucleus, 
HMGB-1 can also translocate to the cytoplasm, as well as the extracellular space via 
multiple pathways. There, HMGB-1 serves as a damage-associated molecular pattern 
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molecule (DAMP) or alarmin to trigger an immunological response to injury or 
inflammation (Oppenheim and Yang 2005; Andersson and Tracey 2011). This process 
occurs primarily, but not exclusively, by binding to the receptor for advanced glycation 
end product (RAGE) (Hori et al. 1995) and toll-like receptors (TLR) 2 and 4 (Park et al. 
2006; Riuzzi et al. 2006; van Beijnum et al. 2008). Quantitating HMGB-1 levels in 
biological fluids is key to exploring its role in physiological and pathological immune 
responses. As an alarmin, HMGB-1 has the capacity to drive pathogenesis in multiple 
inflammatory and immune-mediated systemic skin conditions where it can correlate with 
disease severity such as systemic lupus erythematosus, lupus nephritis (Popovic et al. 
2005; Jiang and Pisetsky 2008; Abdulahad et al. 2011; Ma et al. 2012; Zickert et al. 2012), 
primary Sjogren’s (Dupire et al. 2012) and toxic epidermal necrolysis (Nakajima et al. 
2011). In vasculitic diseases, levels of HMGB-1 might also serve as a marker of disease 
activity (Wibisono et al. 2010; Bruchfeld et al. 2011; Henes et al. 2011; de Souza et al. 
2013).  
Murine studies have shown that HMGB-1 is rapidly released from hypoxic keratinocytes 
(e.g. from free skin grafts or from within blister roofs) and that, when released into the 
circulation, HMGB-1 can mobilise reparative epithelial progenitor cells 
(Lin−/PDGFRα+) from within the MSC-BM population (Tamai et al. 2011). The in vivo 
mobilisation of these cells and the pathways implicated in that process are yet to be fully 
determined although there is preliminary evidence for this BM-skin repair axis (Iinuma 
et al. 2015). The same study identified blister fluid and serum as the main pools of 
HMGB-1 in three RDEB subjects (Tamai et al. 2011). 
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Several studies have suggested that anti-inflammatory antimicrobials may promote 
wound healing and decrease blister formation in patients with EBS (Fine and Eady 1999; 
Retief et al. 1999; Veien and Buus 2000; Weiner et al. 2004). A proof-of-concept study 
in RDEB showed improved wound healing with oral trimethoprim compared to placebo 
(Lara-Corrales et al. 2012) although further studies are required to prove potential benefit. 
Antisense-mediated modulation of splicing where an exon is skipped, in order to restore 
a disrupted reading frame, appears to have an application in selected DEB patients (Goto 
et al. 2006b). More recently, a case study of an individual with a severe form of JEB, with 
compound heterozygous nonsense mutations in LAMA3 (R943X/R1159X), was rescued 
by spontaneous read-through of the R943X allele, providing evidence that this 
phenomenon may lead to milder phenotypes than are usually associated with nonsense 
mutations (Pacho et al. 2011). The authors also investigated the effects of gentamycin on 
read-through of the termination codon (TAG) in that patient and found that read-through 
can be increased up to six-fold. An attempt to explore the potential of thymosin β4, to 
promote wound re-epithelialisation in EB was initiated in 2005, but unfortunately the 
study was terminated due to lack of subject recruitment (Fine 2007). Sulphoraphane, a 
compound found in broccoli, was found to reduce blistering in an EBS mouse model 
(Kerns et al. 2007). Reports of systemic granulocyte colony-stimulating factor (GCSF) 
(Fine et al. 2015), mycophenolate mofetil (El-Darouti et al. 2013), the tumour necrosis 
factor- α (TNF-α) inhibitor, Etanercept (Gubinelli et al. 2010), vitamin E (Ayres 1986) 
and chloroquine (Baer 1961) have shown variable therapeutic impact in DEB.  
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1.4.4.1 Fibroblasts and their role in wound healing 
After skin injury, several events are initiated including inflammation, granulation tissue 
formation, angiogenesis, tissue contraction and tissue remodelling (Clark 1989). Crucial 
to all of these events is the interaction of cells with the extracellular matrix (ECM). After 
a blood clot has formed during the inflammatory response, white blood cells invade the 
wound region by migrating through the ECM. Fibroblasts subsequently migrate into the 
region and begin to replace the blood clot with collagen. Fibroblasts biochemically alter 
the ECM by degrading the fibrin and producing collagen (Lorenz et al. 1992). While new 
tissue is being generated, endothelial cells migrate into the region forming new 
vasculature, angiogenesis. In the final phase of wound healing, the composition of the 
ECM is modified over a period of months, again with key roles by dermal fibroblasts. 
Five (not exclusive) mechanisms exist about ECM-fibroblast interactions: First, ECM 
structure influences fibroblast direction, a phenomenon known as ‘contact guidance’ 
(Clark et al. 1990); secondly, the ECM affects the speed of the fibroblast migration 
(Wojciak-Stothard et al. 1997); thirdly, the ECM alters the production of different 
proteins by the fibroblasts (Clark et al. 1995); fourthly, the ECM alters fibroblast 
behaviour, and finally enabling fibroblasts to organise the thin collagen fibrils into the 
fibrous structures more typical of unwounded dermis (Ehrlich and Krummel 1996). 
 
1.4.4.2 Topography and fibroblasts 
The skin is a prime example of an organ with clear spatial patterns of morphological and 
functional specialisation. For instance, it is remarkable that terminal hairs grow on top of 
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the head but not on the palm (Osterfield et al. 2003). Moreover, a large number of skin 
diseases show striking specificity for particular anatomical sites. Although fibroblasts 
from different anatomical sites are morphologically similar, it has been previously shown 
that fibroblasts from varying sites exhibit differences in their gene expression depending 
on the anatomic site of origin (Chang et al. 2002). For example, fibroblasts derived from 
palms and soles are different from those from other body sites in terms of KRT9 induction 
in non-palmoplantar keratinocytes (Yamaguchi et al. 1999). This observation was 
confirmed by others (Rinn et al. 2006), as well as in observations that adult fibroblasts 
retained features of the embryonic HOX code, the spatial pattern of expression of a family 
of transcription factors that delineate positional identity (Rinn et al. 2008). The expression 
pattern of HOX genes in skin fibroblasts is systematically related to their anatomical site 
of origin. Fibroblasts from different anatomical sites may even be considered distinct cell 
types because their gene expression programmes are as diverse as cells from different 
haematopoietic lineages (Rinn et al. 2006). Cells more closely located to each other are 
more likely to have shared local interactions, and therefore may have greater similarity to 
each other in gene expression. For instance, cells from the hand and feet may share a 
distinct gene expression signature that reflects their spatial position on distal limbs even 
though these two body parts are spatially far apart. Positional identity is also essential 
during wound healing and regeneration. In regenerative therapies based on stem cells, 
fibroblasts may play similar instructional roles by providing the appropriate stem cell 
niche for stem cell differentiation (Watt and Hogan 2000). As well as regional differences 
in fibroblasts, different populations of fibroblasts have been detected in the papillary and 
reticular dermis (Driskell et al 2013). Papillary dermal fibroblasts have been implicated 
in hair regeneration while reticular dermal fibroblasts have a more prominent role in 
wound healing and scarring. 
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1.4.4.3 Autologous vs allogeneic fibroblasts 
Fibroblasts used in tissue engineering may be allogeneic or autologous. In contrast to 
allogeneic cells, autologous fibroblasts carry no risk of rejection or risk of cross-infection. 
However, there is often a delay in culturing autologous cells in order to obtain sufficient 
cell numbers, whereas allogeneic cells can be cryopreserved and therefore are more 
readily available. There have also been several studies investigating the immunological 
impact of allogeneic cells on the recipient. One study looked at the persistence of 
allogeneic fibroblasts in an acute wound (porcine model) and found that after 1 week, 
allogeneic fibroblasts were not detectable by polymerase chain reaction (Price et al. 
2004). Apligraf® (Novartis, Basel, Switzerland) is a living skin substitute composed of 
allogeneic keratinocytes and allogeneic fibroblasts and its application in acute human 
wounds showed that neither foreign cell population was detectable beyond 6 weeks 
(Griffiths et al. 2004). It has therefore been suggested that allogeneic cells are eventually 
silently replaced by host cells. In addition, large trials involving grafting of allogeneic 
skin equivalents onto venous ulcers did not reveal evidence of rejection clinically or 
immunologically in the patients (Falanga et al. 1998). The ideal commercial cellular 
therapy is pre-prepared, allogeneic, off-the-shelf, easy to store and deliver.  
 
1.4.4.4 Murine studies of fibroblast cell therapy for EB 
Several murine studies have focused on developing cell therapies for RDEB. C7 is 
synthesised and secreted by basal keratinocytes and by dermal fibroblasts (Stanley et al. 
1985; Regauer et al. 1990; Woodley et al. 2003; Goto et al. 2006a; Ito et al. 2009), and 
given that fibroblasts are much easier to isolate and maintain in culture than keratinocytes, 
fibroblasts present an attractive target for cell-based therapies in RDEB mouse models. 
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Wild type and COL7A1 gene-corrected human RDEB fibroblasts overexpressing C7 have 
been injected intradermally into immunodeficient mouse skin or into transplanted human 
RDEB skin equivalents (Ortiz-Urda et al. 2003; Woodley et al. 2003). Both these 
interventions led to sustained human C7 deposition and new anchoring fibril formation at 
the DEJ. It was also shown that intradermal injections of wild-type fibroblasts, i.e. without 
COL7A1 correction, could correct the RDEB skin pathology, but only when injected at 
sufficient cell density, i.e., 5 × 106 cells versus 1 × 106 cells (Ortiz-Urda et al. 2003; 
Woodley et al. 2003). Increase in C7 at the DEJ after intradermal injections of wild-type 
human fibroblasts was also confirmed in studies using a hypomorphic c7 mouse model 
of RDEB that expresses c7 at ~10% of normal levels (Fritsch et al. 2008; Kern et al. 
2009). Moreover, intravenously injected wild-type or COL7A1 gene-corrected human 
RDEB fibroblasts could home to wounded mouse skin and improve wound healing 
(Woodley et al. 2007). Collectively, these murine studies provide a rationale for the use 
of allogeneic wild-type or COL7A1 gene-corrected fibroblasts in humans with RDEB. 
 
1.4.4.5 Mode of action of allogeneic fibroblast cell therapy in DEB 
Transcriptomic analysis of serial skin biopsies following injection of allogeneic 
fibroblasts in one subject with RDEB revealed that expression of HBEGF was 
upregulated and that expression levels mirrored those seen for COL7A1 (Nagy et al. 
2011). In vitro studies showed that HB-EGF could upregulate COL7A1 expression in both 
normal control and RDEB keratinocytes and fibroblasts and that this was preceded by 
increased expression of JUN and FOS, components of the AP1 transcription factor that is 
known to bind to and upregulate COL7A1. The interpretation of the in vivo situation was 
that allogeneic fibroblasts were able to induce upregulation of HBEGF, predominantly in 
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neighbouring keratinocytes. The HB-EGF could then lead to a sustained increased in C7 
by acting in an autocrine, paracrine and juxtacrine manner to upregulate COL7A1. The 
new C7 was thought to be predominantly recipient-derived, i.e. mutant but partially 
functional. A slight increase in HBEGF and COL7A1 expression was also noted after 
injection of saline into skin, although upregulation was less marked than following 
fibroblast injection and was for a shorter duration. It is possible that saline induces an 
irritant reaction associated with a relatively milder upregulation of similar growth factors 
and cellular responses to fibroblasts. It is also plausible that the donor fibroblasts can 
release wild-type full length C7 for incorporation into the DEJ during the time (few days) 
the cells are present in the RDEB skin. Evidence for this “direct release” theory is 
supported by studies in mice (Kern et al. 2009), although both mechanisms are not 
mutually exclusive. Although often thought as differentiated somatic cells, cultured skin 
fibroblasts may also contain a sub-population of cells with stem cell properties, capable 
of differentiation into mesoderm, endoderm and ectoderm. Termed MUSE (multilineage-
differentiating stress-enduring) cells, these cells are also found in the skin, bone marrow 
and umbilical cord (Wakao et al. 2011; Liao et al. 2014). 
 
1.4.4.6 Fibroblast cell therapy in DEB 
Initial studies of allogeneic fibroblast injections in RDEB focused on responses at the 
DEJ in intact skin. However, the major clinical burden in affected individuals is poor 
wound healing. The putative upregulation of HBEGF (Iwamoto and Mekada 2000) 
following allogeneic fibroblast injection (Nagy et al. 2011) may have benefits for wound 
healing beyond upregulation of C7, given that HB-EGF has been shown to promote 
keratinocyte migration (Shirakata et al. 2005). However, one caveat may be the effects 
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of HB-EGF on epidermal growth factor receptor (EGFR) signalling and the risk of 
malignancy (Zenz et al. 2003; Kivisaari et al. 2010). Given that individuals with RDEB 
have an increased incidence of squamous cell carcinoma, especially in chronic wounds 
(McGrath et al. 1992b; Pourreyron et al. 2007; Tsukada et al. 2012), further safety 
monitoring of allogeneic fibroblasts injected into RDEB wounds was required. At the 
bedside, allogeneic fibroblasts have been used off-licence to treat a number of patients 
with RDEB (McGrath and Almaani unpublished data). The clinical impression and 
experience indicates that for a subgroup of individuals with RDEB, notably those with 
mild to moderate disease severity and some baseline expression of C7 at the DEJ, 
allogeneic fibroblast therapy may be useful clinically, in contrast to those individuals with 
more severe disease that lack C7. For the latter individuals, alternative cell therapy or 
other strategic approaches that target stem cell correction may be more appropriate. 
 
1.4.4.7 First-in-human study of allogeneic fibroblasts in RDEB 
Based on the mouse data, a proof-of-concept study in 5 RDEB individuals demonstrated 
that a single intradermal injection of allogeneic fibroblasts (5 x 106 cells injected into the 
superficial dermis over a ~1cm2 area) increased COL7A1 expression for at least 3 months 
(the end point of that study) in most individuals (Wong et al. 2008). The study also 
demonstrated the low immunogenicity of allogeneic fibroblasts and lack of host response 
at an immunological and histological level. The injected cells were not detectable at 2 
weeks post-injection, the time-point at which an increase in C7 protein at the DEJ was 
seen. Of note, the increase in C7 was most apparent in RDEB individuals who had some 
baseline expression of C7 compared to those who had a complete absence of the protein. 
However, the increase in C7 was not accompanied by the formation of new, normal-
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appearing anchoring fibrils: there was an increase in the number of fibrillar structures 
below the lamina densa of the basement membrane but these were somewhat wispy and 
lacked characteristic ultrastructural features of mature anchoring fibrils. Nevertheless, 
there was some subjective evidence for increased epidermal-dermal adhesion following 
the allogeneic fibroblast injections (Wong et al. 2008). The increase in COL7A1 and C7 
protein expression beyond the physical presence of the injected allogeneic cells, however, 
were thought to be due to a paracrine effect induced by the fibroblasts. A subsequent 
study was able to show that a single injection of allogeneic fibroblasts could increase 
COL7A1 expression for 3-6 months and C7 protein for 9-12 months (Nagy et al. 2011). 
That study also identified that the paracrine effect was probably mediated by HB-EGF 
(Nagy et al 2011).  
 
 
BM stem cells have a fundamental role in generating erythrocytes, leukocytes and 
platelets, but also demonstrate plasticity in being able to show lineage differentiation into 
tissues of mesodermal, endodermal, and ectodermal origin, including skin (Grove et al. 
2004). Some sub-populations of BM cells can differentiate into keratinocytes (Badiavas 
et al. 2003; Badiavas and Falanga 2003; Borue et al. 2004; Fathke et al. 2004), and in 
humans who have undergone BMT, donor cells that have differentiated into keratinocytes 
can be detected in the epidermis for at least 3 years (Korbling et al. 2002). Further studies 
have shown that the BM is also a source of fibroblast-like cells in the dermis (of 
haematopoietic and mesenchymal lineages) and that the number of these cells increases 
after skin wounding (Fathke et al. 2004; Ishii et al. 2005; Sasaki et al. 2008; Yew et al. 
2011; Tamama and Kerpedjieva 2012). BM cells also contribute to skin development: 
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infusion of BM cells in utero in mice leads to accumulation of a sub-population of these 
cells in the dermis, particularly around developing hair follicles (Chino et al. 2008). 
Overall, however, BM-derived keratinocytes appear to be an extremely rare finding, 
perhaps contributing only ~0.0001–0.0003% of all cells in the new epidermis (Tamai et 
al. 2011; Iinuma et al. 2015). The physiological role of BM cells in epithelial regeneration 
therefore has been questioned, although recent studies focusing on RDEB have started to 
provide new insight into key BM cells and mechanisms germane to skin repair and 
regeneration.  
 
1.4.5.1 Murine studies of bone marrow cells and skin repair 
Initial attempts to use BM cells to correct the inherent skin fragility of RDEB were made 
in the hypomorphic col7a1 knockout mouse that recapitulates some of the features of the 
human disease (Heinonen et al. 1999; Tolar et al. 2009). Murine studies were undertaken 
to explore the skin-bone marrow repair mechanisms, relevant to correcting the C7 
deficiency in RDEB (Tolar et al. 2009). First, congenic (inbred mouse strains) wild-type 
bone marrow cells were given to col7a1 deficient mice and it was shown that a bone 
marrow subpopulation (CD150+ CD48–) migrated to injured skin and secreted C7 with 
partial anchoring fibril restoration (Tolar et al. 2009). Non-manipulated BM cells failed 
to rescue the RDEB mice but alternative use of the signalling lymphocyte activating 
molecule (SLAM)-positive subpopulation of BM cells resulted in new C7 and presence 
of donor cells at the DEJ. Following infusion of SLAM-positive BM cells, there was 
improved healing of blisters on the mouth, paws and histological evidence of rudimentary 
anchoring fibril formation (Tolar et al. 2009). This functional correction of C7 in a mouse 
model of RDEB, alongside other supportive data that identified potential keratinocyte 
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progenitors within the mesenchymal stem cell (MSC) population (Chino et al. 2008), led 
to the first human BMT trial in children with severe RDEB, discussed in Section 1.4.5.3. 
Other studies have also shown correction of RDEB skin defects with BM cells, that can 
occur after in utero infusion of BM cells (Chino et al. 2008), and that BM-derived MSCs 
can stimulate secretion of C7 with partial restoration of the damaged BMZ and less blister 
formation (Alexeev et al. 2011). In a different mouse that lacks type XVII collagen, a 
model for junctional EB-GI, both haematopoietic and non-haematopoietic BM stem cells 
have been shown to correct basement membrane protein expression and lead to 
phenotypic rescue (Fujita et al. 2010). Collectively, these murine studies provide a 
scientific rationale for translation of BM cell therapies into human clinical trials. 
Moreover, several additional mouse models for different forms of EB have been 
developed that may also be useful for assessing BM cell therapy, including the 
hypomorphic c7 mouse (Fritsch et al. 2008) and a hypomorphic model for junctional EB-
GI with spontaneous mutations in the Lamc2 gene (Bubier et al. 2010).  
 
1.4.5.2 Epithelial progenitors within sub-populations of bone marrow stem cells 
A recent study has confirmed that BM contains a specific population of epithelial 
progenitors and that these are mobilised and recruited by specific key factors (Tamai et 
al. 2011). Tamai et al. (2011) used an irradiated mouse model in which green fluorescent 
protein-labelled BMT was performed. Skin grafting in this mouse showed that BM-
derived keratinocytes are not of haematopoietic origin but instead are derived from a 
specific subpopulation of Lineage negative, platelet-derived growth factor receptor alpha-
positive (Lin-/PDGFRα+) BM cells. This is still a somewhat heterogeneous cell 
population that represents ~1 in 450 BM cells. Indeed, these cells may show lineage 
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overlap with other defined subpopulations of mesenchymal stromal cells (MSCs), 
including multi-potent adult progenitor cells, Lin-/SCAR1+/CD45- very small 
embryonic-like stem cells in BM, CD45- unrestricted somatic cell stems in cord blood, 
and nestin-positive cells that maintain the stem cell niche with haematopoietic stem cells 
in BM (Kucia et al. 2006; Morikawa et al. 2009).  
The study by Tamai et al. (2011) proposed that the skin graft acts as a hypoxic bioreactor, 
rapidly releasing the non-histone nuclear protein, high mobility group box-1 (HMGB-1). 
Following skin grafting, HMGB-1 levels in serum increased and HMGB-1 was shown to 
mobilise the Lin-/PDGFRα+ cells from the BM and recruit these cells along concentration 
gradient to the area of hypoxic keratinocytes. Differentiation of these cells into 
keratinocytes was clearly demonstrated. These cells were also shown to persist in the skin 
after several renewals of the murine epidermis, data which support engraftment of a 
murine BM population that has generated keratinocyte stem cells. The study also showed 
that in RDEB the main source of HMGB-1 was hypoxic keratinocytes in blister roofs. 
Moreover, when col7a1 -/- murine skin was grafted, new c7 protein was expressed in the 
grafted skin, co-localising with the GFP +ve Lin-/PDGFRα+ cells. 
 
1.4.5.3 First BMT in RDEB 
Following the effectiveness of BM stem cells in murine RDEB, a clinical trial of whole 
BMT was performed in children with RDEB (Wagner et al. 2010). The approach used 
high dose chemotherapy to immunoablate individuals with RDEB to permit more reliable 
lymphohaematopoietic engraftment. The BM was not filtered so that all the 
haematogenous populations could be preserved, allowing for the possibility that non-
haematopoietic MSC populations might also be needed for clinical benefits. Seven 
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patients entered the trial and 6 underwent BMT. All individuals had some clinical 
improvement and 5 of the 6 showed increased C7 at the DEJ. So far, only the results for 
the first seven patients have been reported in the scientific literature (Wagner et al. 2010). 
This first clinical trial of BMT for RDEB showed that donor cells homed to injured skin, 
C7 expression increased, anchoring fibrils gradually appeared and the response was 
sustained for many years after (current longest follow up is for 8 years, Jakub Tolar, 
personal communication). 
Before the BMT, each individual had more than 50% of their skin covered with blisters 
and erosions. Three of the 6 individuals showed dramatic clinical improvement, such that 
less than 10% of the body surface area remained affected. In the other 3 subjects, there 
was a moderate improvement with less than 25% of the body surface area affected. 
Despite the clinical improvement some toxicity was noted. One patient died before the 
BMT because of heart failure, possibly related to cyclophosphamide toxicity and pre-
existing renal failure. Another individual died 6 months after transplantation due to 
infection secondary to graft failure. To try to reduce morbidity and mortality, additional 
protocols have been developed to use reduced intensity conditioning rather than full 
myeloablation. Modifications to the original protocol, such as the additional subsequent 
infusion of MSCs from the original donor, have also been adopted.  
 
1.4.5.4 Mode of action of BMT in skin repair 
The precise mode of action of BMT leading to clinicopathological improvement in RDEB 
is not known. High levels of chimerism (donor and recipient cells) were noted in the skin 
after BMT, with donor non-haematopoietic cells being the probable source of new C7 at 
the DEJ (Tolar and Wagner 2013a). Notably, although there were some haematopoietic 
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cells in the skin (CD45+), the majority were non-haematopoietic, non-endothelial cells 
(CD45-, CD31-) (Tolar and Wagner 2013a). In spite of the increased C7, however, there 
was a lack of normal anchoring fibrils on transmission electron microscopy. Although the 
lack of these adhesion structures may relate to gradual maturation of new anchoring fibrils 
(as has been observed for several months following burns) (Compton et al. 1989), it is 
plausible that some of the increased C7 may reflect an upregulation of mutant but partially 
functional endogenous C7, similar to the proposed mode of action for allogeneic 
fibroblast therapy (Nagy et al. 2011). Clearly, however, there is more to the reparative 
story in that the transplanted RDEB individual who did not show any increase in C7, also 
showed a sustained clinical response in skin healing and integrity at the DEJ. This may 
indicate the incorporation or availability of additional extracellular matrix proteins that 
can contribute to better skin repair and adhesion, although such a possibility remains 
speculative. Functional improvement in skin adhesion in patients following BMT was 
shown by progressive increase in suction blister times (the time it takes to form a blister 
following placing a negative pressure suction cup on the skin surface) (Wagner et al. 
2010; Tolar and Wagner 2013a). Although the mode of action of BMT in skin repair in 
EB continues to be investigated, current clinical data provide evidence for a sustained 
functional improvement in the majority of patients. 
 
1.4.5.5 Mesenchymal stromal cells  
MSCs are multipotent stem cells that can be found in the bone marrow, skeletal muscle, 
adipose tissue, synovial membranes, dental pulp, periodontal ligaments, cervical tissue, 
menstrual blood, Wharton's jelly, umbilical cord, umbilical cord blood, amniotic fluid, 
placenta, and fetal tissues (Montesinos et al. 2009; Najar et al. 2010). MSCs are of non-
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haematopoietic lineage that are present in tiny quantities in the circulation (1 in every 104 
nucleated cells). MSCs have been shown to differentiate into a number of different cell 
types of stromal lineage including skin cells, osteoblasts, adipocytes and chondrocytes. 
Despite functional heterogeneity, MSCs express similar panels of markers. The 
Mesenchymal and Tissue Stem Cell Committee of the International Society for cellular 
Therapy has proposed four criteria for the determination of MSCs. These include: 1) the 
plastic adherence of isolated cells in culture, 2) the expression of CD105, CD73 and CD90 
in more than 95% of cultured cells, 3) lack of expression of haematopoietic cell markers 
including CD34, CD45, CD14 or CD11b, CD79a or CD19 and HLA-DR in more than 
95% of the cultured cells and 4) the capacity to differentiate into osteoblasts, adipocytes 
and chondroblasts in vitro (Dominici et al. 2006).  
One of the reasons favouring clinical application of MSCs is their low immunogenicity 
and lack of requirement for pre-conditioning (Le Blanc et al. 2003a; Le Blanc et al. 
2003b). Adult human MSCs are reported to express intermediate levels of major 
histocompatibility complex (MHC) class I antigens but do not express human leukocyte 
antigen (HLA) class II antigens on the cell surface (Le Blanc et al. 2003a). Therefore, 
they are unlikely to be rejected or cause graft versus host disease. Cultured MSCs are 
known to exert beneficial effects on wound healing via a number of mechanisms in vitro 
(Kim et al. 2009; Walter et al. 2010; Yoon et al. 2010). The effects go beyond 
differentiation into the cells of the damaged tissue (i.e. direct cellular tissue repair), as 
they have shown not only to have an immunomodulatory effect both in vitro and in vivo, 
but also to have trophic effects through the release of various growth factors and cytokines 
with both paracrine and autocrine functions (Prockop 2009). These factors can inhibit 
fibrosis and apoptosis, enhance angiogenesis and stimulate mitosis. Therefore, permanent 
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engraftment of MSCs is not a prerequisite for therapeutic benefit. In fact, it has become 
increasingly clear that transient engraftment or delivery of MSCs can exert a favourable 
effect through secretion of cytokines and paracrine factors which engage and recruit some 
of the recipient’s own cells towards tissue repair.  
Allogeneic MSCs, have also anti-inflammatory properties. MSCs can home to damaged 
tissue and release various immunomodulatory factors that influence the behaviour of 
dendritic cells, T-cells and natural killer cells. MSCs can reduce B-cell proliferation, 
monocyte maturation, secretion of IFN-γ and TNF-α while promoting induction of T-
regulatory cells and secretion of anti-inflammatory IL-10 from macrophages in direct 
contact with MSCs (Wang et al. 2008). Although the precise micro-environmental 
contributions to tissue repair are not fully known, a more detailed understanding of the 
trophic mechanisms associated with MSCs in tissue regeneration is likely to lead to 
further exploration of their clinical utility. In general, whatever immune conditioning or 
cell population is being planned for use as cell therapy, for diseases such as EB, it is 
evident that treatment that is both systemic and given at an early age is likely to have most 
clinical benefit, certainly for patients with widespread disease. 
 
1.4.5.6 First-in-man studies of mesenchymal stromal cell therapy in DEB 
In RDEB animal models it had been shown that MSCs contribute to skin regeneration 
and accelerate wound healing. Non-tissue matched intradermal human 0.5 x 106 
allogeneic MSCs or vehicle were injected intradermally in two individuals with RDEB 
(Conget et al. 2010). C7 replenishment was confirmed at 12 weeks as well as improved 
wound healing at the MSCs injected wound; with the clinical effects lasting for up to 4 
months. No adverse effects were noted in the injected skin or systemically. Successful 
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topical use of BM cells to heal chronic wounds in other diseases has been previously 
reported (Badiavas and Falanga 2003; Humpert et al. 2005; Falanga et al. 2007), but 




Cord blood (CB) and other parts of the umbilical cord, such as the Wharton’s jelly or 
tissues associated with the placenta, are also rich sources of stem cells. As well as 
haematopoietic stem cells, CB is an important source of other progenitor cells, as well as 
MSCs, of very small embryonic/epiblast -like stem cells and unrestricted somatic stem 
cells, which may have individual or collective value in regenerative medicine. Using 
some stem cell populations, notably the MSCs, a number of clinical studies have been 
initiated, mostly to repair tissue, including some studies on skin. The first transplant in 
humans using CB was reported in 1989 with the use of HLA-matched sibling to treat 
Fanconi anaemia (Gluckman et al. 1989). Subsequently, CB banks were established for 
the collection and cryopreservation of cells and more than 20,000 CB transplants have 
been carried out worldwide. MSCs from CB are similar to BM-derived MSCs in having 
low immunogenicity and are already being used in several regenerative medicine studies. 
That said, comparison of UC cells versus BM stem cells in individuals with RDEB has 
shown better skin engraftment with a BM-derived population (Tolar et al. 2012) and 
therefore the clinical utility of cord cells in EB remains to be determined in future clinical 
trials. Preclinical data, however, have shown that unrestricted somatic stem cells can 
express c7 and accelerate wound healing, improve wound healing and form new skin 
appendages (Liao et al. 2014).  
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1.5 Research aims and objectives 
Allogeneic fibroblasts have been injected previously into the skin of individuals with 
RDEB and have shown potential in COL7A1 upregulation and C7 increase at the DEJ in 
intact skin. At the start of this thesis work in 2010, there had been no published reports 
on the effects of allogeneic fibroblasts on wound healing in RDEB. The precise 
mechanism through which allogeneic fibroblasts may have a beneficial impact on RDEB 
had not been fully characterised. Moreover, therapeutic use of BM-MSCs in RDEB had 
not been tested beyond the initial studies in two patients (Conget et al., 2010).  
The key therapeutic objectives of cell therapy for RDEB must be to improve wound 
healing as well as to improve overall health, given that RDEB as a systemic disease that 
might benefit from early use of systemically delivered therapies.  
The primary aim of this work described in this thesis was to assess the safety and efficacy 
of allogeneic fibroblasts and BM-MSCs in wound healing in adults and children with 
RDEB. It also aimed to assess the feasibility of such treatments in the context of well-
designed clinical trials and translation of the results in the routine clinical setting. The 
work comprises functional studies on the potential mechanism of allogeneic fibroblasts 
in RDEB, as well as two completed early phase clinical trials, one of intradermal 
allogeneic fibroblasts in RDEB wounds in adults, and the other of intravenous allogeneic 
MSCs in children with RDEB. 
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The first hypothesis is that intradermal allogeneic fibroblasts can enhance wound healing 
in RDEB.  
The second hypothesis is that intradermally injected allogeneic fibroblasts enhance 
wound healing by increasing the expression of HBEGF and COL7A1 expression and in 
individuals with RDEB. HB-EGF and EGF cytokines can increase C7 and 
The third hypothesis is that, BM-MSCs, when delivered systemically, have a potential 
therapeutic and anti-inflammatory effect that can improve wound healing and quality of 
life in children with RDEB.  
 
 
 To ascertain whether intradermal injections of allogeneic fibroblasts around 
wound margins in vivo result in HBEGF, COL7A1 upregulation and C7 
production. To investigate the optimal dose and time-points at which recombinant 
growth factors HB-EGF and EGF have the largest effect on COL7A1 expression 
in vitro. 
 To study the wound healing rate of chronic wounds after injections of allogeneic 
fibroblasts or vehicle in the context of a prospective, phase II, randomised and 
blinded clinical trial.    
 To assess the safety and efficacy of systemic allogeneic BM-MSCs in children 
with RDEB in the context of an open label clinical trial. 
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2                                                            MATERIALS AND METHODS 
2.1 Research Ethics  
Clinical trial specific regulatory approvals are mentioned in the relevant chapters. The 
mechanistic studies were performed using research ethics approval by Guy’s Research 
Ethics Committee, Guy’s and St Thomas’ NHS Trust (Characterisation of molecular and 
structural skin abnormalities in inherited skin disorders, Ref: 07/H0802/104). For 
experiments with skin samples from healthy volunteers an informed consent form for 
‘discarded skin’ was used (Immunopathogenesis of Psoriasis/Inflammatory Skin Disease, 
Ref: 06/Q0704/18). Written informed consent was obtained from all patients and healthy 
volunteers.  
 
2.2 Laboratory techniques 
 
2.2.1.1 Isolation of primary keratinocytes from skin biopsies 
Skin punch biopsy specimens were transported in Dulbecco’s modified Eagle’s medium 
(DMEM) (Invitrogen, Paisley, UK) and 10% fetal bovine serum (FBS) (Invitrogen) and 
stored at 4oC for up to 24 hours. Before starting the isolation, a 60 mm Culture dish was 
coated with 1.7 mls of coating matrix and 17 µl of dilution medium (Invitrogen) and 
incubated for 30 minutes at room temperature (RT). The residual coating matrix was 
removed and the coated dishes could be stored at 4oC for several days. Each biopsy 
specimen was placed in an uncoated 100 mm bacterial petri dish and kept moist with 
some medium. The subcutaneous fat and any loose connective tissue were removed using 
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tweezers and a scalpel until only the thin epidermis and the dermis remained. Depending 
on the biopsy size, samples were cut in smaller pieces. The pieces were placed in a 15 ml 
falcon tube with 10 mls of dispase 2 (Stemcell Technologies, Grenoble, France) and 
stored at 4oC overnight. The overnight digested tissue pieces were processed further by 
holding the edge of the dermal part of the tissue with one set of tweezers and the thin 
epidermal part with another set of tweezers and the epidermis was slowly peeled off. The 
epidermis was transferred into another dish with Epilife medium (Invitrogen) with S7 
supplement (Invitrogen). The dermis was preserved for fibroblast isolation, as described 
in Section 2.2.1.2. The epidermis was cut using a sterile scalpel into small pieces. The 
pieces were placed in a falcon tube containing 15-20 mls TrypLE express (Invitrogen). 
The samples were incubated at 37oC for 20 minutes in a shaker or in a tube with gentle 
manual mixing every 5 minutes. An equivalent amount (15-20 mls) of DMEM with 10% 
FBS was then added to the above mix and pipetted vigorously up and down to inactivate 
the trypsin. The solution was passed through a 100 µm mesh filter into a new 50 mls 
falcon tube to remove undigested pieces of tissue. The mixture was centrifuged at 1500 
RPM for 5 minutes. The supernatant was removed and the pellet was resuspended in 5 
mls Epilife medium. The keratinocytes were subsequently seeded out in 5 mls Epilife for 
each 60 mm bacterial culture dish and 50 μl (1/100 of the medium volume) of 10,000 
units penicillin, 10,000 g streptomycin and 25 g amphotericin B/ml (Invitrogen) was 
added. The culture dishes were stored at 37oC and 5% CO2. The medium was changed 
the next day and subsequently every 3 days paying close attention to cell density. 
Adherent cells could be seen in 2-3 days.  
 
P a g e  76 | 275 
 
2.2.1.2 Isolation of primary fibroblasts from skin biopsies 
The above steps were followed until the separation of the dermis and epidermis. After the 
separation, the dermis was placed in DMEM culture medium with 10% FBS. Using sterile 
forceps and a scalpel, the dermis was cut into 1.0 mm3 pieces. Each piece was dried out 
slightly with circular movements on a dry culture dish and placed directly on a 100 mm 
culture dish, whose base was previously scraped with a scalpel to assist cell adherence. 
Up to 10 pieces were placed in each 100 mm dish. The pieces were left to dry, but not 
completely, for a few minutes and then gently, 12-15 mls of DMEM with 10% FBS was 
added, as well as 1/100 of this volume of 10,000 units penicillin, 10,000 g streptomycin 
and 25 g amphotericin B/ml and stored in a 37oC with 5% CO2 incubator. The cell 
medium was replaced with fresh medium every 5 days and growth was seen within 10-
14 days.  
 
2.2.1.3 Maintenance and passage of cells 
Primary cell cultures were maintained by changing growth media three times per week 
for fibroblasts and every two days for keratinocytes on average. When culture dishes 
reached 80-90% confluence, the cells were passaged. A cell suspension was obtained 
following incubation for 10 minutes in 5 ml of trypsin. An equivalent volume of culture 
medium containing 10% FBS was added to neutralise trypsin activity and the mixture 
was centrifuged at 1000 RPM for 5 minutes. The filtrate was discarded by inversion and 
the cell pellet was re-suspended in fresh culture media. Cells were re-plated onto new 
bacterial culture dishes using a split ratio of 1:4 as the seeding density.  
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2.2.1.4 Cryopreservation and recovery of cells 
A cell suspension was obtained and subsequently re-suspended in 10% FBS/Dimethyl 
sulphoxide (DMSO) (Fisher Scientific, Leicestershire, UK) in 1.2 ml cryovials. The cells 
were frozen down initially at -80oC overnight in a freezing container ‘Mr Frosty’ (Fisher 
Scientific) and then transferred to liquid nitrogen for long term storage. Cell s were 
recovered by thawing in a 37oC water bath. The mixture was centrifuged at 1000 RPM 
for 5 minutes, re-suspended in fresh culture medium and re-plated in a bacterial culture 
dish. 
 
2.2.1.5 Prevention and testing for infection 
To prevent contamination of cultured epidermal cells by infection, the cells were 
maintained in a good laboratory practice (GLP) facility and cultures in dedicated class II 
hoods. All surfaces were carefully disinfected with Virkon (Antec International, Suffolk, 
UK); disposable sterile equipment was used and solutions containing antibiotics prior to 
use. Mycoplasma testing of cell cultures was performed periodically (Figure 2.1). To do 
this, cells were centrifuged at 1500 RPM and 1ml of supernatant was removed for testing. 
The supernatant was centrifuged at maximum speed for 30 minutes and the majority of 
the supernatant was removed leaving the pellet ~ 20 μl. The pellet was re-suspended in 
50 μl of TE buffer (10Mm Tris-HCL with 1mM EDTA) with 20 μl proteinase K. The 
samples were incubated for 1 hour at 55oC and the enzyme deactivated at 98-100oC for 
10 minutes using dry heating blocks. The PCR mix was prepared using 2.5 μl 10x buffer, 
1 μl 2mM dNTPs, 0.125 μl Taq polymerase, 13.875 μl nuclease-free H2O and 1.25 μl 
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forward and reverse primers per reaction. The following primer pair was used (van 
Kuppeveld et al. 1992).  
Forward (GPO-3): 5’GGGAGCAAACAGGATTAGATACCCT-3’  
Reverse (MGSO): 5’-TGCACCATCTGTCACTCTGTTAACCTC-3’ 
A GeneAmp PCR System 9700 thermal cycler (Applied Biosystems, Warrington, 
Cheshire, UK) was used. The amplification conditions were 94oC for 1 minute, 55 oC for 
1 minute and 72oC for 1 minute for a total of 35 cycles.  
 
Figure 2.1 PCR testing for mycoplasma contamination. 
Supernatants from 4 different primary cell cultures were subjected to the same sample preparation and PCR 
amplification of each sample were run with the primers mentioned in the text (Lanes 2-5 inclusive). The size of the 
Mycoplasma hominis target amplicon (Lane 7) corresponds to the 270bp band represented by the provided hyperladder 
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Normal human dermal fibroblasts and epidermal keratinocytes were isolated from 6mm 
punch skin biopsies, as described previously in Sections 2.2.1.1 and 2.2.1.2. The skin 
originated from discarded skin of healthy individuals undergoing plastic or reconstructive 
surgery. For the experiments, first and second-passage fibroblasts and keratinocytes were 
plated in 100 mm bacterial culture dishes. Subsequently cells were plated at 30,000 
cells/well into 12-well plates. After being plated, fibroblasts were maintained in DMEM 
containing 10% FBS for 24 hours, then media was changed to DMEM with 1% FBS to 
slow growth on day two and media was changed to DMEM without FBS for two hours 
prior each growth factor stimulation. Keratinocytes were maintained in Epilife with S7 
supplement for two days prior the experiment and media was changed to Epilife without 
supplement S7 two hours prior growth factor stimulation. One, 10 and 100 ng/ml of 
rhHB-EGF and EGF were added to the cells (Recombinant growth factors listed in Table 
2.1). Well duplicates were used for each growth factor dose and time-point, including 
untreated cells. Samples were collected 15, 90 and 180 minutes after the application of 
HB-EGF and EGF. Quantitative real-time PCR was performed with RNA isolated at the 
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Table 2.1 Human recombinant growth factors.  
Human recombinant  
growth factors 
Supplier Catalogue number 
HB-EGF R&D systems 259-HE 
EGF Sigma-Aldrich E9644 
 
Skin biopsy specimens were placed in RNAlater (Ambion, Austin, TX). The samples 
were stored overnight at 4oC and then stored at -20oC until processing.   
 
2.2.3.1 Tissue disruption 
All samples were processed using a polytron homogeniser (Fisher Scientific). A 
maximum of four samples were processed at one time to minimise RNA degradation. 
Initially, three round bottom 14 mls tubes were prepared, one with 1 ml 1% SDS, one 
with 1 ml 100% ethanol, and one with 4 mls dH2O. The polytron was washed in each tube 
in that sequence and the last wash was always dH2O. One ml lysis buffer was added in an 
extra round bottom 14mls tube. The RNAlater with the skin biopsy was emptied into a 
sterile culture dish and the skin biopsy gently wiped dry with paper. Potential technical 
problems arose when the small biopsy specimens became lodged within the homogeniser 
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probe. This problem was minimised by cutting the 4mm diameter biopsy in 4-5 pieces 
prior to the addition of lysis buffer. The tube containing the skin sample and lysis buffer 
were kept on ice at all times. The polytron was used to homogenise the samples and 
overheating was avoided by turning it off every 10-15 seconds. Between samples the 
probe was rinsed three times as described above (in 1% SDS, 100% ethanol and dH2O) 
to avoid cross contamination. 
 
2.2.3.2 Cell membrane disruption 
The culture media was removed from the culture dishes and the cells were washed with 
PBS. For a 12-well plate 300 µl of lysis buffer were used per well. After 2-3 minutes, the 
mixture was pipetted up and down a couple of times and then collected in an eppendorf 
and kept on ice.  
 
2.2.3.3 RNA extraction 
RNA extraction was performed using the Ambion® mirVanaTM miRNA isolation kit 
(Life Technologies, Paisley, UK). The bench was cleaned with RNase zap (Invitrogen), 
70% ethanol and dH2O, in that order. The samples were kept on ice. MiRNA homogenate 
additive was added at 1/10th of the lysate volume (around 400 μl) and mixed by vortexing 
the tube for 15 seconds. The mixture was left on ice for 10 minutes. An equal volume of 
acid-phenol:chloroform from the bottom phase of the bottle was added to the initial lysate 
volume (400 µl) and vortexed for 15 seconds to mix. The samples were centrifuged at 
10,000 RPM for 5 minutes at room temperature to separate the aqueous and organic 
phases. Then the aqueous (upper) phase was removed carefully without disrupting the 
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lower phase, and transferred to a new eppendorf. At that stage the elution solution (30 μl 
per tube) was preheated to 95oC. Next, 1.25 volumes of 100% ethanol were added to the 
aqueous phase recovered previously (e.g for 300 μl, add 375 μl ethanol). For each sample, 
a filter cartridge was placed into each of the collection tubes supplied. Up to 700 μl of the 
lysate/ethanol mix was pipetted onto the filter cartridge. If I had volumes larger than 700 
µl, I applied the mixture in successive applications to the same filter. The tube was 
centrifuged at 10,000 RMP for 1 minute to pass the mix through the tube. The flow 
through was discarded and the above repeated if more than 700 μl were available. Next, 
700 µl miRNA wash solution 1 (supplied by the manufacturer) was applied to the filter 
cartridge and the tube centrifuged for 30 seconds. The flow-through from the collection 
tube was discarded and the filter cartridge replaced into the same collection tube. Then, 
500 μl of wash solution 2/3 (supplied by the manufacturer) was applied and the tube 
centrifuged for another 30 seconds. A centrifuge with a second 500 µl wash solution 2/3 
was repeated. The flow-through was discarded and an extra spin was performed to clear 
the washing buffer. After discarding the flow-through from the last wash, the filter 
cartridge was replaced in a new collection tube. At that stage, 30 μl of the pre-heated 
elution solution was applied, the cap was closed and the tube was left at room temperature 
for 1 minute. The tube was centrifuged for a further 1 minute at 10,000 RPM to recover 
the RNA. The elute was collected and stored at -80oC. 
 
2.2.3.4 RNA quantification and quality control 
RNA concentration was determined using a Nanodrop ND1000 UV-Vis 
spectrophotometer (Labtech International Ltd). The absorbance of each sample at 260 
and 280 nm was also assessed using the same instrument.  
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cDNA was synthesised from RNA extracted from cell monolayer cultures using the high 
capacity reverse transcription kit (Applied Biosystems). RNA samples were taken out of 
-80oC and allowed to thaw on ice for 10 minutes. For a 10 µl master mix reaction per 
well, the components used included 2 μl of 10x RT buffer, 0.8 μl of 25xdNTP Mix, 2 µl 
of 10x RT Random Primers, 1 μl multiscribe RT and 4.2 µl nuclease-free H2O. The 
amount was added to each well of a 96-well plate and an equal amount of RNA (10 μl) 
was added to the master mix. The plate was centrifuged at 10,000 PRM for 15 seconds. 
The reverse transcription was performed in a thermal cycler at 25oC for 10 minutes, 37oC 
for 120 minutes, 4o C for 4 seconds, then held at 4oC and transferred to -20oC for storage. 
 
 
Total mRNA levels were assessed by multiplex real-time PCR using Taqman Gene 
Expression Assays (Life Technologies). The PCR reaction comprised the components: 1 
µl of 20x Taqman Gene Expression Assay (COL7A1 Hs01574745_g1, HB-EGF 
Hs00181813_m1 as FAM target probes), 1 µl of endogenous control VIC probes 
(18sRNA and GAPDH for Chapter 3), 10 μl 2 x Taqman Gene Expression Master Mix, 7 
µl RNAase free H2O (Qiagen, Crawley, UK) and 2 μl cDNA. All Taqman probes were 
purchased from Applied Biosystems. All PCR reactions were carried out in triplicate, in 
96-well plates (Thermo Scientific ABgene, Ashford, UK) covered by optical adhesive 
lids and samples were amplified in an Applied Biosystems 7900HT Sequence Detection 
System. Target gene amplification was performed under the following cycling conditions: 
95oC for 10 minutes and then 95oC for 15 seconds, 60oC for 1 minute for a total of 40 
cycles. Target gene expression was normalised to that of endogenous genes (18S).  
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2.2.5.1 Interpretation of q-PCR data 
qPCR results were analysed using SDS 2.4 software (Life Technologies). Real-time data 
were expressed as mRNA expression fold changes using the comparative CT (2
-ΔΔCt) 
method (Schmittgen and Livak 2008). The ΔΔCt value was calculated using the formula: 
ΔΔCt= (CT, Target - CT, Endogenous) Treated - (CT, Target - CT, Endogenous) 
Untreated. Bar graphs, error calculations and t-tests were performed using Microsoft 
Excel 2010 and GraphPad Prism software (version 5.03, GraphPad, San Diego, CA). 
 
 
2.2.6.1 Immunofluorescent staining of skin specimens 
Normal human skin was used as positive controls and for negative controls the same 
sections without primary antibody incubation were used. OCT-embedded skin biopsies 
were cut using a cryostat at 5 µm thickness and stored at -80oC. Sections were air dried 
for 30 minutes, if freshly cut. If taken out of the freezer they were left for 10 minutes at 
room temperature. Hydrophobic circles were marked around the tissue sections using a 
pen (Abcam, Cambridge, MA, USA) and slides were dried for 5 minutes. The sections 
were then fixed with paraformaldehyde for 5 minutes. All sections were washed in PBS 
for 5 minutes and then blocked for 20 minutes with blocking buffer containing: 10% goat 
serum with 0.1% bovine serum albumin diluted in PBS (BSA/PBS) and 0.1% Tween20. 
Primary and secondary antibodies (Table 2.2) were diluted in blocking buffer and 
incubated for at least 20 minutes on ice. The secondary antibody was stored in the dark. 
The sections were washed once in PBS for 5 minutes. PBS was gently removed with 
paper. Following primary antibody incubation for 30 minutes at RT, sections were 
washed thoroughly with three changes of five minute PBS washes and the appropriate 
P a g e  85 | 275 
 
goat secondary antibody conjugated with Alexa Fluor 488 was applied for 30 minutes at 
room temperature in the dark. Sections were washed in two changes of PBS for 5 minutes 
covered from light. Then sections were lastly rinsed in distilled H2O for 5 minutes also 
protected from the light. Sections were allowed to air dry, were then mounted with DAPI 
and a cover glass was gently applied. The sections were left overnight at room 
temperature in the dark. The sections were kept at 4oC for up to 7 days and at -80oC for 
longer. IgG1 (Sigma-Aldrich, Dorset, UK) was used as isotype control and for negative 
control normal human skin sections without primary antibody incubation. 
 
Table 2.2 Table with primary and secondary antibodies. 

















The skin samples were transported in 10% neutral buffered formalin. Within 48 hours 
tissue was immersed in sequential 70%, 100% ethanol, xylene and paraffin wax using an 
automated tissue processor. Subsequently, it was embedded in paraffin wax, allowed to 
cool at room temperature and was stored at room temperature. Paraffin-embedded 
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samples were cut at 5 μm using a Leica Microtome RM 2125 (Leica Microsystems, 
Milton Keynes, UK). Sections were picked up on silane coated slides (Sigma-Aldrich). 
The paraffin-embedded sections were de-waxed by incubation in xylene for 5 minutes at 
room temperature and then through graded ethanol immersions (of 2 minutes each), 
beginning with 100%, followed by 90%, 70% and finally 50% ethanol. Slides were 
washed in water and then immersed in Mayer’s haematoxylin (Sigma-Aldrich) for 3 
minutes, and then washed and immersed in 0·5% eosin Y (VWR International Ltd, 
Lutterworth, UK) staining solution for 3 minutes. Sections were mounted by covering 




Blood was collected in a gold top BD Vacutainer® tube with HemogardTM Closure (BD 
Diagnostic Systems, Oxford, UK). The tube was left at room temperature for 20 minutes 
prior to centrifuging. Subsequently, the tube was centrifuged for 15 minutes at 3000 RPM 
at 4oC. Once the serum was isolated, it was aliquoted and stored at -80oC. 
 
 
Serum cytokine levels were measured by using a Milliplex kit for interferon-γ (IFN-γ), 
interleukin-17A (IL-17A), interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-10 (IL-
10), and tumour necrosis factor-α (TNF-α) (Millipore Ltd, Watford, UK). Serum samples 
were prepared as detailed in Section 2.2.8. Samples were thawed completely and mixed 
well by vortexing and centrifuging prior use. Sixty µl from each vial of antibody-
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immobilised beads was added to the Mixing bottle and brought to a final volume of 3 mls 
with Bead diluent. The mixed beads were vortex well. The quality controls, the wash 
buffer, the Serum Matrix and the human cytokine standard were prepared as per the 
manufacturer’s instructions. After preparation of all reagents, the assay was conducted. 
Two hundred µl of Wash Buffer were added per well and the plate was shaken for 10 
minutes at room temperature. Subsequently, the Wash buffer was decanted and 25 µl of 
Standard or Control was added to the appropriate wells. The same amount of Assay Buffer 
was added to the background and sample wells. Twenty-five µl of the Serum Matrix, was 
added to the background, standards and control wells. The same amount of undiluted 
sample was added to the sample wells and finally, 25 µl of the Mixed beads to each well, 
while shaking the plate intermittently. The plate was sealed and wrapped with foil and 
incubated overnight at 4oC or for 2 hours at room temperature. Afterwards, the well 
contents were removed and the late washed using a hand-held magnetic plate washer 
(Millipore Ltd). Twenty-five µl detection antibodies were added per well and incubated 
at room temperature for 1 hour. Without aspirating, 25 µl of streptavidin-Phytocoerythrin 
was added per well, incubated for 30 minutes at room temperature and washed twice with 
200 µl Wash Buffer. Hundred and fifty µl of Sheath fluid was added to all wells and the 
plate was run on Luminex® FLEXMAP 3D® System (Millipore Ltd). Each multiplex 
assay was performed in duplicate on two different occasions according to the 
manufacturers' specifications. Standard curves for each cytokine, using each kit, were 
generated by using the reference cytokine concentrations supplied by the manufacturer. 
Raw data (mean fluorescent intensity) from all kits were analysed by MasterPlex 
Quantitation Software (MiraiBio, Inc., Alameda, CA, USA) to obtain concentration 
values. 
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2.3 Wound measurement methodology 
A number of wound measurement devices and software products were reviewed to find 
the most suitable wound measurement product. ElixrTM (previously known as WITA) 
was selected because it had the advantage of a no touch technique reducing patient 
discomfort. It combines a pattern recognition software algorithm with artificial 
intelligence to analyse digital erosion images (iCLRTM technology, Imago Care Ltd). A 
digital photograph was taken of each erosion included in the study, and uploaded onto a 
secure hospital personal computer. The image was subsequently calibrated and the 
erosion edge was traced with a computer mouse. Erosion surface area was then calculated 
by the software (Figure 2.2). The software has good intra-user reproducibility and I 
performed all the tracing and measurements myself. Approval was sought and gained by 
the GSTT Business Management team for the software to be installed onto specific NHS 
computers. 
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Figure 2.2 Demonstration of the wound measurement software. 
(A) Once the digital photo is uploaded on the digital planimetry software, calibration with the ruler in the picture and 
mapping of the wound edge follows. (B) Analysis of the wound surface area and (C) tissue analysis. 
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2.4 Suction blisters 
Suction blister time was measured using a two-chamber negative pressure device with 
three 3mm orifices (NP2 model, Electronic Diversities, Finksburg, USA). The Negative 
Pressure Cutaneous Suction System is a self-contained instrument package. The blisters 
are created through the use of suction chambers that are attached to the patient's skin. 
Briefly, the numbered chambers are connected to the appropriate chamber control 
channel. Once the chamber is secured to the patient's skin, the device is turned on at a 
pressure of 12–15 mm Hg. This pressure creates a suction blister in a healthy person in 
60 minutes. The application of negative pressure from the instrument console, to the 
chamber interior, causes the patient’s skin to be gently drawn through the openings in the 
orifice plate approximately the size of the opening(s) in the orifice plate. The procedure 
caused no discomfort to the children and the discomfort was minimal to the parents. A 
video of the procedure can be found in Tolar et al (2013a). 
 
2.5 Assessment tools 
 
The PaedsQL  Measurement Model is a modular approach to measuring health-related 
quality of life in healthy children and adolescents and those with acute and chronic health 
conditions. It integrates both generic core scales and disease-specific modules into one 
measurement system. The parent and child completed the questionnaires independently 
of one another. If the child or parent had a question about what an item means or how 
they should answer it, I repeated the item to them verbatim.  I asked them to answer the 
item according to what they think the question means.  If they had trouble deciding on an 
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answer, I asked them to choose the response that comes closest to how they feel. The 
child and/or the parent had the option of not answering a question if they truly did not 
understand the question.   
For the child, the PaedsQL asks questions about how he/she feels and what they think 
about their health. For the parent, it assesses health-related quality of life in their children. 
It contained questions about their child’s physical, emotional, social, and school 
functioning in the past one month. According to the dedicated website 
(http://www.pedsql.org/score.html) the PaedsQL  Generic Core Scales are: 
 
Brief (23 items) 
 
Practical (Less than 4 minutes to complete) 
 
Flexible (Designed for use with community, school, and clinical pediatric 
populations). 
 
Developmentally Appropriate (Ages 2-18; Child Self-Report Ages 5-7, 8-12, 13-
18; Parent Proxy-Report Ages 2-4, 5-7, 8-12, 13-18). 
 
Multidimensional (Physical, Emotional, Social, School Functioning). 
 
Reliable (Total Scale Score: 0.88 Child Self-Report; 0.90 Parent Proxy-Report). 
 
Valid (Distinguishes between healthy children and children with acute and chronic 
health conditions; distinguishes disease severity within a chronic health condition). 
 
Responsive to clinical change over time. 
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This is a non-validated, EB-specific questionnaire developed by the Paediatric 
Psychologist Consultant, Dr Christina Liossi, at Great Ormond Street Hospital. The 
questionnaire was developed because there was no existing, validated questionnaire to 
use. The questionnaire scores the pain intensity for different pain sources such as the skin, 
muscle and bones, mouth, teeth, eyes, bowel opening, urination and dressing changes. 
Sleep and fatigue are also assessed with several questions. Full questionnaire is included 
in the CD-ROM enclosed. 
For both the children’s and parents’ questionnaire the score is calculated by computing 
the total score for all pain intensity related items and all other items are reported separately 
(if at all).  
 
 
The GSS or global impression scale, is a well-established rating tool applicable to several 
skin diseases and it is easy to use (. It is a 5-point scale which provides a snapshot of 
disease severity. The purpose is to make a clinical global judgement about the disease 
severity across various time points. There is no validated GSS specific to EB. A generic 
GSS was adjusted for the purpose of the EBSTEM clinical trial. It contains a global 
severity section which takes into account the area of skin affected, how inflamed and how 
painful the skin is. It also contains a second part about global improvement since the 
treatment given in the EBSTEM trial. The same elements as above are assessed.   
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The BEBSS is a validated EB severity scoring system and was considered the best 
available for the purpose of the clinical trials included in this thesis. Eleven items were 
scored: area of damaged skin, involvement of nails, mouth, eyes, larynx and oesophagus, 
scarring of hands, skin cancer, chronic wounds, alopecia and nutritional compromise. 
Area is allocated 50 points, and the 10 other items 5 points each, giving a maximum score 
of 100.  
 
 
The blister manual used in the EBSTEM trial was developed by Dr Jemima Mellerio for 
the study. People with EB pierce their blisters and do their dressings for different parts of 
the body on different days, e.g arms and legs on one day, trunk the next day. Blisters 
present on each day were recorded and then totaled once all body areas are included. A 
body site was only counted once.  Images of different size blisters were included to 
demonstrate tense and flat blisters. If blisters were in clusters, if the skin between them 
was not red or crusty, each blister was included in the count. Individuals were advised to 
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3 MODE-OF-ACTION OF ALLOGENEIC CELL THERAPY IN 
RDEB 
3.1 Intradermal injections of allogeneic fibroblasts in a person with 
RDEB 
 
It has been previously demonstrated that intradermal injections of allogeneic fibroblasts 
in RDEB intact skin can increase C7 expression at the DEJ, although that study did not 
disclose how long the benefits were sustained for or indicate a therapeutic mode of action 
(Wong et al. 2008). A further study attempted to elucidate the mechanism of action of 
allogeneic fibroblast injections in an individual with RDEB who was compound 
heterozygous for a nonsense mutation and a splice-site mutation (p.Arg682*/IVS87+4A
G) in COL7A1 (Nagy et al. 2011). That study showed that a single fibroblast injection 
in an individual with RDEB could lead to increased C7 at the DEJ for ~9 months and 
increased COL7A1 expression for ~3 months. Transcriptomic data demonstrated that the 
elevated COL7A1 expression is associated with increased expression of HBEGF and, in 
vitro, incubation of keratinocytes and fibroblasts with HB-EGF leads to increased 
COL7A1 expression. It was then hypothesised that injection of allogeneic fibroblasts led 
to upregulation of HBEGF in vivo in an autocrine manner (Hashimoto et al. 1994; Goishi 
et al. 1995) (Figure 3.1). 
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Figure 3.1 Schematic representation of the possible mode-of-action of fibroblast injections at the DEJ.  
(a) Normal skin; (b) blister formation in a patient with RDEB; and (c) postulated mechanism by which fibroblast 
therapy may ameliorate the blistering tendency. (a) In normal skin, keratinocytes synthesise C7 molecules (red), which 
assemble into anchoring fibrils. These fibrils entrap the interstitial collagen fibres in the dermis, securing the stable 
association at the dermal–epidermal junction. (b) In most patients with RDEB, there are only a few rudimentary 
anchoring fibrils, allowing formation of blisters below the lamina densa as a result of minor trauma. (c) Allogeneic 
fibroblasts injected directly into the dermis elicit an undetermined reaction that leads to synthesis of HB-EGF, which 
upregulates the synthesis and assembly of the patient’s own mutated C7. The increase in the rudimentary anchoring 
fibrils, which are partially functional, partially stabilises the association of epidermis to the underlying dermis and 
ameliorates the blistering tendency. 
 
These data on mode-of-action of allogeneic fibroblasts however, are limited to 
observations in one patient. Although that study (Nagy et al. 2011) provided novel and 
significant insight into the mechanism of allogeneic fibroblasts, questions about 
mechanism remained unanswered, such as what was the optimal dose of HB-EGF 
underlying C7 responses, or, whether other growth factors might play a role in 
upregulating COL7A1 expression.  
After the Wong et al study (2008) showed potential for wound healing, allogeneic 
fibroblasts were used as an off-label indication in 12 individuals with RDEB (McGrath 
and Almaani, unpublished data). Specifically, similar numbers of cells (5 x 106 per 
centimetre of wound margin) were injected intradermally into the edge of chronic 
wounds. Serial photographs showed that RDEB wounds can heal rapidly following this 
intervention (Figure 3.2).  
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Figure 3.2 Photos showing off-licence use of fibroblasts in a RDEB wound. 
Day 0 represents a wound on the day of injections. Injections were given to the margins of this wound (but not into the 
eroded area). Reduction in size can be seen on Day 7 with complete closure at Day 15 (Photographs kindly provided 
by Dr Almaani, and Professor McGrath).  
 
Based on these observations and the transcriptomic data from Nagy et al. (2011), I aimed 
to: a) ascertain whether intradermal injections of allogeneic fibroblasts around wound 
margins in vivo result in HBEGF, COL7A1 upregulation and C7 production, b) the 
optimal dose and time-points of HB-EGF stimulation of normal and RDEB epidermal 
cells to induce COL7A1 expression in vitro and c) whether EGF stimulation of epidermal 
cells in vitro has the same effect on COL7A1 expression as HB-EGF. 
To demonstrate the first objective, and following informed consent, I selected a female 
individual with RDEB-SG with an open wound on her mid/lower back which was present 
and non-healing for approximately 15 years. The wound edges appeared clean with 
minimal exudate and were covered with an absorbent soft silicone foam dressing 
(Mepilex®, Mölnycke Health Care, Dunstable, UK) which was changed daily. The rest of 
her skin was mildly affected with another large wound on the back of her neck and smaller 
wounds on her knees. She was not on antibiotics and had no background of malignancy. 
She was of Pakistani origin with a homozygous acceptor splice site mutation in COL7A1 
(IVS13-1G>C). She had negative indirect immunofluorescence for both IgG and IgA 
antibodies (screened on normal human skin, split-skin and monkey oesophagus 
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substrates) at baseline and 3 months post fibroblast injections. Approximately, 80 cm of 
wound margin was injected. All injections were given at the same single occasion and no 
further fibroblast injections were administered. She was injected with a total of 20 vials 
of 20 x 106 cells/ml (Vavelta, Intercytex Ltd, UK) receiving 5 x 106 cells per linear 
centimetre of wound margin. EMLA was used before and Entonox during the injections. 
The procedure caused significant localised pain to the patient which subsided rapidly after 
the completion of injections. Initially, weekly telephone calls confirmed that she was 
recovering well and had no significant adverse reactions. During the course of the 
upcoming weeks she reported tightness at the wound margins and increased exudate from 
the wound surface, which needed change of dressing twice daily. The patient remained 
well and also managed to complete her college exams and driving lessons.  
On Day 60 post fibroblast injections, 4mm diameter skin biopsies for direct 
immunofluorescence were taken from 3 different sites as indicated in Figure 3.3. The 
time-point was selected based on the finding from the Nagy et al study (2011) that 
COL7A1 mRNA is increased between Day 15 and Day 90. Initially I examined the effects 
at a protein level with direct immunofluorescence, which was performed for samples from 
all three sites indicated in Figure 3.3.  
 
 
Statistical analyses were performed using Microsoft Excel and GraphPad Prism software 
(version 5.03, San Diego, CA). The error bars represent standard error of the mean. The 
graphs represent results from three technical replicates. 
 




Figure 3.3 Photograph showing the biopsy sites on the back of an individual with RDEB.  
The injected and non-injected wound margins are drawn and indicated with arrows. The black line indicates where the 
cells were injected. The white circles represent the three areas where the skin biopsies were taken from. Site 1 is non-
lesional skin away from the wound margin. Site 2 is adjacent to the injected wound margin. Site 3 is adjacent to the 
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Immunolabelling for C7 revealed linear C7 labelling at the DEJ in normal human skin 
(NHS). There was some baseline C7 staining in the unblistered, non-lesional skin (Site 1) 
at Day 60 which was reduced compared to NHS. C7 staining at the injected wound edge 
(Site 2) was present at Day 60 which was more intense than the patient’s normal looking 
skin but, as expected, reduced compared to normal skin. Site 3 at Day 60 had similar C7 
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Figure 3.4 C7 immunofluorescent staining of the biopsy sites.  
Immunolabelling for C7 using the monoclonal LH7.2 antibody shows some baseline C7 linear staining for the normal looking skin (Site 1) which is reduced compared to normal human skin. At 
Day 60 the injected wound edge (Site 2) demonstrates increased staining intensity as compared to the patient’s normal looking skin. Some C7 deposition is also evident at Day 60 at the non-
injected wound edge. (Bar represents 100µm). E=epidermis; D=dermis; dashed lines represent DEJ.  
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The immunofluorescence findings were supported by the relative mean 
immunofluorescence intensity of C7 at the DEJ (Figure 3.5). The non-injected wound 
edge (Site 3) at Day 60 had similar immunofluorescence intensity to the normal looking 
skin (Site 1). 



















































































Figure 3.5 C7 immunofluorescence intensity of the biopsy sites. 
Using identical image settings demonstrated that the relative mean fluorescence intensity of C7 fluorescence staining 
at the DEJ increased on Day 60 after treatment with fibroblasts (Site 2) compared with untreated, non-blistered skin 
(Site 1). Error bars represent standard deviation. Numbers show the relative immunofluorescence inactivity compared 
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RNA was extracted and levels of COL7A1 and HBEGF were measured with real-time 
PCR. Figure 3.6 shows 4-fold increased, but not significant, expression of COL7A1 at 
Day 60 at Site 2 compared to the patient’s unblistered skin (Site 1) following a single 
series of injections of allogeneic fibroblasts. COL7A1 mRNA levels also increased, at a 
lesser level, 2-fold at the non-injected wound edge (Site 3) as compared to the patient’s 
unblistered skin (Site 1). Site 2 (injected wound edge) showed 1.8-fold change, which 
was not significant, in COL7A1 expression as compared to the non-injected (Site 3) 
wound edge. The COL7A1 expression at the injected wound edge (Site 2) was 
approximately half that of normal human skin. In all samples the COL7A1 expression 
levels were less these of normal human skin, which is consistent with the 
























































































































Figure 3.6 qPCR for COL7A1 expression at Day 60 following a single series of injections of allogeneic 
fibroblasts.  
*** p<0.001, ** p<0.05.  
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Compared to the patient normal skin (Site 1), increase (p<0.05) in HBEGF expression 


























































































































Figure 3.8 shows a series of wound photographs, which demonstrate the reduction in 
wound size over the course of 8 months. During this period the patient required two 
courses of oral antibiotics for wound infections and had one iron infusion. She also 
reported that the healed wound edges broke down secondary to minimal trauma, i.e from 
scratching during her sleep. Despite the above, there was a 30% reduction in the wound 
surface area at Day 233 after the single series of fibroblast injections. This time-point at 
8 months was selected based on the finding of the Nagy et al study (2011) that C7 
labelling persisted for at least 270 days.
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Figure 3.8 Photographs showing the progress of the RDEB wound over the course of 8 months. The patient had not seen any clinical improvement for the past 15 years. 
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3.2 Growth factor experiments 
 
The mechanism leading to formation of new C7 remains largely unknown. The same 
group that tested the effect of fibroblasts into intact (non-blistered) RDEB skin performed 
gene expression profiling to show that, among other factors, the expression of heparin 
binding–EGF-like growth factor (HB-EGF) was increased after intradermal injections of 
fibroblasts (Nagy et al. 2011). Therefore, they hypothesised that this molecule may be a 
key factor stimulating the patient’s own keratinocytes to increase synthesis of mutant, but 
partially functional, C7. The study also showed that recombinant HB-EGF protein can 
increase COL7A1 gene expression in normal or RDEB keratinocytes and fibroblasts and 
that this may provide an explanation for how allogeneic fibroblasts improve skin function 
in RDEB. In recognising the potential of HB-EGF to upregulate C7, it also has to be borne 
in mind that, given the increased risk of SCC in RDEB, that HB-EGF has been implicated 
in RDEB-associated SCCs by stimulating cell proliferation and survival (Kivisaari et al. 
2010). HB-EGF is a member of the EGF family, which includes: EGF, TGFα, 
amphiregulin, epiregulin and betacellulin (Higashiyama et al. 1991). Apart from HB-EGF, 
none of the other EGF family members was upregulated in the transcriptomic data in the 
Nagy et al (2011) study. EGF is commercially available in spray form (1 mg/20 ml) 
(Easyef, Daewoong Pharmaceutical Ltd, South Korea). This product has been used in 
phase III clinical trials and preliminary results have shown positive effects in treatment of 
diabetic foot ulcers (Tuyet et al. 2009).  
Based on the RDEB case study results presented in Section 3.1 and the Nagy et al paper 
(2011), I designed a number of in vitro experiments to assess the effect of HB-EGF and 
EGF on normal and RDEB keratinocytes and fibroblasts. The 1 and 10 ng/ml doses were 
tested in addition to the dose of 100 ng/ml for both growth factors. The 1 and 10 ng/ml 
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doses were selected based on the Nagy et al paper (2011) The dose of 100 ng/ml was 
added, as it was more biologically relevant based on mouse and rat data. EGF doses of 
10ng/ml have been used in mouse colon cell lines (Frey et al. 2004). In a radiotherapy-
induced oral mucositis rat model, survival rate improved when rats were treated with 50 
µg/ml or 100 µg/ml rhEGF (Lee et al. 2007). In a mouse model of small intestinal 
irradiated mucosa regeneration of villi was noticeable in mice treated with more than 0.2 
mg/kg rhEGF, and the villi recovered fully in mice given more than 1 mg/kg rhEGF (Lee 
et al. 2008).  
The normal human cells were derived from discarded human skin after plastic surgery. 
The RDEB keratinocytes were derived from an individual with compound heterozygous 
COL7A1 mutations: c.3632insC (p.Gln1211fs*8) and c.520G>A (p.Gly174Arg) The 
RDEB fibroblasts were derived from an individual with the homozygous COL7A1 
mutation c.8506insC (p.Val2836fs*12). Cells were isolated as described in Section 2.2.1. 
Data represent the average of three technical replicates of a representative experiment. 
 
 
Statistical analyses were performed using Microsoft Excel and GraphPad Prism software 
(version 5.03, San Diego, CA). The error bars represent the standard error of the mean. 
The graphs represent results from three technical replicates.  
 
 
Following addition of HB-EGF, COL7A1 upregulation was observed at 15 minutes and 
persisted for at least 180 minutes in both normal cells types (Figure 3.9 and Figure 3.10). 
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Maximum effect was seen at 90 minutes for both cell types at the dose of 10 ng/ml for the 
fibroblasts and at the dose of 1ng/ml for the keratinocytes.  
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     Figure 3.9 Normal human fibroblasts (NHF) treated with recombinant human HB-EGF (rhHB-EGF). 
     Graph shows the relative fold change in COL7A1 expression after stimulation of NHF with rhHB-EGF. 
     Error bars represent standard error of the mean (SEM). 
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Figure 3.10 Normal human keratinocytes (NHK) treated with recombinant human HB-EGF (rhHB-EGF).  
Graph shows the relative fold change in COL7A1 expression after stimulation of NHK with rhHB-EGF. 
Error bars represent standard error of the mean (SEM). 
 
 
COL7A1 was upregulated at 90 minutes for all EGF doses for both normal cells but to a 
lesser degree compared to HB-EGF stimulation at 1 and 10ng/ml. (Figure 3.11 and Figure 
3.12). The effect was greater at the dose of 10 ng/ml for both normal keratinocytes and 
fibroblasts.  
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Figure 3.11 Normal human fibroblasts (NHF) treated with recombinant human EGF (rhEGF).  
Graph shows the relative fold change in COL7A1 expression after stimulation of NHF with rhEGF. 
Error bars represent standard error of the mean (SEM). 
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Figure 3.12 Normal human keratinocytes (NHK) treated with recombinant human EGF (rhEGF).  
Graph shows the relative fold change in COL7A1 expression after stimulation of NHK with rhEGF. 
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Following addition of HB-EGF, COL7A1 upregulation (up to 2-fold) was observed at 15 
minutes for all doses in RDEB fibroblasts (Figure 3.13) and at 15 minutes for the dose of 
1ng/ml, at 90 and 180 minutes for the doses of 1 and 10ng/ml for RDEB keratinocytes 
(Figure 3.14). The effect was greater in the RDEB keratinocytes (up to 6-fold) at 15 
minutes. The higher dose of 100 ng/ml HB-EGF had an inhibitory effect on COL7A1 
expression in the RDEB keratinocytes at 15 and 90 minutes. 
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Figure 3.13 RDEB fibroblasts treated with recombinant human HB-EGF (rhHB-EGF).  
Graph shows the relative fold change in COL7A1 expression after stimulation of RDEB fibroblasts with rhHB-EGF. 
Error bars represent standard error of the mean (SEM). 
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Figure 3.14 RDEB keratinocytes treated with recombinant human HB-EGF (rhHB-EGF).  
Graph shows the relative fold change in COL7A1 expression after stimulation of RDEB keratinocytes with rhHB-EGF. 
Error bars represent standard error of the mean (SEM). 
 
EGF addition to RDEB fibroblasts led to COL7A1 upregulation at 15 minutes at the dose 
of 1 and 10 ng/ml and at 90 minutes at all doses. EGF addition to RDEB keratinocytes led 
to COL7A1 upregulation at 90 minutes for all doses but to a lesser degree than for the 
RDEB fibroblasts. For the RDEB fibroblasts, EGF led to greater COL7A1 upregulation as 
compared to the HB-EGF stimulation (Figure 3.15 and Figure 3.16). For RDEB 
keratinocytes, HB-EGF had a greater effect than EGF at 15 minutes at the dose of 1ng/ml 
and at 90 and 180 minutes for the dose of 10ng/ml.  
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Figure 3.15 RDEB fibroblasts treated with recombinant human EGF (rhEGF).  
Graph shows the relative fold change in COL7A1 expression after stimulation of RDEB fibroblasts with rhEGF. 
Error bars represent standard error of the mean (SEM). 
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Figure 3.16 RDEB keratinocytes treated with recombinant human EGF (rhEGF).  
Graph shows the relative fold change in COL7A1 expression after stimulation of NHK with rhEGF. 
Error bars represent standard error of the mean (SEM). 
 
 
P a g e  113 | 275 
 
3.3 Discussion 
Chronic, non-healing wounds are hallmark features of RDEB. I demonstrated that 
intradermal injections of allogeneic fibroblasts around wound margins in an individual 
with RDEB result in improved wound healing at 8 months. Multiple separate injections 
given at one time point at a density of 5 million cells per linear cm resulted in 30% 
reduction of the wound size on this individual’s back. The patient had clearly described 
that the wound has never healed or reduced in size for more than a few days over the past 
15 years. The clinical appearance of the wound changed after the injections. There was 
initial deterioration at Day 23 and the wound size reduced slowly after that time-point. 
The deterioration could have been due to mechanical trauma and complicated by a wound 
infection.  There was a 2-fold upregulation of HBEGF by Day 60 compared to the patient’s 
baseline skin and non-injected wound edge. There was a 4-fold upregulation of COL7A1 
at the injected wound edge. The COL7A1 upregulation was not parallel to the wound size 
reduction and lagged. This could be because protein expression follows gene upregulation. 
This would be consistent with findings in the Nagy et al study (2011), where C7 labelling 
was increased and maintained for at least 270 days, while COL7A1 gene expression after 
initial increase returned to baseline at Day 180.  
There was also a 2-fold COL7A1 upregulation at the non-injected wound edge. One can 
speculate that this was a result of cell spillage from the adjacent injected edge because the 
biopsies were taken post injections from the injected and non-injected wound edges. The 
COL7A1 upregulation was closely matched by C7 production at the dermo-epidermal 
junction. The injected wound edge had increased C7 IF intensity which however, was 
around 75% of that of normal human skin. This would explain the fact that the healed 
wound edges were covered with easily damaged skin as described by the patient herself. 
The fact that there was no statistically significant difference in the IF intensity between 
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the patient’s normal looking skin and the injected wound edge could be because the patient 
had some baseline C7 expression as seen in Figure 3.4. The fact that there was some C7 
staining at the non-injected wound edge could be from an indirect effect on the wound 
that extends from the adjacent injected areas or from local spillage of the injected 
fibroblasts to the adjacent skin area. 
 The clinical improvement of 30% reduction in wound size at Day 233 had a significant 
impact on the patient’s daily routine by making it more manageable because of requiring 
smaller dressing sizes. The patient was dependent on her mother for the dressing change 
on her back and after it has reduced in size she was able to change the dressing herself on 
occasion. Although the patient reported the healed edges were friable and would break 
down easily if injured, i.e. by scratching, they would heal faster than what she anticipated 
compared to other wounds on her body.  
The role of HB-EGF and EGF in skin wound healing has been well established (Brown et 
al. 1989; Shirakata et al. 2005), but there is evidence that HB-EGF is implicated in the 
pathogenesis of SCC in RDEB and the over-expression correlates with poor prognosis 
(Kivisaari et al. 2010). EGF, on the other hand, enhances acute wound healing by 
stimulating epidermal and dermal regeneration and not contributing to malignant 
transformation (Berlanga-Acosta et al. 2009). The microarray data from the Nagy et al 
study (2011) did not identify EGF as significantly upregulated post allogeneic fibroblast 
injections. The growth factor experiments described in this thesis, demonstrated that 
treatment with HB-EGF and EGF lead to COL7A1 mRNA upregulation in normal and 
RDEB keratinocytes and fibroblasts. The optimal dose of HB-EGF with the highest 
COL7A1 gene upregulation in normal keratinocytes was 1ng/ml at 90 minutes (15-fold 
upregulation) closely followed by 10ng/ml at 90 minutes (12-fold upregulation). For 
normal fibroblasts, the optimal dose was 10mg/ml at 90 minutes (12-fold). The effect was 
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smaller in RDEB cells. For RDEB fibroblasts, the dose of HB-EGF with the highest 
COL7A1 upregulation was 10 and 100ng/ml at 90 minutes (2-fold). For RDEB 
keratinocytes, the optimal dose was 1ng/ml at 15 minutes (6-fold). The optimal dose of 
EGF for highest COL7A1 upregulation was 10ng/ml at 90 minutes (4-fold) for normal 
keratinocytes and 10 ng/ml at 15 minutes (5-fold) for normal fibroblasts. For RDEB 
keratinocytes the optimal EGF dose was 100ng/ml at 90 minutes (3-fold) and 10ng/ml at 
15 minutes (5-fold) for RDEB fibroblasts. The higher dose of EGF required for the RDEB 
keratinocytes could be because they are less sensitive compared to fibroblasts to the effects 
of EGF. 
HB-EGF is known to be an autocrine growth factor for human keratinocytes (Hashimoto 
et al. 1994) which would explain the more potent effect on COL7A1 upregulation in the 
control and RDEB keratinocytes compared to EGF. The inhibitory effect of 100 ng/ml 
HB-EGF on COL7A1 expression in the RDEB keratinocytes at 15 and 90 minutes could 
be due to an autocrine/paracrine inhibitory signalling of HB-EGF at higher doses. This 
was not observed with the addition of EGF and one can speculate that this is either due to 
higher affinity for the binding receptor or upregulation via a different pathway. EGF is 
known to activate predominantly EGF-R receptor complexes (Holbro et al. 2003); 
whereas HB-EGF binds to tyrosine kinase receptors (Junttila et al. 2000). Collectively, 
the current experiments show differential induction of COL7A1 by low and high doses of 
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4                                    FIBROBLAST CELL THERAPY FOR RDEB 
4.1    Introduction 
A therapeutic challenge has been to develop new gene, protein, cell and drug therapies for 
RDEB. Since the late 1980s, cell therapy clinical trials to improve wound healing in 
RDEB have involved several modalities, including autologous and allogeneic keratinocyte 
grafts and non-adherent dressings (Carter et al. 1987; McGrath et al. 1993; Falabella et 
al. 2000; Blanchet-Bardon and Bohbot 2005), as well as cultured dermal substitutes 
(Hasegawa et al. 2004). Given the orphan disease status of EB, most clinical trials have 
involved only a few affected individuals and the majority has failed to demonstrate clear 
beneficial clinical outcomes.  
One recent innovation has been the use of fibroblast cell therapy. Fibroblasts have the 
capacity to synthesise adhesive components of the skin basement membrane zone 
including C7, as well as potentially augmenting wound healing (El Ghalbzouri and Ponec 
2004). In 2003, two research groups showed that human RDEB fibroblasts, first corrected 
for the COL7A1, and then injected into the dermis of immune-deficient murine models of 
RDEB, could increase C7 expression at the DEJ and thereby restore the inherent basement 
membrane defect in RDEB (Ortiz-Urda et al. 2003; Woodley et al. 2003). Woodley et al. 
(2003) also showed that similar changes in C7 expression were possible using wild type 
control human fibroblasts (i.e. without COL7A1 correction), if the fibroblasts were used 
at sufficient cell density (5 x 106 cells worked, but 1 x 106 did not). Based on these 
findings, in 2008, a proof-of-concept study in five subjects with RDEB demonstrated that 
a single intradermal injection of 5 x 106 allogeneic fibroblasts increased COL7A1 and C7 
expression in the skin of some individuals for at least 3 months, the endpoint of that study 
(Wong et al. 2008). An extended study in one of these individuals demonstrated that a 
P a g e  117 | 275 
 
single injection of allogeneic fibroblasts could increase COL7A1 gene expression for 3–6 
months and C7 protein for 9–12 months (Nagy et al. 2011). Most of the initial human 
studies were performed in intact, unwounded skin, although some of the mouse studies 
showed that intravenously injected COL7A1 gene-corrected fibroblasts could home to 
RDEB wounds and promote wound healing (Woodley et al. 2003). Based on these studies 
and Dr Almaani’s unpublished data about wound healing after intradermal injections of 
allogeneic fibroblasts, I used the same cells in an individual with RDEB (described in 
Chapter 3) and demonstrated that they can promote wound healing in vivo and in vitro. 
The COL7A1 upregulation, followed by C7 increased labelling led to reduction in wound 
size reduction in this one patient. These results were encouraging but preliminary. The 
need to assess the effect of intradermal injections of allogeneic fibroblasts on erosion 
healing in RDEB individuals led to the design and conduct for a prospective, randomised, 
vehicle-controlled trial. 
 
4.2 Study ethics 
The protocol was approved by the U.K. National Research Ethics Committee London-
Dulwich (ref: 10/H0808/146) and the U.K. Medicines and Healthcare Products Regulatory 
Agency (EudraCT number: 2010-023121-38). The trial was registered with 
www.controlled-trials.com (ISRCTN67757229). The trial was conducted in accordance 
with the Declaration of Helsinki principles and the principles of the International 
Committee on Harmonisation Tripartite Guideline on Good Clinical Practice. All 
participants provided written informed consent. 
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4.3 Participants and interventions 
Participants of either sex (aged 16–70 years) were invited to participate if they had a 
diagnosis of RDEB, based on clinical and molecular findings and had at least five open 
skin erosions on the limbs or the trunk, each with a surface area between 5 and 50 cm2. 
Full inclusion and exclusion criteria are listed in Table 4.1. One minor and two substantial 
protocol amendments were submitted after the trial started. These changes included 
adding the option of home follow-up visits, expanding the age range, and exclusion of 
subjects with positive indirect IF for C7 antibodies. 
 
Table 4.1 Inclusion and exclusion criteria. 
 
Inclusion criteria 
 Subjects with a clinical diagnosis of RDEB 
 Subjects who are aged ≥ 16 and ≤ 70 years 
 Subjects with at least five open skin erosions, which are located on the limbs or 
the trunk, each with a surface area between 5 and 50 cm2. The size of these 
erosions must not exceed 50 cm2 at baseline. 
 Subjects who have voluntarily signed and dated an informed consent form prior 
to the first study intervention 
 Subjects, who are, in the opinion of the investigator, able to understand the 
study, cooperate with the study procedures, and are willing to be available for 
all the required follow-up visits 
 
Exclusion criteria 
 Subjects who have received immunotherapy/chemotherapy within 60 days of 
enrolment into this study 
 Subjects with a known allergy to any of the constituents of the product 
 Subjects with known or suspected malignancy 
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 Subjects with intolerance or allergy to additional study associated 
drugs/therapies (e.g. local anaesthetics, etc.) 
 Subjects who have taken systemic antibiotics within 7 days 
 Subjects taking immunosuppressive therapy including systemic steroids (e.g. 
oral prednisolone > 40 mg for more than 1 week) within the 30 days of the first 
treatment or planning immunosuppressive therapy at any time during the study. 
Intranasal/inhaled steroids are acceptable 
 Subjects who have taken any other investigational product within 90 days prior 
to screening or planned use of any other investigational product during the study 
period 
 Subjects who are pregnant, planning pregnancy and women of childbearing 
potential who are not abstinent or practicing an acceptable means of 
contraception, as determined by the investigator, for the duration of the 
treatment phase 
 Subjects with abnormal laboratory findings considered clinically significant 
 Subjects with a known history of poor adherence/compliance with medical 
treatment or follow-up 
 Subjects who are unable to understand the aims, objectives and follow-up 
treatment 
 Subjects with known alcohol or narcotic drug dependence. 
 Subjects who have previously been screened on more than two occasions, or 
who have previously been treated under this protocol. 
 Subjects who have previously been treated with allogeneic fibroblasts and 




Eligible erosions were randomised according to a computer generated 1:1 block 
randomisation schedule, which was provided in a sealed envelope by the trial statistician, 
assigning fibroblasts or vehicle for each erosion. The fibroblast suspension had a cloudy 
appearance, while the vehicle was clear. The trial sponsor, the statistician, myself, 
conducting the follow-up visits and erosion measurements, and all participants with 
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The cell product (ICX-RHY-013) consisted of a suspension of allogeneic human dermal 
fibroblasts in HypoThermosol-FRS (BioLife Solutions Inc., Bothell, WA, U.S.A.) 
presented in a sterile solution. ICX-RHY-013 is designated as an orphan medicinal 
product by the European Medicines Agency for the treatment of EB. The contents of 
HypoThermosol-FRS, the vehicle, are listed in Table 4.2. The human dermal fibroblasts 
were isolated from neonatal foreskin from donors whose mothers had been screened for a 
range of diseases (syphilis, HIV 1/2, hepatitis B and C, HTLV-1/2 and CMV). The 
fibroblasts were cryopreserved, thawed and expanded in culture under good 
manufacturing practice principles at Intercytex Ltd, Manchester, U.K. The product was 
quality control tested, qualified person released, and shipped in prepacked vials to the 
Guy’s Hospital pharmacy at 2–8°C. Cell viability was checked before dispatch, including 
following passage through a 21-G needle, and following one episode of warming to room 
temperature. Each vial contained 20 x 106 cells/mL and the dose used was 0.25 mL of 20 
x 106 cells/mL (ICX-RHY-013) per linear cm of erosion margin, or 0.25 mL vehicle per 
linear cm of erosion margin. The cells had a shelf-life of 11 days, were stored at 2–8°C, 
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 Table 4.2 Vehicle - HypoThermosol®-FRS constituents. 
Dextran-40 
Potassium chloride 
















A 10-point scale (verbal numeric rating scale) was used to record the pain associated with 
each study erosion. Trial subjects were asked to complete a questionnaire and score each 
erosion by completing a 5-point scale for each of the following categories: care, daily 
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Table 4.3 Quality of life measurements. 
A sample table from the case report file representing the questionnaire filled by a patient with three erosions at baseline 
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 Please think about each of your treated erosions, and then score each of the 
categories from 1-5, where 1 indicates that the erosion has minimal impact and 5 
indicates maximum impact.  If the erosion does not affect you at all in this 
category, please enter 0. 
 
 Care – please think about how easy or difficult it is to dress the erosion, and how 
time consuming it is. 
 
 Daily Function – please think about the impact this erosion has on your movement, 
sleeping, grooming, getting dressed and working. 
 
 Appearance – please think about your feelings about the appearance of this 
erosion, the quality of the skin and how fragile it is. 
 
 Concerns – please consider how anxious you feel about the erosion, and how you 
feel about other people’s reaction to it.  
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4.4  Study design 
The participants attended for a screening visit 4 weeks (±2 weeks) prior to the injections 
at the Clinical Research Facilities (CRF) unit at Guy’s Hospital, London, UK. They were 
seen by me for initial assessment and confirmation of eligibility for the study. At the 
screening visit, inclusion and exclusion criteria were verified, informed consent was 
obtained, physical examination was performed, vital signs noted and use of any 
concomitant medications was recorded. Documentation, photography and measurement 
of erosions were performed, and baseline serum biochemistry and haematological 
laboratory parameters were tested, including serum testing for anti-C7 antibodies. At visit 
2 (the day of injections, designated day 0), the screened erosions were photographed and 
measured by me to ensure they still met the inclusion criteria. The fibroblasts or vehicle 
were then injected intradermally into the mid-to-superficial dermis at the erosion margins 
under prior local anaesthesia with lidocaine/prilocaine cream (EMLATM, AstraZeneca, 
Wilmington, NC, U.S.A.) and simultaneous nitrous oxide and oxygen gas (EntonoxTM, 
BOC Healthcare, Worsley, U.K.) inhalation, as required. Injections were administered by 
the principal investigator (Professor McGrath) at the CRF unit at Guy’s Hospital, London, 
in the presence of two CRF nurses. The injections were administered by the principal 
investigator so I, who was performing the subsequent wound measurements, was blinded 
to treatment. All injections of fibroblasts and vehicle were given using the same approach 
for each injection: drawing up the vial contents into a 2-mL syringe using a 19-G sterile 
needle and then injecting into the skin using a 21-G needle. 
All participants continued standard skin care and regular dressing changes. Subjects were 
subsequently assessed at Days 7, 14, 28, 56, and at 3 and 6 Months after the injections on 
Day 0 (Figure 4.1). All assessments were done by me, who was blinded to treatment 
assignment, and were undertaken at the CRF or at the participant’s home. Assessment 
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parameters included erosion photography and measurements of erosion size at all visits, 
safety monitoring blood tests (including IIF for serum C7 antibodies) at Day 28 and 3 
Months and quality of life questions at Day 0 and 3 Months. Adverse events, erosion pain 
and concomitant medications were recorded at each visit. Each subject was loaned a 
digital camera to take weekly photos of the treated erosions for up to 3 months and diary 
cards to record the date any erosions healed as well as adverse events.  
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4.5 Endpoints 
The initial primary outcome measure was the time to complete closure of erosions treated 
with fibroblasts or vehicle. After consultation with the U.K. Medicines and Healthcare 
products Regulatory Agency (MHRA), however, and while the study was still blinded, 
the primary/secondary endpoint designation was changed to a hierarchy of outcomes as 
per the Committee for Medicinal Products for Human Use (CHMP) guideline on clinical 
trials in small populations (CHMP/EWP/83561/ 2005) (source www.ema.europa.eu). The 
first endpoint was the mean change in treated erosion area (cm2) from baseline in erosions 
treated with fibroblasts compared with those treated with vehicle for up to 6 months. Other 
endpoints, in order, were percentage change in erosion area over treated areas, time to 
erosion closure, erosion recurrence (time to recurrence, if healed), and clinical assessment 
by an independent assessor of the treated area compared with baseline (using a 5-point 
scale: 1, a lot worse; 2, a bit worse; 3, much the same; 4, a bit better; 5, much better), 
erosion pain, and healed/not healed for each erosion.  
 
4.6 Statistical analysis 
Final statistical analysis was based on the CHMP guideline on clinical trials in small 
populations. The initial statistical analysis plan was based on the assumption that for 80% 
power, 20 subjects with an average of six erosions per person would have to be 
randomised and treated. The power calculation was based on the fact that 80% power is 
considered the ideal power for a study to detect an effect and 20% chance of error. Owing 
to the rarity of RDEB, however, as well as the inevitable small recruitment numbers for a 
rare disease, and the number of screened erosions that were excluded, a consultation with 
the MHRA led to a protocol amendment, with the aim of making the most efficient use of 
the dataset. There were no known prognostic variables that might be predictors of 
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outcome. The analysis of the study was on a comparative basis, with two-sided statistical 
significance tests performed at the 5% level. A two-way ANCOVA model was used to 
analyse the main efficacy endpoint of average percentage erosion area reduction from Day 
0 to the 6-month assessment period. The ANCOVA model included treatment and patient 
as factors in the model and baseline area as the covariate. Erosion area and % change in 
erosion area were summarised at each study visit and analysed using analysis of 
covariance, with baseline area as a covariate. The study analysis was carried out when all 
patients completed the study and the database was locked. The study was only unblinded 
once the database was locked. The full analysis set comprised all erosions that received 
treatment. All statistical analyses were performed and all data appendices were created 
using the SAS (version 9.1.3; SAS Institute, Cary, NC, U.S.A.) statistical software. 
 
4.7 Trial recruitment and logistics 
Following regulatory and ethics approvals, databases of individuals with EB were 
reviewed in the three U.K. adult specialist centres (London, Solihull and Edinburgh) and 
104 subjects with RDEB were invited to participate between February and December 






P a g e  127 | 275 
 
 
Figure 4.2 Study flow and patient disposition.  
The majority of the subjects initially invited to participate were not screened because they either did not meet the entry 
criteria or declined to participate. Of those screened, additional subjects were excluded because their wounds were not 
chronic (present for at least 4 weeks), or wounds healed spontaneously, or wounds were too small (< 5 cm2) or too large 
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4.8 Results 
Of the 104 individuals assessed for eligibility, 23 potentially met the entry criteria and 
were invited for screening. After screening, 13 subjects with a total of 91 erosions entered 
the run-in phase and 11 subjects were treated with a total of 26 erosions. Baseline 
characteristics of the study population are listed in Table 4.4.  
 
 
Table 4.4 Baseline characteristics of the study participants and their wound measurements.  
(#) Also affects intron 3 donor splice site. (1) Based on indirect immunofluorescence staining. The skin C7 expression 
has been estimated as +, 5–25% of wild type; ++, >50% of wild type; and +++, >75% of wild type. 
Study 
ID 






























9.2 8.5 1.9 2.5 0 5.1 1.2 3.0 
Vehicle 14.2 26.7 17·6 8·4 0 1.5 3.8 0.9 
P2 
1) c.3632insC; p.Gln1211fs*8 
2) c.520G>A; p.Gly174Arg 
27/M Absent  
ICX-
RHY-013 
23.7 25.3 15.5 22.6 25.5 19.0 21.6 7.8 






24/M Absent  
ICX-
RHY-013 
30.3 29.7 6.1 3.3 0 0 0 0 
ICX-
RHY-013 
10.9 42.0 27.9 29.8 20.5 78.6 24.1 8.5 











6.3 18.0 13.0 17.2 7.7 7.3 4.4 15.1 
Vehicle 27.4 33.4 30.7 35.6 36.5 34.7 25.6 9.4 
P5 





26.7 26.0 15.7 5.3 16.4 41.7 4.0 13.0 
Vehicle 13.6 17.4 4.6 3.4 3.8 33.8 13.0 0 
P6 





10.1 8.2 6.3 6.0 5.2 11.0 5.3 6.7 
ICX-
RHY-013 
7.4 20.2 17.5 19.7 18·4 30·3 28·5 16·7 
ICX-
RHY-013 
7.1 18.7 5·8 6.0 5.1 24.3 13.0 8.4 
Vehicle 14.8 13.7 9.8 10.3 9.9 15.0 11.2 12.0 


























Vehicle 15.1 14.2 10.8 11.0 10.7 13.1 10.0 1.5 
P7 
1) c.425A>G; p.Lys142Arg* 
2) c.425A>G; p.Lys142Arg* 
31/M Absent  
ICX-
RHY-013 
18.4 17.4 4.7 6.9 4.8 4.0 1.8 0 
Vehicle 14.2 14.3 7.5 9.6 6.5 5.1 1.4 0 
P9 
1) c.6022C>G; p.Arg2008Gly 







5.1 6.6 0 3.8 0 2·5 4·8 0·9 
Vehicle 9.1 10·4 6·5 11·1 6·1 5·3 2·1 6·7 
P10 
#
1) c.425A>G; p.Lys142Arg 





Vehicle 6.4 5·9 2·6 0 0 0 0 0 
P11 
 






17.3 30.1 20.8 22.3 17.1 3.6 3.2 2.4 
ICX-
RHY-013 
15.4 14.7 13.4 14.0 14.9 0.3 3.8 7.4 
Vehicle 7.8 15.3 18.6 19.7 29.4 12.8 3.7 2.6 
P13 
1) c.1732C>T; p.Arg578* 




8.0 8.1 1.4 1.1 1.2 10.4 2.0 3.4 
Vehicle 9.0 10.5 2.6 1.1 2.3 0.7 0.9 1.7 
 
Between screening and day 0, I excluded two of these recruits because in one case the 
selected erosions had healed spontaneously and in the other case basement membrane 
binding serum anti-C7 antibodies were detected. Eleven subjects and a total of 29 erosions 
were randomised to receive either allogeneic fibroblasts or vehicle. Three erosions were 
not treated because subjects found injection of other erosions too painful. The remaining 
26 erosions were injected and comprised the full analysis set; 14 erosions received active 
treatment and 12 erosions vehicle. There were no subject dropouts and data for all 
endpoints were available for all 26 erosions at 6 months (Figure 4.2). The final trial 
subjects attended the 6-month follow-up visit in May 2012. No protocol deviations were 
reported. 
 




The safety analysis included a total of 15 treated erosions in the fibroblast group and 12 
treated erosions in the vehicle group. For the purpose of the adverse event reporting, we 
included a single erosion that was only partially (20%) treated (incomplete injections due 
to pain). This action explains the discrepancy in the numbers above (14 vs 15). Of the 15 
erosions in the active group and the 12 erosions in the control group, nine (60%) and five 
(42%) erosions, respectively, had at least one local treatment-emergent adverse event 
(TEAE). The majority of the local TEAEs involved procedural complications (such as 
pain, erythema, and pruritus). When subject follow-up was completed, seven of the nine 
(78%) in the active group and five of six (83%) in the vehicle group local TEAEs had 
resolved. Two of the nine erosions (22%) in the fibroblast group and one of the five 




Serial measurements of erosion surface areas following a single injection of 
fibroblasts/vehicle are recorded in Table 5.4. For the primary analysis, fibroblast 
injections produced a greater, but not statistically significant, reduction in erosion area 
than did vehicle alone during the first 28 days. The mean erosion area (in cm2) for the 
active group at day 0 was 19.5 (SD 10.3) vs. 18.7 (SD 9.7) for the vehicle group. At day 
7 it was 10.7 (8.2) vs. 14.0 (10.9); at day 14 it was 11.5 (9.3) vs. 13.8 (12.3); and at day 
28 it was 9.8 (8.7) vs. 13.1 (15.2). These changes over the first 28 days are illustrated in 
Figure 4.3. 
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Figure 4.3 Reduction in erosion size during the first 28 days.  
ICX-RHY-013: allogeneic fibroblasts. 
Error bars represent the standard deviation (SD). 
 
 
Figure 4.4 and Figure 4.5 demonstrate the clinical response to fibroblast or vehicle 
injections in two trial participants. 
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Figure 4.4 Clinical response to fibroblast/vehicle injections in trial subject P3.  
After the data was locked and the trial was unblinded, subject P3 was shown to have had two erosions treated with 
fibroblasts and one with vehicle. Picture (a) represents a randomised erosion treated with fibroblasts on day 0 (recorded 
as 29.7 cm2 on that day in Table 5). Picture (b) shows the same erosion at Day 28 (0 cm2). Picture (c) represents the 
randomised erosion, of the same trial subject, treated with vehicle alone on day 0 (recorded as 36.7 cm2 on that day in 
Table 5). Picture (d) shows the same erosion at Day 28 (45.4 cm2). 
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Figure 4.5 Clinical response to fibroblast/vehicle injections in trial subject P5.  
After the data was locked and the trial was unblinded, subject P5 was shown to have had one erosion treated with 
fibroblasts and one with vehicle. Picture (a) represents the randomised erosion treated with fibroblasts on day 0 (recorded 
as 26.0 cm2 on that day in Table 5). Picture (b) shows the same erosion at Day 28 (16.4 cm2). Picture (c) represents the 
randomised erosion, of the same trial subject, treated with vehicle alone on day 0 (recorded as 17.4 cm2 on that day in 
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Initially, percentage erosion area decreased rapidly after active treatment. For the active 
group vs. vehicle, mean (SD) reduction in erosion area at day 7 was 50% (29%) vs. 32% 
(29%); at day 14 it was 43% (32%) vs. 34% (42%); and at day 28 it was 54% (36%) vs. 
38% (57%). This statistically not significant difference between the groups, however, was 
lost after 28 days. At 6 months, the mean erosion area size was 6.7 (5.4) cm2 in the active 
treatment group and 4.8 (7.1) cm in the vehicle group. The percentage change in erosion 
area for the fibroblast and vehicle groups did not differ significantly at 6 months (p = 
0.42). Mean treatment difference between fibroblasts and vehicle was -23.5% [95% 
confidence interval (CI) -43.5 to -3.5, p = 0.025] at day 7; -19.2% [95% CI -41.7 to 3.4, p 
= 0.089] at day 14; -28.8% (95% CI -65.6 to 8.0, p = 0.11) at day 28. The estimated 
difference between the groups was 1.15 (95% CI -4.7 to 7.0, p = 0.68) at 6 months, thus 
showing no significant difference at this later time point (Table 4.5). On the basis of 
Kaplan–Meier estimates, the 4-week healing rate was 21.4% for the active group vs. 
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Table 4.5 Effect of ICX-RHY-013 versus vehicle on absolute and percentage change in erosion area. 
 Day 0 Day 7 Day 14 Day 28 Day 56 Week 12 Week 26 
Erosion area (in cm2) over 26 weeks 
Mean (SD) 
(ICX-RHY-013) 
19.5 (10.3) 10.7 (8.2) 11.5 (9.3) 9.8 (8.7) 17.0 (21.6) 8.4 (9.4) 6.7 (5.4) 
Mean (SD) 
(vehicle) 
18.7 (9.7) 14.0 (10.9) 13.8 (12.3) 13.1 (15.2) 13.7 (14.3) 8.0 (9.1) 4.8 (7.1) 
Treatment difference (ICX-RHY-013 – Vehicle) 
Difference (95%CI) - 
-4.39 
(-8.91 to 0.12) 
-3.85 
(-9.95 to 2.25) 
-5.20 
(-14.78 to 4.37) 
2.49 
(-11.01 to 15.99) 
-0.09 
(-7.59 to 7.42) 
1.15 
(-4.65 to 6.95) 
p value - 0.056 0.20 0.26 0.70 0.98 0.68 
 Day 0 Day 7 Day 14 Day 28 Day 56 Week 12 Week 26 
Percentage change 
in erosion area (in cm2) over 26 weeks 
Mean (SD) 
(ICX-RHY-013) 
- -49.8 (29.4) -42.8 (32·2) -54.4 (36.0) -18.4 (65.0) -55.9 (39.6) -61.2 (29.3) 
Mean (SD) 
(vehicle) 
- -31.9 (28.6) -33.5 (41.5) -37.8 (57.1) -33.1 (58.7) -62.8 (33.3) -75.8 (30.6) 
Treatment difference (ICX-RHY-013 – Vehicle) 
Difference (95%CI) - 
-23.50 
(-43.48 to -3.51) 
-19.15 
(-41.66 to 3.36) 
-28.83 
(-65.63 to 7.97) 
8.61 
(-38.09 to 55.32) 
3.28 
(-26.27 to 32.83) 
10.33 
(-16.24 to 36.91) 
p value - 0.025 0.089 0.11 0.70 0.81 0.42 
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Clinical assessment of erosion photographs by a blinded independent dermatologist (Dr 
Anna Martinez, Great Ormond Street Hospital, London, U.K.) showed that 78.6% and 
92.8% of the erosions treated with fibroblasts were deemed to show clinical improvement 
from baseline at day 28 and 6 months, respectively (Table 4.6). The comparative figures 
for the vehicle group were 66.7% and 83.3%. Statistically, none of these differences was 



















Table 4.6 Independent, blinded to study treatment assessment of clinical photographs of study erosions. 
 Day 7 Day 14 Day 28 Day 56 Week 12 Week 26 
Total erosions treated with ICX-RHY-013 (n=14) 
Much better 5 (35.7%) 7 (50.0%) 7 (50.0%) 6 (42.9%) 8 (57.1%) 8 (57.1%) 
A bit better 5 (35.7%) 3 (21.4%) 4 (28.6%) 1 (7.1%) 2 (14.3%) 5 (35.7%) 
Much the same 4 (28.6%) 4 (28.6%) 3 (21.4%) 4 (28.6%) 3 (21.4) 1 (7.1%) 
A bit worse 0 0 0 2 (14.3%) 1 (7.1%) 0 
A lot worse 0 0 0 1 (7.1%) 0 0 
Total erosions treated with vehicle (n=12) 
Much better 3 (25.0%) 5 (41.7%) 5 (41.7%) 5 (41.7%) 7 (58.3%) 9 (75.0%) 
A bit better 3 (25.0%) 1 (8.3%) 3 (25.0%) 1 (8.3%) 3 (25.0%) 1 (8.3%) 
Much the same 5 (41.7%) 6 (50.0%) 3 (25.0%) 5 (41.7%) 2 (16.7%) 2 (16.7%) 
A bit worse 1 (8.3%) 0 1 (8.3%) 1 (8.3%) 0 0 
A lot worse 0 0 0 0 0 0 
Estimated odds ratio  
(ICX-RHY-013 – Vehicle) 
2·26 1·83 1.65 0.80 0.76 0.57 
(95%CI) (0.54 to 9.55) (0.42 to 7.96) (0.39 to 6.94) (0.19 to 3.33) (0.17 to 3.44) (0.11 to 2.93) 
p value 0.27 0.42 0.50 0.76 0.73 0.50 
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Pain associated with the fibroblast-injected erosions decreased compared with the vehicle 
group within the first 28 days although this was not significant (p = 0.17 at day 28), and 
with no differences between the two groups for the rest of the study visits (Table 4.7 and 
Table 4.8). Quality-of-life scores in all categories decreased in both the cell and vehicle 
groups during the course of the study (Table 4.9, Table 4.10, Table 4.11 and Table 4.12); 
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Total erosions 14 14 14 14 14 14 14 14 12 12 12 12 12 12 12 12 
Mean 2.3 3.5 1.0 1.0 1.4 1.8 1.4 1.4 3.3 3.1 1.0 1.8 2.2 1.4 2.0 1.2 
Median 1.5 2.5 1.0 0.0 1.0 1.0 0.5 1.0 3.0 2.0 0.5 0.0 0.5 0.0 0.0 0.5 
SD 2.5 3.1 1.1 2.0 1.9 2.4 2.0 1.7 2.8 3.0 1.1 3.0 2.8 2.7 3.2 1.6 
25% quartile 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.5 0.0 0.0 0.0 0.0 0.0 0.0 
75% quartile 5.0 6.0 2.0 1.0 2.0 3.0 2.0 2.0 6.0 6.5 2.0 3.0 4.5 1.5 3.5 2.0 
Minimum 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Maximum 7.0 9.0 3.0 7.0 7.0 7.0 6.0 6.0 7.0 7.0 3.0 8.0 7.0 9.0 10.0 4.0 





Table 4.8  Erosion pain statistical analysis.   





Day 7 Day 14 Day 28 Day 56 Week 12 Week 26 
Estimated treatment difference  
(ICX-RHY-013 - Vehicle) 
-0.48 0.16 -0.64 -1.12 0.51 -0.73 -0.24 
SEM 1.00 0.39 0.87 0.77 1.18 1.05 0.58 
Lower 95% CI -2.65 -0.69 -2.51 -2.78 -2.04 -3.01 -1.50 
Lower 95% CI 1.68 1.00 1.24 0.55 3.05 1.54 1.01 
Statistical significance of treatment difference * p=0.64 p=0.70 p=0.48 p=0.17 p=0.67 p=0.50 p=0.68 
Statistical significance of treatment difference # p=0.40 p=0.36 p=0.48 p=0.42 p=0.19 p=0.47 p=0.20 
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       Table 4.9 Quality of Life Assessment of Care: Intention-to-treat (ITT) Population. 
 
ICX-RHY-013 Vehicle 
Day 0 Week 12 Day 0 Week 12 
Total erosions treated 14 (100.0%) 14 (100.0%) 12 (100.0%) 12 (100.0%) 
Score 0 2 (14.3%) 2 (14.3%) 3 (25.0%) 3 (25.0%) 
Score 1 2 (14.3%) 7 (50.0%) 2 (16.7%) 6 (50.0%) 
Score 2 2 (14.3%) 3 (21.4%) 1 (8.3%) 2 (16.7%) 
Score 3 3 (21.4%) 0 (0.0%) 3 (25.0%) 1 (8.3%) 
Score 4 4 (28.6%) 2 (14.3%) 2 (16.7%) 0 (0.0%) 
Score 5 1 (7.1%) 0 (0.0%) 1 (8.3%) 0 (0.0%) 
 
       Table 4.10 Quality of Life Assessment of Daily Function: Intention-to-treat (ITT) Population. 
 
ICX-RHY-013 Vehicle 
Day 0 Week 12 Day 0 Week 12 
Total erosions treated 14 (100.0%) 14 (100.0%) 12 (100.0%) 12 (100.0%) 
Score 0 3 (21.4%) 4 (28.6%) 2 (16.7%) 4 (33.3%) 
Score 1 2 (14.3%) 3 (21.4%) 1 (8.3%) 3 (25.0%) 
Score 2 2 (14.3%) 3 (21.4%) 2 (16.7%) 3 (25.0%) 
Score 3 1 (7.1%) 3 (21.4%) 2 (16.7%) 2 (16.7%) 
Score 4 0 (0.0%) 1 (7.1%) 0 (0.0%) 0 (0.0%) 
Score 5 6 (42.9%) 0 (0.0%) 5 (41.7%) 0 (0.0%) 
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       Table 4.11 Quality of Life Assessment of Appearance: Intention-to-treat (ITT) Population. 
 
ICX-RHY-013 Vehicle 
Day 0 Week 12 Day 0 Week 12 
Total erosions treated 14 (100.0%) 14 (100.0%) 12 (100.0%) 12 (100.0%) 
Score 0 1 (7.1%) 5 (35.7%) 1 (8.3%) 5 (41.7%) 
Score 1 3 (21.4%) 2 (14.3%) 2 (16.7%) 3 (25.0%) 
Score 2 3 (21.4%) 1 (7.1%) 1 (8.3%) 1 (8.3%) 
Score 3 0 (0.0%) 2 (14.3%) 2 (16.7%) 1 (8.3%) 
Score 4 1 (7.1%) 2 (14.3%) 0 (0.0%) 1 (8.3%) 
Score 5 6 (42.9%) 2 (14.3%) 6 (50.0%) 1 (8.3%) 
 
       Table 4.12 Quality of Life Assessment of Concerns: Intention-to-treat (ITT) Population. 
 
ICX-RHY-013 Vehicle 
Day 0 Week 12 Day 0 Week 12 
Total erosions treated 14 (100.0%) 14 (100.0%) 12 (100.0%) 12 (100.0%) 
Score 0 3 (21.4%) 8 (57.1%) 4 (33.3%) 6 (50.0%) 
Score 1 4 (28.6%) 2 (14.3%) 3 (25.0%) 3 (25.0%) 
Score 2 1 (7.1%) 1 (7.1%) 1 (8.3%) 1 (8.3%) 
Score 3 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (8.3%) 
Score 4 3 (21.4%) 2 (14.3%) 1 (8.3%) 0 (0.0%) 
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4.9 Discussion 
A single intradermal injection of human allogeneic dermal fibroblasts into the margins of 
chronic erosions in subjects with RDEB produced a greater reduction in erosion area, time 
to healing, and in proportion of wounds healed, compared with vehicle within the first 28 
days following treatment. Although the study failed to reach statistical significance 
because of the small number of treated erosions, the results suggest that a greater number 
of chronic RDEB erosions can be expected to heal within 4 weeks following fibroblast 
injection (21.4% vs. 16.7%). Thereafter, the study showed no significant differences 
between fibroblasts and vehicle, although both led to clinical improvement over 6 months 
compared with baseline. Subjective pain scores were reduced in the fibroblast group 
during the first 28 days, and independent assessment of wound healing appearance scored 
better in the fibroblast group at day 28 and 6 months although these differences did not 
reach statistical significance. No significant differences were seen between the two groups 
for other measures. 
One clear limitation of the study is that the natural history of wound healing in RDEB is 
unknown. It has generally been assumed that the extensive skin and mucous membrane 
fragility inherent to RDEB leads to non-healing and persistent erosions. However, the pre-
screening data showed that is not the case. More than 58% of the chronic erosions screened 
in this study were found to have healed or reduced in size by > 10% between screening 
and day 0, and therefore did not meet the set inclusion criteria for the trial. In future, 
interventional wound healing studies in RDEB should have a third arm that includes 
erosions without any intervention to document spontaneous wound healing. 
Finding that erosion size reduced in both the fibroblast and vehicle groups raises the 
question of whether some of the clinical response may be due to the injection itself and/or 
the vehicle alone. Indeed, one other study in chronic wounds in RDEB has shown similar 
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changes for both allogeneic fibroblasts and vehicle, although that trial used a different 
source of cells, vehicle and injection protocol (Venugopal et al. 2013). Nevertheless, 
previous studies have shown that injection of saline into RDEB skin can lead to 
upregulation of COL7A1 expression although this was less in both amount and duration 
compared with fibroblast injection (Nagy et al. 2011).  
One further limitation of this trial was the selected erosion range of 5–50 cm2 and the 
intention to treat these with a single injection. This study indicates that the fibroblasts 
appeared to accelerate wound healing in the first 28 days but not thereafter and that a 
single-injection approach, therefore, may be suitable for smaller wounds but not for larger 
erosions. These observations suggest a probable need for re-treatment, perhaps every 4 
weeks, to try to sustain the rate of re-epithelialisation. On a practical level, however, 
injection pain was a major issue in the study. Delivering the cells and vehicle using a 
syringe/ hypodermic needle was often very painful especially in areas of scarring that had 
developed as a consequence of the disease. Future clinical applications of intradermal cell 
therapy delivery in RDEB, therefore, should address this and are likely to need an 
alternative delivery system, possibly using microneedles or other methods. 
The pain associated with intradermal injection questions whether an alternative approach 
such as topical use of cells onto the erosion surface might suffice? Topical use of cell 
therapy has been used with some success in chronic venous ulcers (Kirsner et al. 2012), 
but in RDEB the results have mostly been disappointing. Wounds in RDEB typically show 
colonisation or infection with a range of Gram positive or negative bacteria, as well as 
abnormal granulation tissue, and therefore cells or recombinant growth factors applied 
topically have often proved a sub-optimal therapeutic approach. Nevertheless, use of 
cultured dermal substitutes has been reported to improved wound healing in some cases 
of RDEB (Falabella et al. 2000; Fivenson et al. 2003; Natsuga et al. 2010), although loss 
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of the grafted material and failure to heal wounds is common in clinical practice. In 
addition, the considerable cost of these dermal substitutes has limited their clinical uptake. 
The main finding of the trial is that intradermally injected allogeneic fibroblasts can 
accelerate the rate of wound healing in RDEB wounds. The clinical utility might be 
extended further provided a less painful means of intradermal delivery could be achieved. 
For individuals with more severe forms of RDEB, however, the considerable extent of the 
erosions means that local injections of fibroblasts might only offer limited clinical benefits 
and an alternative systemic treatment would be preferable. 
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5            ALLOGENEIC BM-MSCS FOR CHILDREN WITH RDEB  
5.1 Introduction 
Clinical experience of RDEB suggests that a systemic therapy, delivered early in life, 
might offer the best disease-modifying potential. The first systemic therapeutic trial for 
children with RDEB was reported in 2010 (Wagner et al. 2010). Six children received 
BMT following myeloablative chemotherapy. Five out of six children showed significant 
clinical improvement, with reduction of blisters and improved wound healing with 
sustained benefits beyond 12 months in some cases (longest follow up is now 8 years and 
improvement has been maintained). This form of therapy, however, was considered high 
risk due to the conditioning chemotherapy required. One patient died due to 
cardiomyopathy before transplantation and one developed severe chemotherapy-related 
sepsis. Since then, over 20 patients with RDEB had received BMT; although the clinical 
data have yet to be published. Data presented in abstract form suggest that changing the 
conditioning to a reduced intensity conditioning regime might be associated with lower 
morbidity and mortality but conclusive data are awaited.  
With regard to alternative systemic cell therapy the only reported clinical experience is 
with allogeneic MSCs given intravenously in adults with RDEB. Again, the main data 
have been reported only in abstract form, although a more detailed clinical synopsis has 
been published very recently (El-Darouti et al. 2015) In this study, 14 RDEB individuals 
received intravenously 2x106 cells/kg of BM-MSCs, with or without cyclosporin, some 
of whom showed clinical improvement and no SAEs. The relative contributions of the 
BM-MSCs or the cyclosporine in some cases, however, were not clear. MSCs represent 
a heterogeneous collection of mostly non-progenitor connective tissue cells that are 
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structurally and functionally different from self-renewing stem cells and progenitors. 
Initially considered to be a population of stromal cells supporting and organising 
parenchymal frameworks, several studies have identified important roles for MSCs in 
modulating tissue inflammation and promoting tissue repair, including skin wounds 
(Chen et al. 2008; Prockop 2009; Tolar et al. 2010; Tolar et al. 2011a). Indeed, there are 
around 200 open clinical trials using BM-MSCs for specific disease indications on 
www.clinicaltrials.gov. Precisely how MSCs impact on the process of tissue repair is not 
fully known, although immunomodulatory changes (T-cells, dendritic cells), a 
stimulatory paracrine function, and local immunosuppressive changes, have been 
observed (Nauta and Fibbe 2007; Walter et al. 2010; Bianco et al. 2013; Fibbe et al. 
2013). Moreover, within murine bone marrow, a sub-population of MSCs (still 
heterogeneous but positive for PDGFRα), has been shown to contribute directly to 
epithelial repair in skin (Tamai et al. 2011).  
Emerging data from the cardiovascular field demonstrated that culture medium 
conditioned by human MSCs significantly reduced infarct size by approximately 50% in 
animal models of myocardial ischaemia injury when administered intravenously in a 
single bolus (Lai et al. 2011). The conditioned medium consisted 10% of an endosomal 
origin protein, known as exosome. The therapeutic activity of the human MSCs was 
attributed directly to the exosomes (Lai et al. 2010). Exosomes are secreted vesicles that 
contain proteins and RNA and serve as mediators of paracrine effect and promote 
communication between cells. The implications of this hypothesis is that if we are able 
to identify these specific molecules, we could replace transplantation of MSCs with 
administration of their secreted exosomes, overcoming the limitations associated with the 
transplantation of viable replicating cells. 
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Although the skin blistering in RDEB is primarily induced by trauma, the failure of 
wounds to heal quickly and the tendency for the repair process to break down due to 
further mechanical injury and secondary bacterial skin infections, typically leads to acute 
and chronic inflammation in the skin. Transcriptomic studies in RDEB wounds have 
identified elevated levels of pro-inflammatory cytokines and matrix metalloproteinases, 
enzymes that breakdown collagen and elastic tissue in skin (Nagy et al. 2011). Clinically, 
prolonged skin inflammation leads to scarring, contractures and an increased risk of 
developing squamous cell carcinomas, particularly in areas of chronic inflammation. 
Thus, innovative therapies that reduce skin inflammation in RDEB potentially may have 
positive clinical benefits in reducing disease burden. Assessing the safety, feasibility and 
potential benefit of intravenous infusions of allogeneic BM-MSCs to children with RDEB 
is the subject of this clinical trial.   
 
5.2  Study design and participants  
This open-label phase I/II trial was approved by the UK Medicines and Healthcare 
Products Regulatory Agency (MHRA), with EudraCT number: 2012001394-87. The UK 
National Research Ethics Committee London Bloomsbury provided ethics and site-
specific approvals (Ref: 12/LO/1258) for Great Ormond Street Hospital. The trial was 
registered prospectively with www.controlled-trials.com (ISRCTN46615946). 
Participants were invited to participate if they were 1–17 years old and had a genetically 
confirmed diagnosis of RDEB with partial or complete deficiency of C7 in their skin. 
Participants were enrolled after written informed consent of the parents and written 
informed assent from the child (if over five years old) was also obtained. Skin biopsies 
obtained for previous diagnostic testing (as part of routine clinical care) were used as 
 P a g e  149 | 275 
 
baseline samples for DIF for C7 and TEM for anchoring fibrils. Children were recruited 
between July and October 2013 and all BM-MSC infusions per individual were 
completed by December 2013. The study was initially designed for the children to be 
followed up clinically for 24 months after their last infusion of BM-MSCs. Due to lack 
of serious adverse events (SAEs) observed, however, and positive outcomes noted by the 
children and their parents, a substantial protocol amendment approved shortening study 
completion and clinical observation to 12 months after each child’s last infusion. 
 
5.3 Production of MSCs  
Bone marrow-derived MSCs are classified as an advanced therapy medicinal product 
(ATMP) and the cells were manufactured according to Good Manufacturing Practice 
(GMP) guidelines. BM-MSCs from the bone marrow of two healthy unrelated donors 
(male donor aged 2 years and female donor aged 10 years) were isolated, cultured and 
packaged at the GMP-licensed Cell Therapy Facility at University Medical Center 
Utrecht (UMC), The Netherlands. Use of these donor cells was approved by the Dutch 
Central Committee on Research Involving Human Subjects (CCMO, Biobanking bone 
marrow for MSC expansion, NL41015.041.12). Cells were cryopreserved with 10% 
DMSO. HLA typing was performed on donor cells but not the recipients of the MSCs. 
The cells were screened against an infectious disease panel in accordance with the EU 
directive 2006/17 (EUD 2006/17/EC). DNA from both donors was screened for COL7A1 
mutations and none were found. The pre-packed, cryopreserved cells were stored at the 
Camelia Botnar Cell Laboratories at Great Ormond Street Hospital in liquid nitrogen. 
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Each child in the trial received three separate intravenous infusions of same donor BM-
MSCs on Day 0, 7, and 28, at a dose of 1-3x106 cells/kg. Each child received either 
20x106 (body weight 5-20 kg) or 40x106 cells (body weight 20.1-40kg) depending on 
their weight. The infusions were administered as day-case procedures at the Somers CRF 
at Great Ormond Street Hospital. Cryopreserved cells were transferred from the Camelia 
Botnar Cell Laboratories in a canister filled with liquid nitrogen. The bags containing 
BM-MSCs were thawed in a 37oC water bath and immediately infused over 10 minutes 
via a peripheral cannula. Vital signs (blood pressure, respiratory rate, heart rate, pulse 
oximetry and temperature) were checked before administration of the cells and thereafter 
every 15 minutes for one hour after the infusion and on discharge. Premedication with 
chlorphenamine was given intravenously 30 min before the cell infusions.  
 
5.4 Objectives of trial  
The primary objective was to assess safety and feasibility. Secondary objectives were to 
assess efficacy on clinical and functional outcomes, as well as skin pathology. I assessed 
participants by conducting six follow up visits over six months and then two further safety 
visits up to 12 months after the last infusion. Structured phone interviews to obtain 
qualitative data were held at nine months. Skin samples were analysed by DIF and TEM 
(at screening and at Day 60) at the National Diagnostic Epidermolysis Bullosa Laboratory 
at St Thomas’ Hospital (Viapath, London, UK). Clinical assessment and photographs 
were undertaken for all participants at each visit. The BEBSS, a Global Severity and 
Improvement Score (GSIS) questionnaire, a Pain Sleep and Fatigue (PSF) assessment, 
and a Paediatric Quality of Life (Paeds QoL) assessment, were completed as per protocol 
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(Figure 5.1). Blister counts and clinical photographs were done by the parents during 
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Figure 5.1 Trial flowchart summarising the trial interventions and assessments per visit.
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5.5 Blood and skin profiling  
Blood samples for haematology and biochemistry were taken and analysed at screening, 
Day 0, 7, 28, 60 and 180 at the Great Ormond Street Hospital pathology laboratories. Sera 
were analysed for C7 antibodies by IIF and ELISA at screening and Day 60 
(Immunobiology Laboratory at St Thomas’ Hospital). Inflammatory serum cytokine 
levels for interleukin IL-4, IL-6, IL-10, IL-17A, interferon-gamma (IFNγ) and tumour 
necrosis factor alpha (TNFα) were also analysed at screening, Day 0, 7, 28, 60 and 180 
(Flow Cytometry facility, Guy’s Hospital). No donor MSC-specific antibodies were 
tested for in any of the recipients’ sera. For cases in which the BM-MSC donor cells were 
sex-mismatched, quantitative donor analysis using FISH was performed on tissue 
sections (Department of Cytogenetics, Guy’s Hospital). Suction blister times were 
performed at screening and Day 100.  
 
5.6 Statistical analysis   
No formal sample size calculations were done because this was primarily a safety clinical 
trial. The paired t-test was used to compare mean differences in continuous outcomes 
between two chosen time points for normally distributed differences. The Wilcoxon 
signed rank test was used for data that were not normally distributed or which could not 
be transformed. The 2-sample test was used to compare differences in change of 
percentage BEBSS total body surface area (TBSA) between children aged ≤ two years 
and aged three years or more. Results are reported as estimates with 95% confidence 
intervals. P values are given but should be regarded as indicative as the study was not 
powered for efficacy. The scales of the paediatric quality of life questionnaire (PaedsQL) 
differed depending on the age of the child, and ranged from either 0–84 (aged 2–4 years) 
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or from 0–92 (aged 5–13 years). In order to make the scales comparable across all 
children, the scores for the younger children (ranged 0–84) were rescaled to 0–92 by 
multiplying by 92/84 (Varni et al. 1999; Varni et al. 2002; Varni et al. 2003). For the 
child version of the Pain Sleep and Fatigue Questionnaire, only patients aged >6 years 
were eligible to complete these. Children who had completed the questionnaire for all the 
seven visits were included in the analysis (n=3/10). One patient did not complete the 
questionnaire at visit 1 (baseline) but completed it at subsequent visits. Analyses were 
performed using the Stata statistical software (StataCorp. 2013, version 13.0).   
 
5.7 Results  
 
Eleven children with RDEB were screened for inclusion into the trial. One child was 
excluded because of both positive ELISA for C7 antibodies and positive IIF with binding 
to skin DEJ (base of salt split skin). Ten children were enrolled at Great Ormond Street 
Hospital (London, UK). Participants fulfilled the eligibility criteria, had a mean age of 
4.6 years (range 1-11), and had a clinical and genetic diagnosis of RDEB. There were a 
total of 163 adverse events (AEs) as summarised in Table 5.1, Table 5.2 and Table 5.3. 
Initially two SAEs were reported but were subsequently downgraded in line with an 
updated protocol (version 4.0, 1st August 2014). Twenty-percent (32/163) of the AEs 
were definitely related to the infusion of BM-MSCs and comprised: DMSO odour, 
nausea, abdominal pain and bradycardia. DMSO odour was noted following 28 of the 30 
infusions and lasted for up to 48 hours. Mild nausea occurred during two infusions; 
abdominal pain and bradycardia were observed during two other infusions. All AEs 
resolved within 15 minutes without treatment. For the remaining AEs, 84 were mild 
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(51%), 46 were moderate (28%) and 1 (0.6%) was severe, consistent with complications 
related to RDEB and the children’s age-related events, rather than the BM-MSCs. The 
mild/moderate AEs included vomiting and pain on swallowing due to oesophageal 
strictures, corneal abrasions, recurrent spontaneous and trauma-induced blistering, 
wound infections and age-related accidental injuries. No adverse events resulted in either 
discontinuation or reduction in the dose of the study drug. Thirty infusions were 
administered as planned and all follow up visits were completed. The intravenous 
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Table 5.1 Summary of adverse events. 
  N %  
Total number of patients in study  10 100 
Number of patients who experienced adverse events  10 100 
Total number of adverse events reported  163 100 
  Number of events   % 
Intensity      
Mild  101 62.0 
Moderate  59 36.0 
Severe 3 2.0 
Serious     
 Yes 0 0.0 
Relationship to study drug     
Definitely 32 20.0 
Possibly 3 2.5 
Likely 1 0.6 
Unlikely 4 1.8 
Not related 123 75.0 
Outcome     
Resolved 153 94.0 
Continuing, but no further follow up required 10 6.0 
Frequency     
Single occurrence 144 88.0 
Intermittent 14 9.0 
Continuous 5 3.0 
Action taken     
None  107 65.0 
Required concomitant medication 56 35.0 
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Table 5.2 Intensity of adverse events by relationship to MSC infusion. 





Relationship to MSC infusion (n (%))  
Definitely Possibly Likely Unlikely Not related Total 
Mild 18 (18.0) 3 (3.0) 0 (0.0) 3 (3.0) 77 (76.0) 101 (62.0) 
Moderate 12 (20.0) 0 (0.0) 1 (1.7) 1 (1.7) 45 (76.0) 59 (36.0) 
Severe 2 (67.0)* 0 (0.0) 0 (0.0) 0 (0.0) 1 (33.0) 3 (2.0) 
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Table 5.3 Adverse event by system organ class and relationship to MSC infusion.  
MSC: Mesenchymal stromal cells; EB: Epidermolysis Bullosa; DMSO: Dimethyl sulphoxide. 
 Relationship to MSC infusion  





Total number of 
patients in study 




experienced                
adverse events 
 10       
 
Ear, Nose and Throat 
 















 Epistaxis 1 0 0 0 0 1 1 
 Sore throat 3 0 0 0 0 3 3 
         
Eyes Total in class 5 0 0 0 0 24 24 
 Conjunctivitis 1 0 0 0 0 1 1 
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 Relationship to MSC infusion  





 Corneal abrasion 4 0 0 0 0 20 20 
 Sore eyes 1 0 0 0 0 3 3 
         
Dermatological Total in class 8 0 3 1 3 23 30 
 
Spontaneous skin/mucosal 
blisters and wounds 
7 0 2 0 0 12 14 
 
Trauma induced skin/mucosal 
blisters and wounds 
2 0 0 0 0 4 4 
 Dry skin 2 0 0 0 0 2 2 
 Fine hair growth 1 0 1 0 0 0 1 
 Milia 1 0 0 0 1 0 1 
 Pruritus 4 0 0 1 1 2 4 
 Rash 2 0 0 0 1 3 4 
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 Relationship to MSC infusion  





         
Lymph nodes Total in class 1 0 0 0 0 1 1 
 Lymphadenopathy 1 0 0 0 0 1 1 
         
Gastrointestinal Total in class 9 3 0 0 1 20 24 
 Abdominal pain 1 1 0 0 0 0 1 
 Gastro-oesophageal reflux 1 0 0 0 0 1 1 
 Constipation 2 0 0 0 0 2 2 
 Diarrhoea 5 0 0 0 0 9 9 
 Increased appetite 2 0 0 0 1 1 2 
 Nausea 2 2 0 0 0 1 3 
 Vomiting 5 0 0 0 0 6 6 
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 Relationship to MSC infusion  





         
Respiratory Total in class 3 0 0 0 0 4 4 
 Cough 3 0 0 0 0 4 4 
         
Cardiovascular Total  in class 1 1 0 0 0 0 1 
 Bradycardia 1 1 0 0 0 0 1 
         
Genitourinary system Total in class 1 0 0 0 0 1 1 
 Reduced urine output 1 0 0 0 0 1 1 
         
Musculoskeletal Total in class 1 0 0 0 0 1 1 
 Joint pain 1 0 0 0 0 1 1 
Infections Total in class 8 0 0 0 0 20 20 
 Fever 2 0 0 0 0 2 2 
 Respiratory tract infections 5 0 0 0 0 10 10 
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 Relationship to MSC infusion  





 Skin infection 5 0 0 0 0 7 7 
 Urinary tract infection 1 0 0 0 0 1 1 
         
Medical and surgical 
procedures 
Total in class 5 0 0 0 0 6 6 
 Oesophageal dilatation 4 0 0 0 0 4 4 
 
Routine surgical procedure                                         
Related to complications of 
EB 
1 0 0 0 0 1 1 
 Dental procedure 1 0 0 0 0 1 1 
         
Accidental injuries Total in class 5 0 0 0 0 18 18 
 Accidental injuries 5 0 0 0 0 18 18 
         
DMSO odour Total in class 10 28 0 0 0 0 28 
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 Relationship to MSC infusion  









         
Mood Total in class 1 0 0 0 0 1 1 
 Irritability 1 0 0 0 0 1 1 
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Blood monitoring assessments did not reveal any adverse impact of the BM-MSCs on 
renal, liver or bone marrow function. Due to skin fragility and scarring, venous access 
was difficult, thus some bloods tests were unobtainable. I did not identify any rash or 
signs of allergic reaction during the infusions. Anti-C7 antibodies were detected by serum 
ELISA at baseline in 9/10 participants and levels remained similar after treatment. None 
of these positive sera showed binding to the skin basement membrane by IIF. Following 
MSCs, there were no major changes in the ELISA or IIF data (Table 5.4). Skin biopsies 
revealed no change in C7 deposition and no new formation of anchoring fibrils at Day 60 
when compared to baseline. FISH analysis of skin specimens from four children who 
received sex-mismatched BM-MSCs taken on Day 60 did not show evidence of donor 
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Table 5.4 Summary of anti-BP180, anti-BP-230 and anti-C7 antibody levels (in units) by ELISA in the 
sera of the children. 
BP180 = bullous pemphigoid antigen-180; BP230= bullous pemphigoid antigen-230 C7=collagen VII 
 
Patient ID Pre-treatment (screening) Post-treatment (Day 60) 
 BP180 BP230 C7 B180 BP230 C7 
A 42 29 13 27 34 13 
B 68 66 35 58 50 23 
C 32 32 15 54 31 11 
D 97 68 24 97 97 28 
E 2 2 1 2 3 1 
F 45 48 10 42 40 13 
G 60 41 29 52 50 17 
H 42 28 16 51 48 19 
I 28 28 4 32 29 4 
J 70 47 20 48 46 18 
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The BEBSS and Global Severity Scores (GSS) were completed for all 10 participants. 
Mean disease severity, as measured by total BEBSS, improved by 5.2 points (95% CI -
10.7, 0.3; p=0.06) and also mean BEBSS total body surface area (TBSA%) showed 
improvement by 5.9 points at Day 60 (-15.3, 3.5; p=0.19). The improvement was 
sustained, and at Day 180 had improved by 6.9 points for the BEBSS (-12.7-1.1; p=0.03) 
and 8.9 points for the TBSA (-18.9, 1.1; p=0.07). Mean reduction in TBSA was greater 
in children under the age of two years (n=4) as compared to baseline by 4.4 (-31.7, 23) at 


















Figure 5.2 Disease severity score. 
Birmingham Epidermolysis Bullosa Severity Scores (BEBSS) for each patient (N=10) by number of days from first 
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Figure 5.3 Percentage total body surface area (TBSA%) affected by EB. 
This is calculated from BEBSS for each patient (N=10) by number of days from first MSC infusion. 
 
Mean global severity score reduced from 7.0 to 4.6 at Day 60 with mean difference from 
baseline -2.4 (-3.4, -1.4; p<0.001) and to 5.4 at Day 180 with mean difference from 
baseline 1.6 (-3.0, -0.24; p=0.03) (Figure 5.4). 




Figure 5.4 Global severity score. 
Global Severity Scores for each patient (N=10) by number of days from first MSC infusion (top); Distribution of global 
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Pain, sleep and fatigue questionnaires were completed independently for children over 6 
years old (n=4) as well as by the parents. Mean pain score reported by parents showed 
reduction from 26.1 at baseline to 20.6 at Day 60 (-16.3, 5.3, p=0.28) and to a lesser 
degree 23.1 at Day 180 (-14.7, 8.7, p=0.58). Mean pain score reported by children aged 
6 or over (n=3) showed no change from baseline 20 to 20 at Day 60 but reduced to 11.3 













Figure 5.5 Parent and child versions of pain scores from Pain, Sleep and Fatigue Questionnaire.  
Top = parent: Graph showing distribution of scores with means and range by number of days from first MSC infusion 
(N=10). Bottom = child: Graph showing distribution of scores with means and range by number of days from first 
MSC infusion (N=4). *Patient G was < 6 years at baseline and so was not eligible to complete the questionnaire at visit 
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Paeds QoL (Parent version) was completed for children over two years (n=8); and Paeds 
QoL (Child version) was completed by children over five years (n=5) as per questionnaire 
guidance. Similarly, mean quality of life score (higher is worse) reported by parents 
showed improvement from 41.9 at baseline to 37.5 at Day 60 (-8.1, -0.7, p=0.03) and to 
a lesser degree 39.0 at Day 180 (-7.5, 1.8, p=0.19) (). Mean age-adjusted quality of life 
score reported by children aged 5 or above (n=5) showed improvement from 32.4 at 
baseline to 27.2 at Day 60 (-25.6, 15.2, p=0.52) and to a lesser degree 29.6 by Day 180 (-
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Figure 5.6 Parent and child versions of paediatric quality of life scores (PaedsQL). 
Top = parent. Graph shows distribution of scores with means and range by number of days from first MSC infusion 
(N=8). *PaedsQL parent version can only be completed for children over 2 years.  
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Mean pruritus score (children’s report) showed improvement by 1.3 (-4.2, 1.5; p=0.18) 
by Day 60 and this was sustained at Day 180 (-4.2, 1.5, p=0.18) (Figure 5.7).  
                        
 
Figure 5.7 Pruritus scores by number of days from the first MSC infusion. 
Top graph shows pruritus scores (pruritus scale of the pain, sleep and fatigue questionnaire); for each patient (N=4). 
Bottom graph shows distribution of scores with means and range by number of days from first MSC infusion (N=4). 
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Median blister count at baseline was 5.5 and reduced to 3.5 by Day 60 and remained thus 
at Day 180 (Figure 5.8).  
 
 
Figure 5.8 Blister count. 
Distribution of blister count for each patient (N=10) by number of days from first MSC infusion (top); distribution of 
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Serial clinical photographs of skin erosions revealed improved wound healing and 
lessening in skin redness Figure 5.9, Figure 5.10 and Figure 5.11. A summary of the 
clinical secondary outcome measures is shown in Table 5.5. 
                  
Figure 5.9 Improved wound healing and reduced skin erythema 8 weeks after the third infusion of BM-
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Table 5.5 Summary of baseline characteristics and clinical secondary outcome measures. 
BEBSS: Birmingham Epidermolysis Bullosa Severity Score, scale range: 0-100: TBSA: Total Body Surface Area; Global Severity Score Scale range: 0 – 12; PaedsQLTM: Paediatric quality of life 
questionnaire - parent version: child aged 2-4 years (range:0-84), 5-7 years (range:0-92), and 8-12 years (range:0-92) and child version: child aged 5-7 years (range:0-92) and 8-12 years (range:0-92); Pain 
scale range: 0-80; Fatigue score scale range: 0-10; Pruritus score scale range: 0- 10. **Child was aged < 6 years at baseline. Abbreviations: M= male; F=female; CA=Complete absence; PA=Partial 
absence, IF=immunofluorescence; NA= not applicable.      
 Subject A Subject B Subject C Subject D Subject E Subject F Subject G Subject H Subject I Subject J 
Clinical 
characteristics 
          
Age (years) 1 1 1 1 4 7 5 7 10 11 
Sex M M M F M F F F F M 
Body mass 
index (kg/m2) 
17 15 15 17 15 13 14 12 15 14 
Molecular 
characteristics 
































(+/-)  c.4621delG, 
p.Gly1541Thrfs*67 





















Skin C7 protein 
expression by 
IF 
CA PA PA CA CA CA CA CA CA CA 
Disease 
Severity 
          
BEBSS 15 21 39 18 32 33 36 31 35 23 
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 Subject A Subject B Subject C Subject D Subject E Subject F Subject G Subject H Subject I Subject J 
BEBSS TBSA 
(%) 
13∙5 13 47 12∙8 19 29 26∙5 31 28 13 
Global severity 
score 
10 6 6 7 6 9 6 7 7 6 
Blister count 6 1 3 2 6 19 22 6 5 2 
Pain sleep and 
fatigue 
questionnaire 




NA NA NA NA NA NA NA** 18 34 8 
Pain score 
Parent version 




NA NA NA NA NA NA NA 2 6 2 
Fatigue score 
Parent version 




NA NA NA NA NA NA NA 8 8 4 
Quality of life 
questionnaire 
          
PaedsQL score 
(Child version) 
NA NA NA NA NA 4 44 32 47 35 
PaedsQL score 
(Parent version) 
12 NA NA 30 39 54 50 50 59 41 
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Mean suction blister time increased from 613.2 seconds at baseline to 716.4 by Day 100 
(p=0.12). Eight out of 10 children showed increased times following BM-MSCs (Figure 
5.12). 
 
Figure 5.12 Suction blister times.  
Three areas of skin, each 3-millimeter diameter, on the thigh were exposed to continuous negative pressure (12 inches 
of mercury). Time to blister formation was determined with a stop watch. Two measurements, one pre-infusion (Visit 
1) and one 100 days post-infusion (Visit 6) are shown all trial children. Results indicate increased skin resistance after 
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Mean serum IFN-γ levels reduced from 1,871 (95% CI 11, 3,730) pg/ml at baseline to 
337 (-26, 700) pg/ml at Day 180 (p=0.09); IL-17A levels reduced from 668 (-149, 1,485) 
pg/ml at baseline to 49 (-0.65, 100) pg/ml at Day 180 (p=0.21); IL4 levels remained 
essentially unchanged from 993 (-196, 2,182) pg/ml at baseline to 700 (-296, 1,697) pg/ml 
at Day 180 (p=0.83); IL-6 levels decreased from 312 (8, 616) pg/ml at baseline to 106 (-
17, 229) pg/ml at Day 180 (p=0.47); IL-10 levels decreased from 323 (-29, 676) pg/ml at 
baseline to 176 (-152, 505) pg/ml at Day 180 (p<0.01) and TNF-alpha levels decreased 
from 123 (16, 230) pg/ml at baseline to 22 (9-36) pg/ml at Day 180 (p=0.63). The 
reduction in cytokine levels between Day 60 and Day 180 was significant for IL-10 
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Figure 5.13 Inflammatory serum cytokines.  
Levels of interleukin (IL)-10 (A), IL-4 (B), IL-10 (C), IL-17A (D), Tumour necrosis factor (TNF)-alpha (E) and 
Interferon (IFN)-gamma (F) (human T-cell and B-cell cytokines) in sera of the trial patients (•). Mean value indicated 
by line (–). 
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Semi-structured telephone interviews were conducted with the parents of all trial 
participants at 9 months after the last MSC infusion. The parents recalled their experience 
of caring for their children with RDEB prior to and during the clinical trial. The rate of 
wound healing improved with chronically ulcerated areas of skin beginning to heal. The 
general improvement to skin condition, together with increase in skin resilience in 
trauma, enabled the children to participate more fully in play and family life.  
“There was an improvement in the colour of her skin and we noticed how quickly 
everything healed. I am sure [name of patient] was in less pain. [name of patient] was 
more able to cope with her [sibling] being rougher with [name of patient]. We could 
reduce the oramorph by a fifth before the bandage changes. I am sure she was 
experiencing less pain. [name of patient]’s skin was more resistant so she was more 
prepared to let her sister fling her about the room, you know, like big sisters do. Or maybe 
it was because she was in less pain. [the skin] could bump but not blister. Or if her sister 
was doing ‘row row row’, it would leave finger marks on her [previously before the 
clinical trial], but not [now, during the clinical trial]. [name of patient’s sibling] was just 
braver, more able to exist as a functional sister. It was very important for us that [name 
of sibling] was able to interact with her more like normal siblings. It makes you realise 
how many times you say stop, don’t do that, how you are always on edge” 
Some parents reported a reduction in the amount of the time required to provide skin care 
for their children. The amount of dressings required has also reduced. A parent reported 
about 50% reduction in dressings.  
One parent described he often need to return home to assist with his child’s skin care 
prior to the clinical trial. During the clinical trial, he saw a reduction in unscheduled 
absence from work as his child’s skin condition improved. One parent reported that the 
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improvement to her child’s skin condition was one of the key factors that enabled her to 
take up part-time employment after the clinical trial commenced.  
“[I took time off work] 4 or 5 times a month. I have to change a shift, ring a colleague 
and disrupt a shift. I haven’t taken any days off [since the clinical trial started]. You can 
see the difference.” 
The improvement to the children’s RDEB has led to improved quality of family life with 
two families reporting they went abroad for holidays and one family reporting regular 
visits to the zoo since the clinical trial began, which they would not have otherwise done 
if their children’s skin condition did not improve.  
“As you can imagine, his skin was all healed up. We were able to put him in the water. 
Every single day, he was in the ocean. We had to do the dressings everything but the 
difference was that he can do that and he didn’t feel pain. [He had] some areas with little 
blisters. He was very happy to be in the water. That’s why we’d try what we can to go on 
holiday again. [the clinical trial made a] big difference for him.” 
The parents of all the children had a more positive outlook for the future of their child 
with the parents of one child stated that the improvement to their child’s RDEB condition 
was a contributing factor to their decision to have another child.  
“Before we even had [name of child] we wanted 3 or 4 children–it was never an option 
to have just 1 child.  If things had been really bad with [name of child], like she wasn’t 
going to walk, I don’t think we would have had another child.  It’s very difficult to know. 
The fact that we made the decision to have the second one [child] was because of the 
hope we had from the trial and it certainly has contributed to our decision.” 
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5.8 Discussion   
This was an open, uncontrolled clinical trial of intravenous infusions of BM-MSCs in 
children with RDEB. Availability of BM-MSCs as a pre-manufactured, quality controlled 
product without HLA matching makes it a safe therapeutic option for children with this 
severe genetic skin condition. The administration of 1–3 million cells/kg in 3 infusions 
over 30 days was well tolerated and without significant AEs. Children (>6 years of age) 
and their parents directly reported increased speed of wound healing, reduction in blister 
numbers, reduction in pruritus, increased skin resistance to trauma and reduced pain 
during dressing changes. All parents reported improvement of their children’s skin 
disease, more evident after the second or third infusions. The degree and duration of 
clinical improvement was variable, ranging from 3–6 months after the first infusion.  
No increase in C7 deposition or the formation of new anchoring fibrils was seen at Day 
60 after the first infusion. Thus, there is no evidence to indicate that allogeneic MSCs 
directly recover the inherent skin pathology in RDEB. The mechanism of action through 
which the MSCs improve wound healing in RDEB is not known but the benefits appear 
to be indirect and trophic in nature.  
The cytokine data showed reduction in immune and pro-inflammatory serum levels of 
IFN-γ, IL-6, IL-17A, IL-10 and TNF-α. IL-4 levels remained essentially unchanged. 
More specifically, higher levels of IFN-γ levels are found in DEB subjects, whereas IFN-
γ blockers have been successfully proposed as possible pharmacological approach for 
DEB patients (Skurkovich and Skurkovich 2007). IL-6 is predominantly a pro-
inflammatory cytokine, whose levels are higher in DEB patients with a more severe 
phenotype (Odorisio et al. 2014). IL-6 levels also positively correlate with disease 
severity (Kawakami et al. 2005; Annicchiarico et al. 2015). Therefore, one can postulate 
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that the reduction in its levels, although non-significant as in this study, could suppress 
the inflammatory cascade seen in RDEB. Interestingly, IL-17, a major inflammatory 
cytokine, was found to be elevated in the blister of patients with bullous pemphigoid and 
led the IL-17-induced MMP-9 associated inflammatory response (Le Jan et al. 2014). IL-
17 and MMP-9 also positively related to treatment response (Le Jan et al. 2014). MMP-
9 has been identified as potential therapeutic targets in DEB patients (Lettner et al. 2015) 
and therefore, the reduction in IL-17A levels, detected in this study, could be relevant. 
Levels of IL-10, an anti-inflammatory cytokine, initially increased by Day 60 and 
dropped at Day 180. Finally, TNF- α levels decreased in the study patients, which would 
be expected, if we assume that the BM-MSCs infusions triggered a systemic anti-
inflammatory response. The finding that the majority of the cytokine levels reduction 
occurred between 2 and 6 months is perhaps unexpected. I can speculate that the MSCs 
alter the innate immunity system balance and lead to ongoing activation of an anti-
inflammatory cascade which lasts beyond the presence of the cells in the circulation. 
There are still very limited data about the levels and role of these cytokines in EB and the 
majority of data are extrapolated from other inflammatory skin diseases. 
Collectively, the tolerance data appear encouraging, although it should be noted that a 
zero event rate for a serious AE in just 10 patients is compatible with an upper 95% 
confidence interval of over 30%. 
The natural history of generalised RDEB is one of progressively worsening blistering, 
scarring and contractures; spontaneous improvement is very rare and limited to cases of 
bullous disease of the newborn, or subjects with atypical COL7A1 mutations that lead to 
leaky splice sites or in-frame exon skipping, or individuals who develop skin patches of 
revertant mosaicism, none of which were present in the trial participants. In this early 
phase trial, safety was the primary outcome, therefore, it was not powered to determine 
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efficacy and to demonstrate benefit. The changes observed in pain scores, BEBSS and 
BEBSS TBSA, while not conclusively indicating benefit, are promising and the results 
will inform the design of a more definitive future trial. With regard to descriptive data 
and potential clinical impact, parents noted significant reduction in pruritus, and pain 
reductions that allowed children to bathe and perform other activities previously 
unthinkable due to painful wounds. Increased energy levels and improved appetites were 
also evident. The parents perceived skin redness, itching, skin resilience, wound healing 
and pain control were the key areas of noticeable change to their children’s disease. 
Although healing of individual wounds can occur spontaneously in RDEB, in this study 
there was clinical improvement of the total body surface area as well as objective 
increased suction blister times signifying increased skin resilience in 8/10 children. The 
rate of wound healing improved with chronically ulcerated areas of skin beginning to 
show signs of healing, often for the first time in months or years. The general 
improvement in skin condition, together with increase in skin resilience to trauma, 
enabled the children to participate more fully in play and family life. Overall, the changes 
in efficacy outcomes were promising, although it should be remembered that this is an 
unblinded study of participants who are keen to help, thus giving a potential for positive 
information bias.  
The small sample size and the lack of a control group are limitations to this study. RDEB 
is a rare genetic skin disease with an incidence of 1 in 17,000 live births and therefore an 
underpowered study was justified with the trend of the results presented being more 
helpful in data interpretation of secondary outcome measures compared to absolute p-
values. Inclusion of a control group raised both ethical and practical concerns: it was 
considered unethical for children to participate in a study in which they would receive a 
non-active substance and be subjected to skin biopsies and multiple blood tests. 
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Moreover, the preservative in the BM-MSCs is DMSO which produces an odour shortly 
after infusion and therefore providing an adequate control was deemed impractical.  
Aside from this trial, the only other study reporting both cutaneous and systemic positive 
outcomes for RDEB has been the report of whole BMT following myeloablation (Wagner 
et al. 2010). However, there was a high mortality rate of >20% in that cohort. Reduced 
intensity conditioning regimens for BMT are being studied in other clinical trials although 
detailed safety and efficacy data for those treatments have not yet been published. There 
were no safety concerns in the use of allogeneic BM-MSCs in children with RDEB in 
this trial and there were suggestions of clinical benefit. Intravenous infusions of 
allogeneic un-matched BM-MSCs, without any pre-conditioning, are safe and appear to 
improve some of the clinical manifestations of RDEB until such a time that more curative 
therapies are developed. 
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6                              CONCLUSIONS AND FUTURE DIRECTIONS 
6.1 General discussion 
RDEB is an inherited trauma-induced blistering skin disease caused by mutations in 
COL7A1. The need for a safe, effective and ideally systemic therapy for this debilitating 
disease has always been great.  
The focus of this thesis has been to assess the effect of allogeneic cell-based therapies in 
RDEB, both at preclinical and clinical levels. The aim was to improve the understanding 
of the mechanism of action of intradermal injections of skin-derived fibroblasts and their 
effect on wound healing in individuals with RDEB. I also attempted to investigate the 
role of EGF in COL7A1 expression in normal and RDEB skin cells using in vitro studies. 
The effect of allogeneic fibroblast injections on intact skin had only been assessed in a 
previous study of five adult individuals with RDEB (Wong et al. 2008). Based on this 
single, proof-of-concept study and the findings of mine and other mechanistic studies 
(Nagy et al. 2011) I coordinated and conducted a prospective, blinded, vehicle-controlled 
clinical trial to assess the effect on wound healing and safety of intradermal injections of 
allogeneic fibroblasts. I managed to demonstrate that a single series of fibroblasts 
injections enhances wound healing compared to vehicle in the first 28 days. However, 
RDEB is a genetic, systemic disease so early intervention and a systemic approach to 
treatment is the key. Thereafter, I assessed the safety and efficacy of intravenous infusions 
of BM-MSCs in children with RDEB. Although MSCs have been used in many medical 
conditions, they had only been administered intradermally in two individuals with RDEB 
(Conget et al. 2010). The study, described in this thesis, was the first to assess the effect 
of these cells in the context of a prospective, open label study in children with RDEB.  
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6.2 Summary of key findings 
A single series of intradermal injections of allogeneic fibroblasts around the margins of a 
chronic RDEB wound led to HBEGF and COL7A1 increase, albeit not statistically 
significant, in mRNA expression compared with normal looking RDEB skin at the 
injected edge. This finding added further support to earlier studies in another individual 
with RDEB showing increased HBEGF expression after injections in intact skin (Nagy 
et al. 2011). These molecular changes were supported by IF and clinical findings. C7 
staining at the injected site was increased at approximately 75% of normal human skin. 
This led to clinical improvement of the wound size and reduction in size over 8 months.  
The in vivo experiments were followed by in vitro studies, where I was able to show that 
HB-EGF could upregulate COL7A1 expression in both normal control and RDEB 
keratinocytes and fibroblasts, notwithstanding its association with malignant processes 
(Kivisaari et al., 2010). It is also of interest that RDEB cells, especially fibroblasts, lack 
responsiveness to HB-EGF, when compared with normal human epidermal cells. A 
closely related growth factor, EGF was also found to upregulate COL7A1 in both normal 
control and RDEB fibroblasts. EGF was more potent than HB-EGF in upregulating 
COL7A1 in RDEB fibroblasts in vitro. The novel finding that EGF plays a role in 
COL7A1 upregulation in RDEB epidermal cells could have implications about its 
potential use alone or in combination as a therapeutic tool in non-healing RDEB wounds.  
With regard to individuals living with RDEB, the question of whether intradermal 
injections of allogeneic fibroblasts can accelerate erosion closure had not been answered 
at the start of this thesis. Most of the initial human studies were performed on intact, 
unwounded skin, although some of the mouse studies showed that intravenously injected 
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COL7A1 gene-corrected fibroblasts could home to RDEB wounds and promote wound 
healing (Woodley et al. 2003). I therefore conducted a prospective, randomised, double-
blind, vehicle-controlled trial of individuals with RDEB to assess the effect of intradermal 
injections of allogeneic fibroblasts on erosion healing. A single series of intradermal 
injections of human allogeneic dermal fibroblasts into the margins of chronic erosions in 
subjects with RDEB produced a greater, but not statistically significant, reduction in 
erosion area, time to healing, and in proportion of wounds healed, compared with vehicle 
within the first 28 days following treatment. Although the study failed to reach statistical 
significance because of the small number of treated erosions, the results suggest that a 
greater number of chronic RDEB erosions can be expected to heal within 4 weeks 
following fibroblast injection (21·4% vs. 16·7%). Thereafter, the study showed no 
significant differences between fibroblasts and vehicle, although both were associated 
with clinical improvement over 6 months compared with baseline.  
RDEB is a life-long condition that affects people from birth. Therefore, studies in children 
had long been anticipated in an attempt to assess treatment safety in this population and 
to ameliorate the condition early in life. The phase I, proof-of-principle study was 
designed and conducted by me to assess the safety and efficacy of intravenous MSCs in 
10 RDEB children. The infusions were tolerated well with no safety concerns. No 
increase in C7 or formation of new anchoring fibrils was seen. Parents reported reduced 
skin redness and inflammation, improved wound healing, reduction in pruritus, increased 
skin resistance to trauma and reduced pain during dressing changes. But it should be 
remembered that this is an unblinded study of participants who are keen to help, thus 
giving a potential for positive information bias. 
Collectively, these findings provide some insight into the mode-of-action of 
intradermally administered allogeneic fibroblast. Furthermore, allogeneic cell therapies 
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were tested in adults and children with RDEB proving that they are safe to use and have 
a positive, but non-significant, clinical impact on the disease severity. Further studies are 
required to elucidate the underlying mechanisms and test new treatments in individuals 
with RDEB. 
 
6.3 Limitations and challenges 
Conducting clinical trials in the NHS setting is challenging and the process can be 
laborious. In particular, recruiting trial participants in a rare disease, such as RDEB, poses 
three main challenges, subject availability, access and knowledge.  
The first challenge is study participant availability. There are three independent adult and 
paediatric EB centres in the UK, in London (the largest adult and paediatric centre), 
Solihull (adult centre), Birmingham (paediatric centre) and Edinburgh (both adult and 
paediatric centre). All of them have their own databases and access to them is restricted 
for clinical purposes, unless the Investigator holds an honorary contract with the relevant 
NHS Trust. There is a national database for all UK individuals diagnosed with EB but 
once again access is password restricted and it can only be used for clinical reasons and 
not to identify potential research subjects for clinical trials – all factors that generate 
logistical and practical difficulties. The RDEB individuals are located across the UK; they 
can be difficult to reach and to attend scheduled study-related hospital visits. In many 
cases, during the study, the study visits had to be coordinated with regular hospital 
appointments to ensure compliance and availability. Figure 6.1 shows the number of 
places I had to travel to, for the purpose of the fibroblast trial, in order to ensure all trial 
data is collected when patients could not travel to London.  
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Figure 6.1 Map showing the areas where I had to travel to conduct the home visits during the fibroblast 
trial. 
 
Lack of availability for study participation and scheduled trial reviews can also be due to 
illness, since RDEB individuals are chronically ‘ill’. Many of them develop recurrent 
wound infections, undergo complex eye or hand surgeries with long recovery periods and 
essentially any illness has a much greater impact on their well-being with a prolonged 
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recovery period, compared to individuals with other illnesses. In the fibroblast study, 
these concurrent illnesses played a large role in subject selection because, according to 
the study entry criteria, study subjects should not have taken antibiotics within 1 week of 
screening and injections. Even when geographical location and illness do not pose a 
problem, the participation of an RDEB individual depends greatly on the availability and 
well-being of their carer. In the severe cases of RDEB, parents are usually full-time 
carers, who have to care for other household members and may themselves become 
unwell. This was also taken into account in my study. Moreover, a number of people with 
RDEB (usually with the generalised intermediate form rather than the generalised severe) 
declined to participate in the study because they were in full-time occupation.  
A third challenge to patient recruitment was the limited knowledge about the IMP. Some 
RDEB individuals were familiar with the fibroblast cell therapy option, but a large 
number, especially female subjects, were concerned about local skin pain as a result of 
the injections. Also the fact that the fibroblasts remain an investigational drug for 
treatment of chronic wounds without the assurance of clinical effectiveness was a 
negative factor for several, mostly young, potential study participants.  
In the paediatric trial, the parents were highly motivated and fewer challenges in 
recruitment were encountered. Early phase interventional trials in paediatric population 
are fewer compared to adult populations due to safety considerations. Mine was the first 
European medicinal clinical trial in the paediatric RDEB population; therefore, 
anticipation and eagerness for participation promoted recruitment. Parents were 
understandably anxious about the phase 1/2 trial, since the IMP was a new, experimental 
form of systemic treatment in this disease. The consent process took much longer and in 
cases of children over the age of five, assent was also required. 
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From the beginning of the fibroblast trial, a somewhat unexpected phenomenon became 
apparent, namely the natural history of some seemingly chronic wounds to actually 
undergo dynamic changes in wound size and healing, showing in some cases complete 
healing within a few weeks. This phenomenon of natural healing in RDEB has not been 
documented previously according to my knowledge. The patients though, were aware of 
it, and reported that most of their skin wounds would heal spontaneously and 
subsequently break down again. Notably, within a particular area, the healing of older 
wounds was often compounded by the appearance of adjacent and sometimes overlapping 
newer wounds (Figure 6.2 and Figure 6.3). Perhaps it would be more appropriate rather 
than describing individual chronic wounds, to refer to areas of chronic trauma that break 
down and heal continuously. Further discussions with the patients and their carers 
revealed that the majority of wounds follow a cyclical pattern of wound formation and 
healing. Initially, a blister develops after minimal trauma or spontaneously, and then after 
a few days the roof of the blisters becomes detached and a new wound forms. The wound 
remains open for days to weeks (depending on disease severity) and subsequently shows 
signs of gradual healing with reduction in size and usually crusting. The same cycle is 
repeated endless times during the life of an RDEB patient. Most of wounds screened for 
this trial were well-defined but others had irregular edges and it was difficult to 
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Figure 6.2 An individual with severe generalised RDEB with evidence of spontaneous wound healing on 
his back. 
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Figure 6.3 Further examples of spontaneous wound healing of wounds screened for the fibroblast trial. 
 
In the fibroblast trial, despite use of topical anaesthesia, in individuals with more severe 
disease, associated with scarring and contractures, pain was a major issue. One of the 
reasons for severe pain during the intradermal injections was the temperature of the cells. 
The fibroblasts/vehicle are kept a 4oC and could only remain out of the fridge for a limited 
time (< 1 hour) in order to be viable, so they were injected cold into the dermis, which 
caused significant pain. An additional reason for the pain is the fact that the fibroblast 
preparation is very concentrated and generates a ‘pressure’ feeling when injected in the 
 P a g e  201 | 275 
 
dermis, even more so when the area has chronic scarring. Lastly, the delivery method via 
a hypodermic needle is another cause for pain, especially when multiple injections are 
needed in order to cover the, quite often, irregular wound margins. On the other hand, the 
pain usually subsides within a few minutes after the end of the injections and no additional 
analgesia is needed. 
Although skin biopsies were not obtained during the fibroblast trial, the phenotype and 
genotype correlation allowed me to postulate about baseline C7 levels in some RDEB 
individuals. Also some patients had direct immunofluorescence performed in the past for 
previous diagnostic studies and I was aware of their baseline C7 levels. In Chapter 3, I 
demonstrated increased C7 labelling at Day 60 (close to 75% of normal human skin) 
compared to the patient’s un-blistered skin following a single series of injections of 
allogeneic fibroblasts. In some cases, prolonged wound healing was also seen in patients 
with no detectable baseline C7, which was partially unexpected. Previous murine studies 
using fibroblast injections showed that new C7 protein can be generated in the absence 
of baseline C7 (Ortiz-Urda et al. 2003). Also, a pilot study in two patients with severe 
RDEB suggested that intradermal injection of allogeneic mesenchymal stem cells into 
chronic ulcerated sites can accelerate re-epithelialisation of these wounds even in 
individuals with no detectable C7 at baseline (Conget, et al. 2010).  
 
6.4 Future directions 
 
Local administration of HMGB-1 was shown to promote tissue regeneration in 
myocardial infarction or diabetic ulcer by attenuating the inflammation or promotion of 
angiogenesis (Straino et al. 2008; Takahashi et al. 2008). BM-MSCs secrete the TNF-α-
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TSG-6 protein (Choi et al. 2011) and promote IL-10 production, both of which possess 
anti-inflammatory properties (Nemeth et al. 2009). It has also been previously shown that 
skin grafts, including RDEB skin, release HMGB-1, which mobilises BM-derived 
PDGFRα+ MSCs into the circulation, which in turn play a major role in skin regeneration 
(Tamai et al. 2011). In the context of RDEB, BM-derived PDGFR-α+ MSCs have been 
shown to migrate to RDEB mouse skin and restore c7 at the BM (Iinuma et al. 2015). 
These cells are recruited to damaged skin by release of HMGB-1 from hypoxic 
keratinocytes in RDEB blister roofs, with involvement of a stromal derived factor 1 alpha 
(SDF1-α) / C-X-C chemokine receptor type 4 (CXCR-4) signalling axis (Iinuma et al. 
2015). Nevertheless, the precise nature and mechanism(s) of the anti-inflammatory 
responses induced by the MSCs in RDEB skin are not known. Recently, it was 
demonstrated, in a skin injury mouse model, that systemic administration of HMGB-1 
mobilised endogenous PDGFRα+ BM-MSCs into the circulation, in skin grafts and 
suppressed inflammation (Aikawa et al. 2015). Both of these studies provide encouraging 
data about the systemic use of HMGB-1 for some forms of RDEB and also several other 
non-EB wound healing or skin tissue injury pathologies, including common conditions 
such as chronic venous leg ulcers. 
 
 
6.4.2.1 BMT protocol refinement 
Strategies to improve BMT outcomes include reduced intensity conditioning, and 
selection of more appropriate BM cell subpopulations, such as MSCs or PDGFRα+ cells. 
Reducing the degree of immunomyeloablative conditioning used for transplantation must 
be weighed against the patient’s likelihood of developing graft-versus-host disease, a 
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major immune complication associated with whole BMT. BMT protocol changes have 
been made to reduce side-effects and improve the speed of recovery. For example, the 
intensity of the conditioning regimen has been reduced from a combination of busulfan, 
fludarabine, and cyclophosphamide to combination therapy with fludarabine and low 
doses of cyclophosphamide and radiation (Tolar and Wagner 2013a). Of the 20 patients 
with RDEB who received blood and marrow transplantation, five died from disease 
progression or complications of transplantation, and all those treated with a non-
myeloablative regimen are alive (Tolar and Wagner 2013a). The new conditioning 
regimen is associated with substantially less toxicity, but although disease amelioration 
is still substantial, it may be less impressive than the original myeloablative protocols 
used, although full outcomes have yet to be published. Clinical application of BMT is 
also being expanded to generalised severe and generalised intermediate junctional EB, 
although RDEB remains the predominant clinical indication for now. 
 
6.4.2.2 Co-infusion of MSCs 
In view of the high mortality of the initial BMT protocols, MSCs were added as part of 
the more recently revised treatment regime. This was based on the theory that co-infusion 
of allogeneic MSCs post BMT can shift from a pro-inflammatory to an anti-inflammatory 
environment. This could be achieved by reducing early toxicity due to GvHD. (Tolar et 
al. 2011b). This was likely to make the BMT safer, especially in the setting of RDEB, 
where large areas of skin consist of open wounds colonised with bacteria. Co-infusion of 
MSCs early after BMT was also thought to promote engraftment. Therefore, infusion of 
MSCs was added to subsequent protocols of BMT and cord blood trials (Professor M. 
Jonkman, personal communication) that used reduced intensity conditioning. The data 
available so far in abstract form show that the addition of MSCs does not appear to have 
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added clinical benefits, although the reduced intensity conditioning has reduced patient 
mortality (Tolar et al. 2015).  
A potential solution sought is the co-administration of MSCs to promote engraftment, 
exhibit local immunosuppressive effects and support local progenitor cells (Perdoni et al. 
2014). Expression of TNFα-TSG-6 by MSCs has been associated with both improved 
wound healing and anti-inflammatory effects at wound sites (Qi et al. 2014). Notably, 
exposure of MSCs to TGF-β, TNF-α or SDF1-α has been shown to upregulate col7a1 
expression and c7 protein secretion in a time and concentration-dependent manner 
(Perdoni et al. 2014). In theory, this should bring C7 levels toward the 30% of the amount 
of wild-type C7 that is believed to be adequate for preventing blistering in RDEB (Fritsch 
et al. 2008). Other studies have investigated pre-conditioning of MSCs for potential 
clinical benefit in RDEB. Moreover, these cytokines also lead to increased MSC 
production of the anti-inflammatory protein tumour necrosis factor-stimulated gene 6 
protein (TSG-6) that has already been implicated in the indirect trophic benefits of 
allogeneic MSCs (Pittenger et al. 1999; Lee et al. 2009). Thus, future clinical trials are 
likely to assess systemic delivery of COL7A1-supplemented autologous RDEB MSCs, 
with possible pre-conditioning. 
 
 
6.4.3.1 Gene editing 
The limitations of localised cell and protein therapies, haematopoietic cell 
transplantation, and gene therapy vectors have made gene-editing nucleases an attractive 
option for RDEB therapy. These reagents can be rationally designed and engineered to 
mediate a break in the DNA strand at a user-defined locus resulting in a 100- to 1000-
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fold rate increase in homologous recombination (Taghian and Nickoloff 1997; Donoho 
et al. 1998). Candidate platforms for gene editing include zinc-finger nucleases (ZFNs), 
transcription activator–like effector nucleases (TALENs), and the clustered regularly 
interspaced short palindromic repeats (CRISPR)-Cas9 nuclease system. ZFNs, TALENs, 
and CRISPR-Cas9 function similarly, in that they all bind a user-defined DNA sequence 
and mediate a break in one or both of the DNA strands. However, their architecture and 
engineering processes differ greatly. 
ZFNs are heterodimeric DNA-binding proteins fused to a fokI nuclease domain and co-
localise to a target site to mediate a DNA break. The relatively small size of ZFN arrays 
makes them highly attractive for use for many gene delivery platforms; however, the 
challenges of requisite purchase or the acquisition of specialised starting materials and 
generation methodologies could restrict their widespread use. Similar to ZFNs, TALENs 
function as dimeric proteins and are tethered to the FokI nuclease; however, the region in 
which DNA cleavage occurs is larger (Christian et al. 2010; Cermak et al. 2011). 
TALENs comprise repeating elements that each contact a single base of DNA. The most 
recently described gene-editing platform is the highly user-friendly CRISPR-Cas9 system 
(Jinek et al. 2012). Nuclease-free targeting of the COL7A1 locus has also been 
demonstrated by Sebastiano et al (2014), the corrected cell types in these experiments 
were iPSCs derived from RDEB keratinocytes and fibroblasts. The corrected iPSCs were 
then transformed into corrected keratinocytes, which were used to create autologous 
epithelial grafts with normal C7 composition. 
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iPSCs represent, in principle, a nearly inexhaustible source of somatic cell types for tissue 
regeneration and ex vivo modelling of genetic disease (Hanna et al. 2007; Thatava et al. 
2011; Yusa et al. 2011). Skin cells from RDEB and JEB patients can be reprogrammed 
to pluripotency, thereby providing new tools with which to investigate the mechanisms 
underlying EB pathology in vitro (Tolar et al. 2011c; Tolar et al. 2013b). Furthermore, 
keratinocytes isolated from an unblistered patch of skin from a patient with RDEB, were 
reprogrammed into iPSCs (Tolar et al. 2014). The healthy patch of skin was determined 
to be a result of somatic mosaicism, and iPSCs cells derived from this healthy patch 
produced functional, biologically relevant levels of C7. RDEB iPSCs cells can also be 
differentiated into keratinocytes and fibroblasts, and can be used to construct full-
thickness three-dimensional skin equivalents (Itoh et al. 2011; Uitto et al. 2012; Itoh et 
al. 2013). Finally, differentiation of iPSCs to non-haematopoietic MSCs has been 
reported and represents another option to address the systemic manifestations of RDEB, 
although further studies are required to ascertain whether the iPSC–MSC described in 
these studies are similar to the mouse Lin-PDGFRα+ mesenchymal cells in their capacity 
to migrate to wounds and mediate C7 deposition (Zhao et al. 2015). 
 
 
In EB, revertant mosaicism, the coexistence of mutant cells carrying germline mutations 
and revertant cells that have spontaneously corrected the germline mutation by a somatic 
reverse mutation, has been described in patients with mutations in the COL17A1, 
COL7A1, FERMT1, KRT14, and LAMB3 genes (Kiritsi et al. 2014). Autologous punch 
grafting of healthy looking but genetically affected skin to treat chronic wounds in 
patients with the junctional form of EB showed initially a high healing rate of 70% but 
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recurrence of blisters was seen in all grafted areas (Yuen et al. 2013). Transplantation of 
revertant skin in an individual with junctional EB, resulted in revertant epidermis which 
expressed amounts of laminin-332 comparable with normal-appearing human skin 
(Gostynski et al. 2014). DNA analysis of the revertant skin cells confirmed that the 
acceptor sites were populated by the transplanted revertant keratinocytes. The grafted site 
remained blister-free for at least 18 months. This study raised hopes for using revertant 
cells to treat larger areas of mutant skin. The major challenges would be to find new 
methods for higher in vitro expansion of revertant keratinocytes and identifying the 
revertant skin patches. 
 
 
The use of human recombinant C7 protein as a potential treatment for patients with RDEB 
was first described in 2004 with the demonstration that intradermal injections of the 
protein could localize to the BMZ and produce functional anchoring fibrils in murine and 
human RDEB skin models (Woodley et al. 2004a). Recent studies aiming to address the 
stability of c7 in vivo have demonstrated that both endogenous and exogenous C7, 
administered via fibroblasts or MSCs, have a half-life of about one month (Kϋhl et al. 
2016). Subsequent studies extended these findings into a col7a1−/− murine model, 
showing similar benefit (Remington et al. 2009). Although these mice developed 
antibodies against the C7 protein, this did not preclude formation of anchoring fibrils and 
improvement of the disease phenotype. Given the presumed advantage of a systemic 
intravascular delivery method—which could theoretically provide recombinant C7 
protein to all mucocutaneous lesions rather than being restricted to injection sites—this 
same group provided evidence in 2013 that intravenous infusions of recombinant C7 
could home to the DEJ and form anchoring fibrils in an RDEB skin mouse model 
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(Woodley et al. 2013). Although these preclinical studies hold translational potential and 
provide proof-of-concept for recombinant protein-based therapies, the likely need for 
repeated injections, with the associated costs and the possibility of anti-C7 antibody 
formation, may limit the efficacy of this approach (Bruckner-Tuderman 2009).  
In the case of RDEB, protein replacement consists in delivering recombinant human C7 
protein locally or systemically. Injection of C7 corrected the subepidermal blistering and 
restored C7 expression in the BMZ for at least 2 months after a single injection. These 
results were supported further by intradermal injection of human C7 in a murine model 
of RDEB (Remington et al. 2009). The injected human C7 incorporated stably into the 
BMZ of RDEB mice, formed anchoring fibrils, and corrected the disease phenotype, 
leading to markedly prolonged survival. Remarkably, the treated RDEB mice developed 
circulating anti-human C7 antibodies that did not bind to the mouse’s BMZ, nor did it 
prevent anchoring fibrils formation. Finally, treatment of the mice with an anti-CD40L 
mAb prevented the production of anti-human C7 antibodies. 
The question whether a structural protein of the skin such as C7 would be able to home 
to skin, incorporate into the BMZ, and form anchoring fibrils after systemic injection had 
never been addressed previously. Indeed, protein replacement therapy is usually used in 
systemic diseases such as haemophilia or in lysosomal storage disorders, in which 
systemic delivery of a normal recombinant protein into the circulation allows it to reach 
therapeutic levels in the relevant target organs (Desnick and Schuchman 2012). 
To answer this question, Woodley et al. (2013) used venous tail injection of human 
recombinant C7 in two immunodeficient murine models. In the first model, human C7 
was injected intravenously into wild-type mice with full-thickness skin wounds. C7 
homed to the wounded skin only, where it formed anchoring fibrils as shown by electron 
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microscopy, and it improved wound healing. In the second model, C7 was injected 
intravenously in a murine model with grafted murine RDEB skin. C7 homed only to the 
RDEB skin graft, and it restored DE adhesion, C7 expression, and anchoring fibrils 
formation. In both of these models, the contribution of human C7 to anchoring fibrils 
formation was confirmed by labelling using gold particles attached to an antibody specific 
for human C7. Remarkably, the injected human C7 remained stably incorporated in the 
BMZ for at least 3 months after one injection. Translation of these results from a mouse 
model weighing 35 grams injected with 60 μg of C7 protein to children and adults 
weighing 35–70 kg would need a dose of 60–120 mg of C7 per infusion, respectively, 
which does seem theoretically achievable. 
Despite the initial preclinical positive studies, human trials of C7 protein therapy were 




It is also likely that some individuals with EB will benefit from a new group of 
compounds that have the capability of inducing read-through of nonsense mutations 
(Arakawa et al. 2003; Cardno et al. 2009). Several recessive forms of EB involve loss-
of-function mutations. Notably, in RDEB, ~15% of all pathogenic mutations involve 
nonsense mutations (Dang and Murrell 2008) and these are likely to be a focus for read-
through therapeutics. Such drugs can increase mRNA expression by ~5-10%, leading to 
increased protein synthesis (Rowe and Clancy 2009). Given that mouse models of RDEB 
have indicated that it is necessary to have 30-40% of the normal levels of c7 at the DEJ 
to prevent blistering (Fritsch et al. 2009; Kern et al. 2009), the use of a systemic read-
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through drug in appropriate patients may help contribute towards this target and 
complement other therapies. 
Gentamicin, an aminoglycoside antibiotic, and its derivatives are old drugs traditionally 
used to resolve serious Gram-negative bacterial infections and are known to be ototoxic 
and nephrotoxic in some patients. Interestingly, this class of antibiotics has been shown 
in some cases to “read-through” premature stop codons generated by nonsense mutations 
in certain types of gene defects. Approximately 10–25% of RDEB patients have nonsense 
mutations resulting in a truncated C7 or no C7 at all. Woodley et al (2013) identified, and 
characterised 22 RDEB patients, of whom two had nonsense COL7A1 mutations. They 
cultured their keratinocytes and fibroblasts with varying doses of aminoglycoside 
antibiotics. Without aminoglycosides, these cells synthesised no C7. By contrast, in the 
presence of noncytotoxic doses of aminoglycosides, both the RDEB cultured 
keratinocytes and the fibroblasts synthesised and secreted full-length C7 at a level 
between 10 and 35% that of normal cells (Cogan et al., 2014). The C7 generated was 
structurally identical to normal C7 and incorporated correctly into the DEJ of a human 
skin equivalent in vitro. RDEB cells expressing C7 also exhibited a reversal of the 
abnormal cellular motility that is characteristic of RDEB cells.  
A more recent study looked at the association of scarring and fibrosis in RDEB and how 
this is regulated by TGF-β expression and its role as phenotype modulator (Odorisio et 
al. 2014). Based on evidence that losartan has an anti-fibrotic effect in diseases such as 
Marfan syndrome (Lacro et al. 2014), Nystrom et al investigated the effect of losartan on 
TGF-β in a mouse model of RDEB (Nystrom et al. 2015). The group managed to show 
that losartan reduced tissue inflammation by reducing TGF-β levels; reducing the 
expression of TNF-α in RDEB paws and as a result reducing fibrosis progression in vivo. 
The delay of mitten deformity formation by a 7-week treatment in the c7 hypomorphic 
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mice corresponds roughly to a delay of 2 years in patients with severe RDEB (Fritsch et 
al. 2008) A major limitation is, however, that it does not reduce skin blistering, the 
primary manifestation of RDEB. 
Furthermore, a phase 3 comparative study of the healing of chronic wounds of RDEB 
individuals using decellularised human amniotic membrane and standard of care wound 
dressing Mepitel® (www.molnlycke.com) is undergoing in Paris, France 
(NCT02286427; https://clinicaltrials.gov). 
Progress has also been made in EBS treatment. In vitro studies on EBS keratinocytes 
showed a significant upregulation of IL-1ß, while treatment with anti-IL-1ß antibody 
successfully resulted in reduced IL-1ß and stabilisation of the intermediate filament 
network (Wally et al. 2013b). Based on these preclinical findings, a double-blinded, 
randomised, placebo-controlled pilot study investigated the use of a topical 1% diacerein, 
a prodrug of the IL-1 converting enzyme inhibitor rhein (Moldovan et al. 2000). The 
investigators managed to show a 66-78% reduction in blister numbers in 2 out of 4 
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7                                                                                           APPENDIX A 
7.1 Contents of enclosed CD-ROM 
The CD-ROM enclosed with this thesis contains documents used in the clinical trials 
described in Chapter 5 and Chapter 6. The CD-ROM contents are in Adobe Acrobat 
format, i.e. PDF. To view this material, the Acrobat Reader browser plug-in is required. 
The plug-in can be downloaded from Adobe’s website: http://www.adobe.com/. 
The main menu is divided into two sections, which include documents related to the 
Fibroblast trial (Chapter 5) and the EBSTEM trial (Chapter 6). Specifically, for Chapter 
5 these include the trial protocol, participant information sheets, letters of invitation and 
a trial advert to improve recruitment. There are also samples of the case report form which 
was used to record the trial visit activities for each participant and the patient diary which 
was given to each trial participant on Day 0. 
The second section includes documents related to the EBSTEM trial (Chapter 6). These 
comprise of the trial protocol, age-appropriate participant information sheets, the case 
report form, participant diary and additional trial-specific documents. These include 
quality of life, pain sleep, fatigue and severity questionnaires and an EB-specific blister 
count manual. The section also contains documents relating to the BM-MSCs storage, 
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